<html lang="en"><head><!-- Shady DOM styles for custom-style --><!-- Shady DOM styles for dom-template --><!-- Shady DOM styles for dom-repeat --><!-- Shady DOM styles for array-selector --><!-- Shady DOM styles for dom-if --><!-- Shady DOM styles for state-modifier --><style scope="state-modifier">a[inherit].state-modifier {
  color: inherit;
}</style><!-- Shady DOM styles for browser-ui --><!-- Shady DOM styles for outlined-text-field --><style scope="outlined-text-field">outlined-text-field {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: column;
}

outlined-text-field span.outlined-text-field {
  display: flex;
  flex-direction: row;
  align-items: center;
}

outlined-text-field input.outlined-text-field {
  height: 40px;
  padding: 0 33px 0 16px;
  
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  flex-grow: 1;
}

outlined-text-field[orig] input.outlined-text-field {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-text-field[dense] input.outlined-text-field {
  height: 32px;
}

outlined-text-field[uppercase] input.outlined-text-field {
  text-transform: uppercase;
}

outlined-text-field:not([wizard-focused]):hover input.outlined-text-field {
  border-color: #737375;
  color: #414447;
}

outlined-text-field:not([wizard-focused]):focus-within input.outlined-text-field,outlined-text-field[wizard-focused] input.outlined-text-field {
  border-color: #3574e0;
  caret-color: #80a5f1;
}

outlined-text-field[wizard-focused] input.outlined-text-field {
  border-width: 2px;
}

outlined-text-field input.outlined-text-field::placeholder {
  color: #65686c;
}

outlined-text-field[uppercase] input.outlined-text-field::placeholder {
  text-transform: none;
}</style><!-- Shady DOM styles for mat-keyword-editor --><!-- Shady DOM styles for mat-chips-input --><!-- Shady DOM styles for mat-input-chip --><!-- Shady DOM styles for pat-dialog --><style scope="pat-dialog">pat-dialog {
  background: white;
  position: absolute;
  border-radius: 8px;
  
  box-shadow: 0 24px 38px 3px rgb(0 0 0 / 14%),
              0 9px 46px 8px rgb(0 0 0 / 12%),
              0 11px 15px -7px rgb(0 0 0 / 20%);
  z-index: 1;
  display: flex;
  flex-direction: column;
}

pat-dialog:not([open]) {
  display: none;
}</style><!-- Shady DOM styles for mat-tabs --><!-- Shady DOM styles for filter-chip --><style scope="filter-chip">filter-chip {
  align-items: center;
  background-color: #fff;
  border-color: #dadce0;
  border-radius: 8px;
  border-style: solid;
  border-width: 1px;
  color: #606368;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 32px;
  letter-spacing: 0.2px;
  padding: 0 16px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

filter-chip[disabled] {
  background-color: #e8e8e8;
  border-color: #e8e8e8;
  color: #a9abad;
  cursor: auto;
}

filter-chip svg.filter-chip {
  visibility: collapse;
  font-size: 18px;
  width: 0;
  height: 18px;
}

filter-chip[selected] svg.filter-chip {
  visibility: visible;
  margin: 0 8px;
  width: 18px;
}

filter-chip[selected] svg.filter-chip path.filter-chip {
  fill: #4577d1;
}

filter-chip:not([disabled]):hover {
  background-color: #f7f8f8;
  border-color: #d7d9dc;
  color: #454649;
}

filter-chip:not([disabled]):hover:active {
  background-color: #eff0f0;
  border-color: #d2d5d8;
  color: #222326;
}

filter-chip:not([disabled]):focus {
  background-color: #e7e8e8;
  border-color: #232528;
  color: #202124;
}

filter-chip:not([disabled])[selected] {
  background-color: #e9f0fd;
  border-color: #e9f0fd;
  color: #4577d1;
  padding-left: 0;
}

filter-chip:not([disabled]):focus[selected] {
  background-color: #d5e1fb;
  border-color: #d5e1fb;
  color: #2550a0;
}

filter-chip:not([disabled]):hover[selected] {
  box-shadow: rgba(0, 0, 0, 0.2) 0px 3px 1px -2px,
    rgba(0, 0, 0, 0.14) 0px 2px 2px 0px, rgba(0, 0, 0, 0.12) 0px 1px 5px 0px;
}

filter-chip:not([disabled]):hover:active[selected] {
  background-color: #abc8f2;
  border-color: #abc8f2;
  color: #2a54a3;
}</style><!-- Shady DOM styles for figure-callout --><style scope="figure-callout">figure-callout:not([filenames=""]) a.figure-callout {
  cursor: zoom-in;
  text-decoration: underline;
  text-decoration-color: #ddd;
}</style><!-- Shady DOM styles for mat-button --><style scope="mat-button-0">.mat-button-0 {
  ;
  align-items: center;
  border-radius: 4px;
  color: hsl(217 4% 39%); 
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: 0.2px;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

.mat-button-0[filled] {
  background-color: hsl(217 73% 54%); 
  color: white;
}

.mat-button-0[filled]:hover {
  background-color: hsl(217 60% 47%);
}

.mat-button-0[filled]:focus {
  background-color: hsl(217 59% 44%);
}

.mat-button-0[filled]:active {
  background-color: hsl(217 59% 45%);
}

.mat-button-0[filled][disabled] {
  background-color: hsl(217 2% 90%); 
  color: hsl(217 1% 65%);
}</style><!-- Shady DOM styles for search-term-wizard --><style scope="search-term-wizard">search-term-wizard:not([open]) {
  display: none;
}

search-term-wizard .header.search-term-wizard {
  border-bottom: 1px solid #e5e5e5;
  padding: 24px;
  padding-bottom: 0;
}

search-term-wizard .title.search-term-wizard {
  color: #3c4043;
  font-family: Google Sans,Roboto,Arial,sans-serif;
  font-size: 22px;
  user-select: none;
  margin: 0 48px;
}

search-term-wizard #panels.search-term-wizard > *.search-term-wizard:not([selected]) {
  display: none;
}</style><!-- Shady DOM styles for outlined-textarea --><style scope="outlined-textarea">outlined-textarea {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: row;
  
  position: relative;
}

outlined-textarea span.outlined-textarea {
  display: flex;
  flex-direction: column;
  flex-grow: 1;
  justify-content: center;
}

outlined-textarea span.right-button-container.outlined-textarea {
  position: absolute;
  right: 0;
  height: 100%;
}

outlined-textarea textarea.outlined-textarea {
  padding: 16px 16px 0 16px;
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  resize: none;
}

outlined-textarea[dense] textarea.outlined-textarea {
  padding: 8px;
}

outlined-textarea[has-icon] textarea.outlined-textarea {
  padding-right: 38px;
}

outlined-textarea[orig] textarea.outlined-textarea {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-textarea:not([rows]) textarea.outlined-textarea {
  height: 40px;
}

outlined-textarea textarea.resizable.outlined-textarea {
  resize: vertical;
}

outlined-textarea textarea.outlined-textarea:focus,outlined-textarea[wizard-focused] textarea.outlined-textarea,outlined-textarea textarea.outlined-textarea:focus:hover {
  border-color: #3574e0 !important;
  
  outline: none !important;
}

outlined-textarea textarea.outlined-textarea:hover {
  border-color: #202124;
  color: #414447;
}

outlined-textarea.hasValue textarea.outlined-textarea {
  border-color: #888d91;
  color: #45474a;
}

outlined-textarea #helperText.outlined-textarea {
  color: #6a6c71;
  font-size: 12px;
  letter-spacing: 0.3px;
  margin-left: 17px;
  margin-top: 6px;
  user-select: none;
}

outlined-textarea:not([helper-text]) #helperText.outlined-textarea {
  display: none;
}

outlined-textarea[error] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
  color: #3d4043;
}

outlined-textarea textarea.outlined-textarea::placeholder {
  font-size: 14px;
  font-weight: 400;
}

outlined-textarea:not([error]):not([disabled]) textarea.outlined-textarea::placeholder {
  color: #6a6c71;
}

outlined-textarea[error] textarea.outlined-textarea::placeholder {
  color: #c84132;
}

outlined-textarea[error] #helperText.outlined-textarea {
  color: #cd5648;
}

outlined-textarea[error] textarea.outlined-textarea:focus {
  border-color: #c84031;
  border-width: 2px;
  outline: none !important;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover {
  border-color: #97231b;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover::placeholder,outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover + #helperText.outlined-textarea {
  color: #a94945;
}

outlined-textarea[disabled] textarea.outlined-textarea {
  border-color: #e9e9e9;
  color: #b5b6b8;
}

outlined-textarea[disabled] #helperText.outlined-textarea {
  color: #c4c6c7;
}

outlined-textarea[error][disabled] {
  opacity: 50%;
}

outlined-textarea[error][disabled] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
}

outlined-textarea[error][disabled] #helperText.outlined-textarea,outlined-textarea[error][disabled] textarea.outlined-textarea {
  color: #a94945;
}

outlined-textarea[error][disabled] textarea.outlined-textarea::placeholder {
  color: #c84132;
}</style><!-- Shady DOM styles for chemistry-search-term-wizard --><style scope="chemistry-search-term-wizard">chemistry-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

chemistry-search-term-wizard .suggestions.chemistry-search-term-wizard {
  margin-top: 4px;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard svg.chemistry-search-term-wizard {
  margin-right: 24px;
}

chemistry-search-term-wizard path.chemistry-search-term-wizard {
  fill: #5f6368;
}

chemistry-search-term-wizard .help.chemistry-search-term-wizard {
  margin-left: 12px;
  margin-right: 0;
  cursor: pointer;
}

chemistry-search-term-wizard outlined-text-field.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard mat-button.chemistry-search-term-wizard {
  margin-left: 48px;
}

chemistry-search-term-wizard filter-chip.chemistry-search-term-wizard {
  margin-right: 4px;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard outlined-text-field[batchMode].chemistry-search-term-wizard {
  display: none;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard:not([batchMode]) {
  display: none;
}</style><!-- Shady DOM styles for text-search-term-wizard --><style scope="text-search-term-wizard">text-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

text-search-term-wizard > span.text-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

text-search-term-wizard > span.text-search-term-wizard svg.text-search-term-wizard {
  margin-right: 24px;
}

text-search-term-wizard path.text-search-term-wizard {
  fill: #5f6368;
}

text-search-term-wizard outlined-text-field.text-search-term-wizard {
  flex-grow: 1;
}

text-search-term-wizard mat-button.text-search-term-wizard {
  margin-left: 48px;
}

text-search-term-wizard filter-chip.text-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for classification-wizard --><style scope="classification-wizard">classification-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

classification-wizard > span.classification-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

classification-wizard .suggestions.classification-wizard {
  margin-top: 4px;
}

classification-wizard > span.classification-wizard svg.classification-wizard {
  margin-right: 24px;
}

classification-wizard path.classification-wizard {
  fill: #5f6368;
}

classification-wizard outlined-text-field.classification-wizard {
  flex-grow: 1;
}

classification-wizard mat-button.classification-wizard {
  margin-left: 48px;
}

classification-wizard filter-chip.classification-wizard {
  margin-right: 4px;
}

classification-wizard .no-matches.classification-wizard {
  margin-left: 64px;
}

classification-wizard .table-container.classification-wizard {
  max-height: 300px;
  overflow: scroll;
  margin-top: 8px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar {
  -webkit-appearance: none;
  width: 10px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar-thumb {
  border-radius: 5px;
  background-color: #5f636880;
  -webkit-box-shadow: 0 0 1px rgba(255,255,255,.5);
}

classification-wizard table.classification-wizard {
  margin-left: 51px;
  max-width: 575px;
}

classification-wizard tr.classification-wizard {
  margin-top: 4px;
}

classification-wizard tr.classification-wizard suggestive-chip.classification-wizard {
  margin-right: 8px;
}

classification-wizard #spinner.classification-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}</style><!-- Shady DOM styles for suggestive-chip --><!-- Shady DOM styles for mat-checkbox --><!-- Shady DOM styles for measure-search-term-wizard --><style scope="measure-search-term-wizard">measure-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

measure-search-term-wizard > span.measure-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

measure-search-term-wizard .suggestions.measure-search-term-wizard {
  margin-top: 4px;
}

measure-search-term-wizard > span.measure-search-term-wizard svg.measure-search-term-wizard {
  margin-right: 24px;
}

measure-search-term-wizard path.measure-search-term-wizard {
  fill: #5f6368;
}

measure-search-term-wizard outlined-text-field.measure-search-term-wizard {
  flex-grow: 1;
}

measure-search-term-wizard mat-button.measure-search-term-wizard {
  margin-left: 48px;
}

measure-search-term-wizard filter-chip.measure-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for numerical-search-term-wizard --><style scope="numerical-search-term-wizard">numerical-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

numerical-search-term-wizard .suggestions.numerical-search-term-wizard {
  margin-top: 4px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard svg.numerical-search-term-wizard {
  margin-right: 24px;
}

numerical-search-term-wizard path.numerical-search-term-wizard {
  fill: #5f6368;
}

numerical-search-term-wizard outlined-text-field.numerical-search-term-wizard,numerical-search-term-wizard outlined-textarea.numerical-search-term-wizard {
  flex-grow: 1;
}

numerical-search-term-wizard mat-button.numerical-search-term-wizard {
  margin-left: 48px;
}

numerical-search-term-wizard filter-chip.numerical-search-term-wizard {
  margin-right: 4px;
}

numerical-search-term-wizard #spinner.numerical-search-term-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}

numerical-search-term-wizard #suggestions.numerical-search-term-wizard {
  margin-left: 58px;
  display: flex;
  flex-direction: column;
  align-items: flex-start;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard mat-checkbox.numerical-search-term-wizard {
  margin-right: 8px;
}</style><!-- Shady DOM styles for text-button --><style scope="text-button">text-button {
  align-items: center;
  border-radius: 4px;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: .25px;
  margin: 6px 0;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
  line-height: 36px;
  text-decoration: none;
  text-transform: none;
  color: #5f6368;
}

text-button:hover {
  background-color: #f8f9fa;
}

text-button:active {
  background-color: #d5e2fa;
}

text-button[selected] {
  background-color: #e8f0fe;
  color: #1967d2;
}

text-button[selected]:active {
  background-color: #d2e3fc;
}</style><!-- Shady DOM styles for mat-spinner --><!-- Shady DOM styles for requery-tile --><style scope="requery-tile">requery-tile {
  display: flex;
  justify-content: space-between;
  align-items: center;
  box-sizing: border-box;
  min-height: 40px;
  padding: 8px 12px 8px 8px;
  gap: 8px;

  border-radius: 16px;
  background: #f7f8f9;
  color: #1f1f1f;
}

requery-tile:hover {
  background: #d7d8d9;
}

requery-tile > [slot="image"] {
  flex-shrink: 0;

  border-radius: 8px;

  background: #fff;
}

.label.requery-tile {
  flex-grow: 999;

  font: 16px/20px "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
}

.search-icon.requery-tile {
  flex-shrink: 0;

  width: 24px;
  height: 24px;
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/search/default/24px.svg');
}</style><!-- Shady DOM styles for s-more-inline --><style scope="s-more-inline">s-more-inline {
  display: block;
  margin-top: 24px;
  padding: 16px;
  padding-top: 0;
  position: relative;

  line-height: 18px;
  text-overflow: ellipsis;
  white-space: nowrap;
  cursor: pointer;
}

hr.s-more-inline {
  background-color: #dadce0;
  margin-top: 18px;
  position: absolute;
  border: 0;
  height: 1px;
  left: 0;
  width: 100%;
}

.button.s-more-inline {
  display: flex;
  align-items: center;
  justify-content: center;

  position: relative; 
  margin: 0 auto;

  font: 400 14px Roboto, arial, sans-serif;
  height: 36px;
  width: 300px;
  border-radius: 18px;
  background-color: #f1f3f4;
}

.button.s-more-inline:hover {
  background-color: #d8d7dc;
}

.button.s-more-inline > [slot] {
  padding-right: 8px;
}

.expand.s-more-inline {
  display: inline-block;
  width: 20px;
  height: 20px;
}

.expand.less.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_less/default/20px.svg');
}

.expand.more.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_more/default/20px.svg');
}</style><!-- Shady DOM styles for workspace-ui-search --><!-- Shady DOM styles for keyword-wizard --><style scope="keyword-wizard">keyword-wizard {
  display: inline-block;
}

iron-icon.keyword-wizard {
  height: 20px;
    width: 20px;
    color: #999;
    cursor: pointer;
}

iron-icon[active].keyword-wizard {
  color: #4285f4 !important;
}

iron-icon.keyword-wizard:hover {
  color: #ccc;
}

#wizardIcon.keyword-wizard {
  padding-left: 1px;
    height: 16px;
    width: 16px;
    margin: 4px 1px 1px 1px;
}

#wizard.keyword-wizard {
  padding: 0;
    left: 0;
    top: 37px;
    position: absolute;
    background-color: white;
    z-index: 2;
    overflow: hidden;
}

.wizard-header.keyword-wizard {
  display: block;
    width: 100%;
    color: #737373;
    text-transform: uppercase;
    font-size: 13px;
    margin: 16px 0 6px 12px;
}

.filter-chips.keyword-wizard {
  margin-left: 20px;
}

.chip.keyword-wizard {
  background-color: #ebebeb;
    color: #6a6a6a;
    display: inline-block;
    font-size: 13px;
    font-family: inherit;
    border-radius: 12px;
    padding: 6px 12px;
}

.chip.keyword-wizard:hover {
  cursor: pointer;
}

.chip[selected].keyword-wizard {
  background-color: #4285f4;
    color: white;
}

.input-label.keyword-wizard {
  display: inline-block;
    font-size: 13px;
    font-family: inherit;
}

.keyword-input.keyword-wizard {
  display: inline-block;
    border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    padding: 3px;
}

.keyword-input.keyword-wizard::placeholder {
  font-style: italic;
}

.keyword-input.keyword-wizard:hover,.keyword-input.keyword-wizard:focus {
  border-color: #4284f4;
    border-width: 1px;
    outline: none;
}

.cpc-field.keyword-wizard {
  display: inline-block;
    margin: 6px 0 0 24px;
}

#checkboxCPC.keyword-wizard:hover {
  cursor: pointer;
}

.checkbox-label.keyword-wizard {
  font-size: 13px;
    font-style: italic;
    color: #737373;
}

.chemistry-field.keyword-wizard {
  display: block;
}

#inputChem.input-batch.keyword-wizard {
  height: 150px;
    border: 1px solid #dfe1e5;
    padding: 6px;
}

#inputChem.keyword-wizard {
  resize: none;
    height: 15px;
    vertical-align: text-top;
    font-size: 13px;
    font-family: inherit;
    padding: 2px;
}

.chem-type-label.keyword-wizard {
  display: inline;
    font-size: 13px;
    margin-left: 12px;
    margin-right: 4px;
}

#chemType.keyword-wizard {
  border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    margin: 6px;
    padding: 2px;
    outline: none;
    font-family: inherit;
    font-size: 13px;
}

.import.keyword-wizard {
  font-size: 13px;
    font-family: inherit;
}

.import-text.keyword-wizard {
  vertical-align: middle;
    display: inline-block;
}

.import-button.keyword-wizard {
  margin: 6px 0 0 24px;
}

.import-button.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.import-button.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard {
  float: right;
    padding: 12px;
}

.wizard-buttons.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    margin: 2px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
}

@media screen and (max-width: 700px) {
#wizard.keyword-wizard {
  width: 275px;
}

.chip.keyword-wizard {
  margin: 4px 2px;
}

.keyword-input.keyword-wizard {
  width: 82%;
      margin: 4px 12px 12px 24px;
}

.search-within.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 225px;
      margin: 12px 0 6px 0;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  margin-top: 6px;
}

#inputChem.keyword-wizard {
  width: 82%;
      padding: 2px;
      margin: 8px 12px 12px 24px;
}

#inputChem.input-batch.keyword-wizard {
  width: 220px;
      padding: 4px;
}

#chemType.keyword-wizard {
  width: 150px;
}

.import-text.keyword-wizard {
  margin: 6px 12px 6px 24px;
      width: 220px;
}

iron-icon.help-header.keyword-wizard {
  display: none;
}

}

@media screen and (min-width: 700px) {
#wizard.keyword-wizard {
  width: 540px;
}

.chip.keyword-wizard {
  margin: 0 2px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 240px;
      margin: 12px 16px 6px 6px;
}

.cpc-inputs.keyword-wizard {
  display: inline;
}

.find-patents.keyword-wizard .keyword-input.keyword-wizard {
  width: 53%;
      margin: 4px 10px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard::placeholder,#inputAnd.keyword-wizard::placeholder,#inputExact.keyword-wizard::placeholder,#inputOr.keyword-wizard::placeholder,#inputMinus.keyword-wizard::placeholder {
  color: white;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  width: 35%;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  width: 42%;
      margin: 6px 4px;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

#inputChem.keyword-wizard {
  width: 290px;
      margin: 2px 12px 2px 6px;
}

#inputChem.input-batch.keyword-wizard {
  width: 280px;
      padding: 6px;
}

.import-text.keyword-wizard {
  margin: 6px 12px;
      width: 415px;
}

#chemType.keyword-wizard {
  width: 105px;
}

iron-icon.keyword-wizard:hover.help-header {
  cursor: default;
}

iron-icon.help-header.keyword-wizard {
  height: 16px;
      padding: 0 2px 2px 2px;
      color: #a3a3a3;
}

.help.keyword-wizard p.keyword-wizard {
  margin: 0 0 8px 0
}

.help.keyword-wizard .q.keyword-wizard {
  font-family: monospace;
      color: #0b8043;
      white-space: nowrap;
}

.help.keyword-wizard {
  z-index: 4;
      position: absolute;
      right: 10px;
      padding: 12px;
      border-radius: 2px;
      border: 1px solid #e0e0e0;
      box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.2), 0 6px 10px 0 rgba(0, 0, 0, 0.3);
      background: white;
      font-size: 13px;
      line-height: 20px;
      width: 450px;
      max-height: 400px;
      overflow: auto;
}

#withinHelp.keyword-wizard {
  top: 75px;
}

#chemHelp.keyword-wizard {
  top: 0;
}

#searchBooleanHelp.keyword-wizard {
  top: 140px;
}

}</style><!-- Shady DOM styles for bottom-bar --><style scope="bottom-bar">.fixed.bottom-bar {
  display: block;
  position: fixed;
  height: 46px;
  bottom: 0;
}

.fixed[medium].bottom-bar {
  height: 280px;
}

.fixed[large].bottom-bar {
  height: 480px;
}

.shadow.bottom-bar {
  background: white;
  padding: 16px;
  border-radius: 8px 8px 0px 0px;
  box-shadow: 0px 8px 10px 1px rgba(0,0,0,.14), 0px 3px 14px 2px rgba(0,0,0,.12), 0px 5px 5px -3px rgba(0,0,0,.2);
}

.oneline.bottom-bar {
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  cursor: pointer;
}

.button.bottom-bar {
  cursor: pointer;
}

.buttonAlign.bottom-bar {
  margin-top: -4px;
}

.header.bottom-bar {
  height: 30px;
  font-family: 'Google Sans';
  font-size: 18px;
  padding-bottom: 8px;
}

.list.bottom-bar {
  overflow-y: auto;
  line-height: 20px;
}

.definition.bottom-bar {
  padding: 0px 0px 4px 0px;
  cursor: pointer;
}

[medium].bottom-bar .content.bottom-bar {
  height: 230px;
}

[large].bottom-bar .content.bottom-bar {
  height: 430px;
}

[medium].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 200px;
}

[large].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 400px;
}

[hidden].bottom-bar {
  display: none;
}

.label.bottom-bar {
  font-family: 'Google Sans';
  font-size: 12px;
  line-height: 16px;
  font-weight: 400;
  padding: 6px 0px 4px 0px;
  color: #1f1f1f;
}

[pad].bottom-bar {
  margin-left: 16px;
}

.layout.vertical.bottom-bar {
  display: flex;
  flex-direction: column;
}

.layout.horizontal.bottom-bar {
  display: flex;
  flex-direction: row;
}

.flex.bottom-bar {
  flex: 1;
  flex-basis: 0.000000001px;
}

.layout.start.bottom-bar {
  align-items: flex-start;
}

.layout.center.bottom-bar {
  align-items: center;
}

.layout.end.bottom-bar {
  align-items: flex-end;
}

.flex-2.bottom-bar {
  flex: 2;
}

.flex-3.bottom-bar {
  flex: 3;
}

.flex-4.bottom-bar {
  flex: 4;
}

.flex-5.bottom-bar {
  flex: 5;
}

.flex-6.bottom-bar {
  flex: 6;
}

.flex-7.bottom-bar {
  flex: 7;
}

.flex-8.bottom-bar {
  flex: 8;
}

.flex-9.bottom-bar {
  flex: 9;
}

.flex-10.bottom-bar {
  flex: 10;
}

.flex-11.bottom-bar {
  flex: 11;
}

.flex-12.bottom-bar {
  flex: 12;
}</style><!-- Shady DOM styles for landscape-link --><!-- Shady DOM styles for landscape-summary-box --><!-- Shady DOM styles for search-state --><!-- Shady DOM styles for iron-overlay-backdrop --><!-- Shady DOM styles for opaque-animation --><!-- Shady DOM styles for iron-dropdown --><!-- Shady DOM styles for iron-meta --><!-- Shady DOM styles for iron-icon --><style scope="iron-icon-0">.iron-icon-0 {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;-ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;-ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
        position: relative;

        vertical-align: middle;

        fill: currentcolor;
        stroke: none;

        width: 24px;
        height: 24px;;
}

.iron-icon-0[hidden] {
  display: none;
}</style><!-- Shady DOM styles for iron-iconset-svg --><!-- Shady DOM styles for iron-list --><!-- Shady DOM styles for paper-icon-item --><!-- Shady DOM styles for paper-item-body --><!-- Shady DOM styles for paper-item --><!-- Shady DOM styles for dropdown-menu --><!-- Shady DOM styles for chips-input --><!-- Shady DOM styles for input-chip --><!-- Shady DOM styles for keyword-editor --><!-- Shady DOM styles for paper-ripple --><!-- Shady DOM styles for paper-button --><!-- Shady DOM styles for date-editor --><!-- Shady DOM styles for metadata-editor --><!-- Shady DOM styles for restrict-editor --><!-- Shady DOM styles for overlay-tooltip --><style scope="overlay-tooltip">overlay-tooltip {
  display: none;
        color: #fff;
        background-color: #000;
        padding: 10px 12px;
        border-radius: 3px;
        font-size: 13px;
        font-weight: normal;
        line-height: normal;
        position: fixed;
        z-index: 100;
}

#arrow.overlay-tooltip {
  width: 0;
        height: 0;
        border-style: solid;
        border-width: 0 6px 8px 6px;
        border-color: transparent transparent #000 transparent;
        position: absolute;
        top: -8px;
        left: calc(50% - 6px);
}</style><!-- Shady DOM styles for query-renderer --><!-- Shady DOM styles for result-nav --><style scope="result-nav">result-nav {
  display: block;
        white-space: nowrap;
        padding: 0 30px;
        line-height: 30px;
        height: 30px;
        margin-top: 17px;
        font-weight: 500;
        font-size: 15px;
}

state-modifier.result-nav {
  color: #333;
}

state-modifier[disabled].result-nav {
  pointer-events: none;
        color: #ccc;
}</style><!-- Shady DOM styles for raw-html --><!-- Shady DOM styles for paper-material --><style scope="paper-material-0">.paper-material-0 {
  display: block;
        position: relative;
}

.paper-material-0[elevation="1"] {
  box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.14),
                    0 1px 5px 0 rgba(0, 0, 0, 0.12),
                    0 3px 1px -2px rgba(0, 0, 0, 0.2);
}

.paper-material-0[elevation="2"] {
  box-shadow: 0 4px 5px 0 rgba(0, 0, 0, 0.14),
                    0 1px 10px 0 rgba(0, 0, 0, 0.12),
                    0 2px 4px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="3"] {
  box-shadow: 0 6px 10px 0 rgba(0, 0, 0, 0.14),
                    0 1px 18px 0 rgba(0, 0, 0, 0.12),
                    0 3px 5px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="4"] {
  box-shadow: 0 8px 10px 1px rgba(0, 0, 0, 0.14),
                    0 3px 14px 2px rgba(0, 0, 0, 0.12),
                    0 5px 5px -3px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="5"] {
  box-shadow: 0 16px 24px 2px rgba(0, 0, 0, 0.14),
                    0  6px 30px 5px rgba(0, 0, 0, 0.12),
                    0  8px 10px -5px rgba(0, 0, 0, 0.4);
}

.paper-material-0[animated] {
  transition: box-shadow 0.28s cubic-bezier(0.4, 0, 0.2, 1);
}

.paper-material-0 {
  ;
}</style><!-- Shady DOM styles for search-box --><style scope="search-box">.layout.horizontal.search-box,.layout.vertical.search-box {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-box {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-box {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-box {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-box {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-box {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-box,.layout.center-center.search-box {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-box,.layout.center-center.search-box {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-box {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-box {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-box {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.inputbox.search-box {
  border: 1px solid #ccc;
        padding: 0 12px;
        background: white;
}

.inputbox[focused].search-box {
  border: 1px solid #4285f4 !important;
}

.inputbox.search-box:hover {
  border: 1px solid #999;
}

#searchInput.search-box {
  font-family: inherit;
        font-size: 16px;
        padding: 8px 0;
        outline: none;
        border-right: none;
        width: 100%;
        margin-right: 0;
        border: 0;
}

#searchButton.search-box {
  cursor: pointer;
        background-color: #4285f4;
        border: none;
        color: #fff;
        vertical-align: top;
        width: 70px;
        height: 37px;
        outline: none;
}

.suggest-bg.search-box {
  display: inline-block;
        min-width: 0;
        white-space: nowrap;
}

#suggestMenu.search-box {
  position: absolute;
        margin-top: 38px;
        width: 100%;
        background: white;
        z-index: 1;
}

#suggestMenu.search-box .row.search-box {
  font-size: 13px;
        line-height: 28px;
        white-space: nowrap;
        overflow: hidden;
        text-overflow: ellipsis;
        padding: 4px 2px;
        cursor: pointer;
}

.row[selected].search-box {
  background: rgba(0, 0, 0, 0.05);
}

.suggest-icon.search-box {
  height: 20px;
        width: 20px;
        padding: 0 12px 0 6px;
        transition: transform .15s linear;
        transform: scale(1);
}

.suggest-icon[hide].search-box {
  transform: scale(0);
}

#corpora.search-box {
  padding: 6px 0;
        user-select: none;
}

#corpora.search-box iron-icon.search-box {
  height: 20px;
        width: 20px;
        color: #ccc;
        cursor: pointer;
}

#corpora.search-box iron-icon[active].search-box {
  color: #4285f4 !important;
}

#corpora.search-box iron-icon.search-box:hover {
  color: #999;
}</style><!-- Shady DOM styles for iron-media-query --><!-- Shady DOM styles for paper-header-panel --><!-- Shady DOM styles for iron-a11y-announcer --><style scope="iron-a11y-announcer">iron-a11y-announcer {
  display: inline-block;
        position: fixed;
        clip: rect(0px,0px,0px,0px);
}</style><!-- Shady DOM styles for iron-autogrow-textarea --><!-- Shady DOM styles for iron-input --><!-- Shady DOM styles for paper-input-char-counter --><!-- Shady DOM styles for paper-input-container --><!-- Shady DOM styles for paper-input-error --><!-- Shady DOM styles for paper-input --><!-- Shady DOM styles for paper-textarea --><!-- Shady DOM styles for paper-toast --><style scope="paper-toast-0">.paper-toast-0 {
  display: block;
        position: fixed;
        background-color: #323232;
        color: #f1f1f1;
        min-height: 48px;
        min-width: 288px;
        padding: 16px 24px;
        box-sizing: border-box;
        box-shadow: 0 2px 5px 0 rgba(0, 0, 0, 0.26);
        border-radius: 2px;
        margin: 12px;
        font-size: 14px;
        cursor: default;
        -webkit-transition: -webkit-transform 0.3s, opacity 0.3s;
        transition: transform 0.3s, opacity 0.3s;
        opacity: 0;
        -webkit-transform: translateY(100px);
        transform: translateY(100px);font-family: 'Roboto', 'Noto', sans-serif;
        -webkit-font-smoothing: antialiased;
}

.paper-toast-0.capsule {
  border-radius: 24px;
}

.paper-toast-0.fit-bottom {
  width: 100%;
        min-width: 0;
        border-radius: 0;
        margin: 0;
}

.paper-toast-0.paper-toast-open {
  opacity: 1;
        -webkit-transform: translateY(0px);
        transform: translateY(0px);
}</style><!-- Shady DOM styles for paper-toolbar --><!-- Shady DOM styles for search-footer --><style scope="search-footer">#footer.search-footer {
  font-size: 13px;
        margin-top: 10px;
        background: #fafafa;
        padding: 20px 10px;
        align-items: center;
        border-top: 1px solid #ebebeb;
}

#footer.search-footer .links.search-footer > *.search-footer {
  display: inline-block;
        margin: 0 12px;
}

.layout.horizontal.search-footer,.layout.vertical.search-footer {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-footer {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-footer {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-footer {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-footer {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-footer {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-footer {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-footer {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-footer {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-footer {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-footer {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-footer {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-footer {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-footer {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-footer {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-footer {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-footer {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-footer {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-footer {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-footer {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-footer {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-footer {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-footer {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-footer {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-footer {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-footer {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-header --><style scope="search-header">search-header {
  display: block;
}

.lockup-logo.search-header,.lockup-text.search-header {
  display: inline-block;
}

.lockup-logo.search-header {
  width: 74px;
        height: 24px;
        background-image: url('https://www.gstatic.com/images/branding/googlelogo/1x/googlelogo_color_74x24dp.png');
        background-size: 74px 24px;
}

.lockup-text.search-header {
  font-family: "Product Sans", Arial, Helvetica, sans-serif;

        
        font-size: 22.1px;

        
        text-rendering: optimizeLegibility;

        
        position: relative;
        top: -6px;
        left: -5px;

        
        -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
}

.lockup-brand.search-header {
  opacity: 0.54;
}

@media (-webkit-min-device-pixel-ratio: 1.5), (min-resolution: 144dpi) {
.lockup-logo.search-header {
  background-image: url('https://www.gstatic.com/images/branding/googlelogo/2x/googlelogo_color_74x24dp.png');
}

.lockup-text.search-header {
  font-size: 21.3px;
          left: -7px;
}

}

header.search-header {
  background-color: #fafafa;
        border-bottom: 1px solid #ebebeb;
        color: #333;
        height: 60px;
        width: 100%;
        z-index: 1;
        display: block;
}

[latestStyle].search-header header.search-header {
  background-color: transparent;
}

.headerpad.search-header {
  margin-left: 16px;
}

[wide].search-header .headerpad.search-header {
  margin-left: 32px;
}

.leftheader.search-header {
  width: 322px;
}

header.search-header h1.search-header {
  display: none;
}

header.search-header h1.search-header state-modifier.search-header {
  color: #777;
        text-decoration: none;
        display: inline-block;
}

[wide].search-header header.search-header h1.search-header {
  box-sizing: border-box;
        margin: 0;
        padding: 20px 0 10px;
        font-size: 20px;
        font-weight: 400;
        white-space: nowrap;
        display: block;
}

search-box.search-header {
  height: 37px;
        padding: 0 16px;
        width: 900px;
        align-self: center;
}

.layout.horizontal.search-header,.layout.vertical.search-header {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-header {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-header {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-header {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-header {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-header {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-header {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-header {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-header {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-header {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-header {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-header {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-header {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-header {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-header {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-header {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-header {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-header {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-header {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-header {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-header {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-header {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-header {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-header {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-header {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-header {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-ui --><style scope="search-ui-0">.search-ui-0 paper-button.search-ui {
  display: inline-block;
        text-align: center;
        font-family: inherit;
}

.search-ui-0 .layout.horizontal.search-ui,.search-ui-0 .layout.vertical.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.search-ui-0 .layout.inline.search-ui {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.search-ui-0 .layout.horizontal.search-ui {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.search-ui-0 .layout.vertical.search-ui {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.search-ui-0 .layout.wrap.search-ui {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.search-ui-0 .layout.no-wrap.search-ui {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .flex.search-ui {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.search-ui-0 .flex-auto.search-ui {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.search-ui-0 .flex-none.search-ui {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.search-ui-0 .layout.start.search-ui {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.end.search-ui {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.search-ui-0 .layout.baseline.search-ui {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.search-ui-0 .layout.start-justified.search-ui {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .layout.end-justified.search-ui {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.search-ui-0 .layout.around-justified.search-ui {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.search-ui-0 .layout.justified.search-ui {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.search-ui-0 .self-start.search-ui {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.search-ui-0 .self-center.search-ui {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.search-ui-0 .self-end.search-ui {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.search-ui-0 .self-stretch.search-ui {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.search-ui-0 .self-baseline.search-ui {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.search-ui-0 .layout.start-aligned.search-ui {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.search-ui-0 .layout.end-aligned.search-ui {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.search-ui-0 .layout.center-aligned.search-ui {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.search-ui-0 .layout.between-aligned.search-ui {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.search-ui-0 .layout.around-aligned.search-ui {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.search-ui-0 {
  display: block;
        min-width: 350px;
        height: 100%;
}

.search-ui-0 #content.search-ui {
  height: 100%;
}

.search-ui-0 #leftBarOverflow.search-ui {
  padding-right: 16px;
}

.search-ui-0 [wide].search-ui #leftBarOverflow.search-ui {
  overflow: auto;
}

.search-ui-0 #leftBar.search-ui {
  box-sizing: border-box;
        color: #666;
        font-size: 13px;
        padding: 16px 0 16px 16px;
        border-bottom: 1px solid #e5e5e5;
}

.search-ui-0 [wide].search-ui #leftBar.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;

        -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
        position: relative;
        width: 350px;
        margin-bottom: 0;
        padding-bottom: 0;
        border-bottom: none;
}

@media print {
.search-ui-0 #leftBar.search-ui {
  display: none !important;
}

}

.search-ui-0 #leftBar.search-ui h3.search-ui {
  text-transform: uppercase;
        font-size: 13px;
        font-weight: normal;
        margin-top: 6px;
        margin-bottom: 6px;
        cursor: default;
        display: inline-block;
        color: #a3a3a3;
}

.search-ui-0 #closeButton.search-ui {
  position: absolute;
        right: 0;
}

.search-ui-0 #searchTermsHeader.search-ui {
  position: relative;
}

.search-ui-0 #searchTermsQ.search-ui iron-icon.search-ui {
  height: 16px;
        padding: 0 2px 2px 2px;
        color: #a3a3a3;
}

.search-ui-0 #searchTermsHeader.search-ui:hover iron-icon.search-ui {
  color: #4285f4;
}

.search-ui-0 #closeLeftBar.search-ui {
  height: 16px;
        width: 16px;
        padding: 0 0 8px 0;
        cursor: pointer;
}

.search-ui-0 #compactQuery.search-ui iron-icon.search-ui {
  height: 20px;
}

.search-ui-0 #backToResultsButton.search-ui {
  color: #fff;
        background: #4285f4;
        margin-top: 20px;
        text-align: center;
}

.search-ui-0 #main.search-ui {
  display: block;
        min-height: calc(100vh - 127px);
}

@media print {
.search-ui-0 [wide].search-ui main.search-ui {
  margin-left: 0;
}

}</style><!-- Shady DOM styles for import-list --><!-- Shady DOM styles for iron-request --><!-- Shady DOM styles for iron-ajax --><!-- Shady DOM styles for paper-dialog --><!-- Shady DOM styles for coverage-stats --><!-- Shady DOM styles for iron-image --><!-- Shady DOM styles for iron-selector --><!-- Shady DOM styles for paper-card --><!-- Shady DOM styles for paper-checkbox --><!-- Shady DOM styles for landing-page --><!-- Shady DOM styles for remote-fetch --><!-- Shady DOM styles for paper-spinner --><style scope="paper-spinner-0">.paper-spinner-0 {
  display: inline-block;
        position: relative;
        width: 28px;
        height: 28px;
}

.paper-spinner-0 #spinnerContainer.paper-spinner {
  width: 100%;
        height: 100%;

        
        direction: ltr;
}

.paper-spinner-0 #spinnerContainer.active.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite;
        animation: container-rotate-paper-spinner-0 1568ms linear infinite;
}

@-webkit-keyframes container-rotate-paper-spinner-0 {
to {
  -webkit-transform: rotate(360deg)
}

}

@keyframes container-rotate-paper-spinner-0 {
to {
  transform: rotate(360deg)
}

}

.paper-spinner-0 .spinner-layer.paper-spinner {
  position: absolute;
        width: 100%;
        height: 100%;
        opacity: 0;
        white-space: nowrap;
        color: #4285f4;
}

.paper-spinner-0 .layer-1.paper-spinner {
  color: #4285f4;
}

.paper-spinner-0 .layer-2.paper-spinner {
  color: #db4437;
}

.paper-spinner-0 .layer-3.paper-spinner {
  color: #f4b400;
}

.paper-spinner-0 .layer-4.paper-spinner {
  color: #0f9d58;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0;
        -webkit-animation-duration: 5332ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-name: fill-unfill-rotate-paper-spinner-0;
        animation-duration: 5332ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
        opacity: 1;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-1.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-2.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-3.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-4.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
}

@-webkit-keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  -webkit-transform: rotate(135deg)
}

25% {
  -webkit-transform: rotate(270deg)
}

37.5% {
  -webkit-transform: rotate(405deg)
}

50% {
  -webkit-transform: rotate(540deg)
}

62.5% {
  -webkit-transform: rotate(675deg)
}

75% {
  -webkit-transform: rotate(810deg)
}

87.5% {
  -webkit-transform: rotate(945deg)
}

to {
  -webkit-transform: rotate(1080deg)
}

}

@keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  transform: rotate(135deg)
}

25% {
  transform: rotate(270deg)
}

37.5% {
  transform: rotate(405deg)
}

50% {
  transform: rotate(540deg)
}

62.5% {
  transform: rotate(675deg)
}

75% {
  transform: rotate(810deg)
}

87.5% {
  transform: rotate(945deg)
}

to {
  transform: rotate(1080deg)
}

}

@-webkit-keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@-webkit-keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

.paper-spinner-0 .circle-clipper.paper-spinner {
  display: inline-block;
        position: relative;
        width: 50%;
        height: 100%;
        overflow: hidden;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after {
  left: 45%;
        width: 10%;
        border-top-style: solid;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after,.paper-spinner-0 .circle-clipper.paper-spinner::after {
  content: '';
        box-sizing: border-box;
        position: absolute;
        top: 0;
        border-width: 3px;
        border-radius: 50%;
}

.paper-spinner-0 .circle-clipper.paper-spinner::after {
  bottom: 0;
        width: 200%;
        border-style: solid;
        border-bottom-color: transparent !important;
}

.paper-spinner-0 .circle-clipper.left.paper-spinner::after {
  left: 0;
        border-right-color: transparent !important;
        -webkit-transform: rotate(129deg);
        transform: rotate(129deg);
}

.paper-spinner-0 .circle-clipper.right.paper-spinner::after {
  left: -100%;
        border-left-color: transparent !important;
        -webkit-transform: rotate(-129deg);
        transform: rotate(-129deg);
}

.paper-spinner-0 .active.paper-spinner .gap-patch.paper-spinner::after,.paper-spinner-0 .active.paper-spinner .circle-clipper.paper-spinner::after {
  -webkit-animation-duration: 1333ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-duration: 1333ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.left.paper-spinner::after {
  -webkit-animation-name: left-spin-paper-spinner-0;
        animation-name: left-spin-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.right.paper-spinner::after {
  -webkit-animation-name: right-spin-paper-spinner-0;
        animation-name: right-spin-paper-spinner-0;
}

@-webkit-keyframes left-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(130deg)
}

50% {
  -webkit-transform: rotate(-5deg)
}

to {
  -webkit-transform: rotate(130deg)
}

}

@keyframes left-spin-paper-spinner-0 {
0% {
  transform: rotate(130deg)
}

50% {
  transform: rotate(-5deg)
}

to {
  transform: rotate(130deg)
}

}

@-webkit-keyframes right-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(-130deg)
}

50% {
  -webkit-transform: rotate(5deg)
}

to {
  -webkit-transform: rotate(-130deg)
}

}

@keyframes right-spin-paper-spinner-0 {
0% {
  transform: rotate(-130deg)
}

50% {
  transform: rotate(5deg)
}

to {
  transform: rotate(-130deg)
}

}

.paper-spinner-0 #spinnerContainer.cooldown.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
        animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
}

@-webkit-keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}</style><!-- Shady DOM styles for paper-spinner-lite --><!-- Shady DOM styles for concept-card --><!-- Shady DOM styles for concept-mention --><style scope="concept-mention">.block.concept-mention {
  display: block;
}

[hidden].concept-mention {
  display: none !important;
}

.invisible.concept-mention {
  visibility: hidden !important;
}

.relative.concept-mention {
  position: relative;
}

.fit.concept-mention {
  position: absolute;
        top: 0;
        right: 0;
        bottom: 0;
        left: 0;
}

body.fullbleed.concept-mention {
  margin: 0;
        height: 100vh;
}

.scroll.concept-mention {
  -webkit-overflow-scrolling: touch;
        overflow: auto;
}

.fixed-bottom.concept-mention,.fixed-left.concept-mention,.fixed-right.concept-mention,.fixed-top.concept-mention {
  position: fixed;
}

.fixed-top.concept-mention {
  top: 0;
        left: 0;
        right: 0;
}

.fixed-right.concept-mention {
  top: 0;
        right: 0;
        bottom: 0;
}

.fixed-bottom.concept-mention {
  right: 0;
        bottom: 0;
        left: 0;
}

.fixed-left.concept-mention {
  top: 0;
        bottom: 0;
        left: 0;
}

#target.concept-mention:hover {
  background-color: #e8f0fe;
}

#target[noicon].concept-mention {
  padding: 1px;
}

#target.concept-mention:hover[noicon] {
  border: 1px solid #e8f0fe;
        padding: 0;
}

#target.concept-mention {
  display: inline-block;
}

.inline-icon.concept-mention {
  cursor: pointer;
        height: 12px;
        width: 12px;
        padding-left: 4px;
        color: #5e6368;
}

concept-card.concept-mention {
  z-index: 1;
        position: absolute;
}</style><!-- Shady DOM styles for fterm-concept-card --><!-- Shady DOM styles for fterm-concept-mention --><!-- Shady DOM styles for paper-fab --><!-- Shady DOM styles for paper-icon-button --><!-- Shady DOM styles for paper-icon-button-light --><!-- Shady DOM styles for classification-tree --><style scope="classification-tree">.layout.horizontal.classification-tree,.layout.vertical.classification-tree {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.classification-tree {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.classification-tree {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.classification-tree {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.classification-tree {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.classification-tree {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.classification-tree {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.classification-tree {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.classification-tree {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

classification-tree {
  display: block;
        line-height: 20px;
}

.wrap.classification-tree {
  padding: 6px 12px;
}

.wrap.classification-tree:hover {
  background: #fafafa;
}

.description.classification-tree {
  padding-left: 4px;
}

iron-icon.classification-tree {
  color: #eaeaea;
}

.code[first].classification-tree {
  font-weight: 500;
}

.code[additional].classification-tree {
  font-style: italic;
}</style><!-- Shady DOM styles for classification-viewer --><style scope="classification-viewer">.table.classification-viewer {
  border: 1px solid #eaeaea;
        display: block;
}

.more.classification-viewer {
  padding: 6px 12px;
        cursor: pointer;
        font-style: italic;
        color: #aaa;
}

.more.classification-viewer:hover {
  background: #fafafa;
}

.chip.classification-viewer {
  display: inline-block;
        padding: 4px 6px;
        border-radius: 2px;
}

.chip[additional].classification-viewer {
  font-style: italic;
}</style><!-- Shady DOM styles for image-carousel --><style scope="image-carousel">image-carousel {
  display: block;
}

.thumbnails.image-carousel {
  display: block;
        background-color: transparent;
        padding: 7px;
        white-space: nowrap;
        overflow: auto;
        font-size: 0;
}

.thumbnails.image-carousel img.image-carousel {
  margin-right: 7px;
        cursor: zoom-in;
}

.thumbnails.image-carousel img[selected].image-carousel {
  outline: solid 3px #4285f4;
}

.thumbnails.image-carousel img.image-carousel:last-of-type {
  margin-right: 0;
}</style><!-- Shady DOM styles for image-viewer --><!-- Shady DOM styles for patent-result --><style scope="patent-result">#wrapper.patent-result {
  padding: 20px;
        max-width: 1050px;
        outline: 0;
}

.scroll-target.patent-result:before {
  display: block;
        content: '';
        visibility: hidden;
}

h1.patent-result {
  font-weight: 500;
        font-size: 20px;
        margin: 0 0 20px 0;
}

h3.patent-result {
  font-size: 15px;
        font-weight: 500;
        margin: 28px 0 18px 0;
}

dl.patent-result {
  line-height: 1.5;
        font-size: 0;
}

dt.patent-result,dd.patent-result {
  display: inline;
        font-size: 13px;
        margin: 0;
}

dt.patent-result {
  font-weight: 500;
        color: #000;
}

dt.patent-result::after {
  content: ': ';
}

dd.patent-result {
  color: #aaa;
}

dd.patent-result ~ dd.patent-result::before {
  content: ', ';
}

dt.patent-result + dd.patent-result::before {
  content: '';
}

dd.patent-result ~ dt.patent-result::before {
  display: block;
        content: '';
        margin-top: 8px;
}

dd.patent-result core-icon.patent-result {
  width: 14px;
        height: 14px;
        vertical-align: top;
        color: inherit;
}

.table.patent-result {
  display: table;
        border-collapse: collapse;
        border-spacing: 0;
        border: 1px solid #eaeaea;
        width: 100%;
        box-sizing: border-box;
}

.tr.patent-result {
  display: table-row;
        border-bottom: 1px solid #eaeaea;
}

.th.patent-result,.td.patent-result {
  display: table-cell;
        padding: 10px 12px;
}

.thead.patent-result {
  display: table-header-group;
}

.tbody.patent-result {
  display: table-row-group;
}

.th.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.td.patent-result {
  vertical-align: top;
}

.td.patent-result > p.patent-result {
  margin-top: 0;
}

.nowrap.patent-result {
  white-space: nowrap;
}

.knowledge-card.patent-result {
  border: 1px solid #e5e5e5;
        border-radius: 2px;
}

.knowledge-card.patent-result > header.patent-result {
  -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
        background: #4285f4;
        color: #fff;
        padding: 20px 12px;
}

.knowledge-card.patent-result > header.patent-result state-modifier.patent-result,.knowledge-card.patent-result > header.patent-result a.patent-result {
  color: inherit;
        margin: 0 12px 0 0;
        display: inline-block;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result,.knowledge-card.patent-result > header.patent-result .tagline.patent-result {
  margin: 0;
        font-weight: normal;
        padding-top: 4px;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result {
  font-size: 20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result {
  background: #3367d6;
        padding: 10px 12px;
        margin: 20px -12px -20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result core-icon.patent-result {
  margin-right: 12px;
        width: 24px;
        height: 24px;
}

.knowledge-card.patent-result dl.patent-result {
  padding: 16px 12px;
}

.knowledge-card.patent-result hr.patent-result {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 0;
}

.main-link.patent-result {
  margin: 14px;
        font-weight: 500;
}

.footer.patent-result h3.patent-result state-modifier.patent-result,.footer.patent-result h3.patent-result a.patent-result {
  float: right;
        font-weight: 400;
        font-size: 13px;
        line-height: 24px;
}

.footer.patent-result dl.patent-result {
  margin-left: 30px;
}

.footer.patent-result > ul.patent-result > li.patent-result {
  margin-bottom: 8px;
}

h3.patent-result .righthead.patent-result {
  color: #aaa;
        font-weight: 400;
        font-size: 13px;
        cursor: help;
}

.tooltip-hint.patent-result {
  border-bottom: 1px dotted #ccc;
}

[marginRight].patent-result {
  margin-right: 60px;
}

.flex-width.patent-result {
  min-width: 0;
        word-break: break-word;
}

.responsive-table.patent-result {
  width: 100%;
        overflow-x: auto;
        overflow-y: hidden;
}

.layout.horizontal.patent-result,.layout.vertical.patent-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.flex.patent-result,.flex-1.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-2.patent-result {
  -ms-flex: 2;
        -webkit-flex: 2;
        flex: 2;
}

.flex-3.patent-result {
  -ms-flex: 3;
        -webkit-flex: 3;
        flex: 3;
}

.flex-4.patent-result {
  -ms-flex: 4;
        -webkit-flex: 4;
        flex: 4;
}

.flex-5.patent-result {
  -ms-flex: 5;
        -webkit-flex: 5;
        flex: 5;
}

.flex-6.patent-result {
  -ms-flex: 6;
        -webkit-flex: 6;
        flex: 6;
}

.flex-7.patent-result {
  -ms-flex: 7;
        -webkit-flex: 7;
        flex: 7;
}

.flex-8.patent-result {
  -ms-flex: 8;
        -webkit-flex: 8;
        flex: 8;
}

.flex-9.patent-result {
  -ms-flex: 9;
        -webkit-flex: 9;
        flex: 9;
}

.flex-10.patent-result {
  -ms-flex: 10;
        -webkit-flex: 10;
        flex: 10;
}

.flex-11.patent-result {
  -ms-flex: 11;
        -webkit-flex: 11;
        flex: 11;
}

.flex-12.patent-result {
  -ms-flex: 12;
        -webkit-flex: 12;
        flex: 12;
}

@media print {
#text.patent-result {
  flex-direction: column-reverse !important;
}

}

patent-result-ref-list.patent-result {
  width: 100%;
}

patent-result-ref-list.patent-result + patent-result-ref-list.patent-result {
  margin-left: 10px;
}

[narrow].patent-result {
  flex-direction: column-reverse !important;
}

.famheader.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.collapse.patent-result {
  color: #616161;
        font-size: 13px;
        cursor: pointer;
}

#imageDrag.patent-result {
  position: fixed;
        cursor: col-resize;
}

#imageDrag.patent-result div.patent-result {
  width: 4px;
        height: 100%;
        margin: 0 4px;
        background: #eee;
}

#imageDrag.patent-result:hover {
  background: #eee;
}

#imageDrag.patent-result:hover div.patent-result {
  background: #ccc;
}

.imageWrapper.patent-result {
  position: fixed;
        top: 60px;
        background: white;
        margin-left: 12px;
}

#notices.patent-result {
  padding: 20px;
}

#figures.patent-result {
  background: #efefef;
}

.headerButton.patent-result {
  color: #3c80f6;
        cursor: pointer;
        display: inline-block;
        padding: 0 14px;
        line-height: 27px;
}

.headerButton.patent-result iron-icon.patent-result {
  width: 16px;
        height: 16px;
}

.tr.conceptDomain.patent-result {
  display: table-row;
}

.responsive-grid.patent-result {
  display: grid;
        gap: 8px;
        grid-template-columns: none;
}</style><!-- Shady DOM styles for family-viewer --><!-- Shady DOM styles for app-row --><!-- Shady DOM styles for application-timeline --><style scope="application-timeline">.layout.horizontal.application-timeline,.layout.vertical.application-timeline {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.application-timeline {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.application-timeline {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.application-timeline {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.application-timeline {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.application-timeline {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.application-timeline {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.application-timeline {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.application-timeline {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.wrap.application-timeline {
  padding: 16px 12px;
}

.event.application-timeline {
  padding: 3px 0;
}

[date].application-timeline {
  color: #5f6368;
        font-size: 13px;
        padding: 3px 0;
        width: 70px;
        line-height: 16px;
}

[critical].application-timeline [date].application-timeline {
  color: #202124;
        font-weight: 500;
        line-height: 18px;
}

.line.application-timeline {
  margin: 9px 6px;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
}

.dot.application-timeline {
  margin: 3px 0;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
        display: inline-block;
}

[critical].application-timeline .line.application-timeline {
  background: #4285f4;
}

[current].application-timeline .line.application-timeline {
  background: #81c995;
}

[current][critical].application-timeline .line.application-timeline {
  background: #81c995;
}

.title.application-timeline {
  font-size: 13px;
        padding: 3px 0;
        line-height: 16px;
}

.title-text.application-timeline {
  color: #5f6368;
}

.description-item.application-timeline {
  font-size: 12px;
        padding: 6px 0;
        max-width: 300px;
}

#legal.application-timeline {
  height: 14px;
        width: 14px;
        padding: 0 3px 1px 3px;
        vertical-align: text-bottom;
}

#icon.application-timeline {
  height: 12px;
        width: 12px;
        padding: 0 3px 3px 3px;
        vertical-align: text-bottom;
}

.unknown.application-timeline {
  font-style: italic;
}

.not_active.application-timeline {
  text-decoration: line-through;
}

.active.application-timeline {
  font-weight: 500;
}

#cc[this].application-timeline {
  color: #202124 !important;
        text-decoration: underline;
}

#cc[this].not_active.application-timeline {
  text-decoration: line-through underline;
}

hr.application-timeline {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 10px 0 16px 0;
}

.header.application-timeline {
  font-size: 13px;
        line-height: 20px;
        font-weight: 500;
        color: #202124;
        padding-bottom: 8px;
}

.block.application-timeline {
  padding: 0 6px 0 0;
}

.year.application-timeline {
  color: #5f6368;
        font-size: 13px;
        font-weight: 500;
        padding: 3px 1px;
        width: 70px;
}

.expand.application-timeline {
  cursor: pointer;
        padding: 6px 0 3px 0;
}</style><!-- Shady DOM styles for patent-text --><style scope="patent-text">.layout.horizontal.patent-text,.layout.vertical.patent-text {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-text {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-text {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-text {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-text {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-text {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-text {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-text {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-text {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-text {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-text {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-text {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-text {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-text {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-text {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-text {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-text {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-text {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-text {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-text {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-text {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-text {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-text {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-text {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-text {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-text {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

patent-text {
  display: block;
}

#text.patent-text {
  line-height: 20px;
        min-width: 0;
}

#margin.patent-text {
  width: 16px;
}

#createHighlight.patent-text {
  position: relative;
        width: 16px;
        height: 16px;
        cursor: pointer;
}

.notranslate.patent-text > .google-src-text.patent-text {
  display: none;
}

.notranslate.patent-text:hover,mark.patent-text {
  background-color: #fbfcae;
}

.description-paragraph.patent-text {
  margin-block-start: 1em;
        margin-block-end: 1em;
}

.claim-text.patent-text {
  margin: 14px 0 0 20px;
}

.claim-dependent.patent-text {
  margin-left: 40px;
        color: #888;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim-text.patent-text {
  height: 0;
        width: 0;
        visibility: hidden;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim.patent-text:after {
  content: ""
}

.patent-full-image.patent-text {
  max-width: 100%;
        height: auto;
}

.small-patent-image.patent-text {
  display: inline;
}

ul.patent-text {
  padding: 0 0 0 50px;
}

li.patent-text {
  list-style-type: none;
        position: relative;
}

ol.claims.patent-text li.patent-text {
  list-style-type: decimal;
        font-weight: bold;
}

ol.claims.patent-text li.patent-text > *.patent-text {
  font-weight: normal;
}

li.patent-text > para-num.patent-text {
  position: absolute;
        left: -45px;
        color: #888;
}

mark.patent-text {
  background: #fff59d;
}

mark.searchText.patent-text {
  background: #80deea;
}

.searchTextHeader.patent-text {
  font-weight: 500;
}

pre.patent-text {
  white-space: pre-wrap;
}

heading.patent-text {
  display: block;
        font-weight: 500;
        font-size: 13px;
}

#comment.patent-text {
  width: 16px;
        height: 16px;
}

[has-search][no-results].patent-text {
  display: none;
}

.highlight.patent-text {
  background-color: #fef7e0;
}</style><!-- Shady DOM styles for para-num --><!-- Shady DOM styles for result-container --><style scope="result-container">paper-spinner.result-container {
  position: absolute;
        
        top: calc(50%  + 56px - 16px);
        left: calc(50% + 175px - 16px);
}</style><!-- Shady DOM styles for scholar-result --><!-- Shady DOM styles for search-result --><style scope="search-result">.layout.horizontal.search-result,.layout.vertical.search-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

search-result {
  display: block;
        font-size: 13px;
}

#mainContainer.search-result {
  min-height: calc(100vh - 127px);
        color: #333;
}

#compactQuery.search-result {
  padding: 18px 20px 10px 20px;
        cursor: pointer;
}

#compactQuery.search-result > span.search-result {
  padding: 0 14px 0 0;
}

#compactQuery.search-result iron-icon.search-result {
  padding-right: 6px;
        height: 16px;
        width: 16px;
}</style><!-- Shady DOM styles for webdoc-result --><!-- Shady DOM styles for iron-pages --><!-- Shady DOM styles for paper-tab --><!-- Shady DOM styles for paper-tabs --><!-- Shady DOM styles for debug-info --><!-- Shady DOM styles for search-paging --><!-- Shady DOM styles for search-result-item --><!-- Shady DOM styles for search-result-image --><!-- Shady DOM styles for search-result-entities --><!-- Shady DOM styles for search-result-measures --><!-- Shady DOM styles for search-results --><!-- Shady DOM styles for summary-box --><!-- Shady DOM styles for timeline-page --><!-- Shady DOM styles for iron-localstorage --><!-- Shady DOM styles for search-app --><style scope="search-app">search-app {
  display: block;
        height: 100%;
}

#toast.search-app {
  min-height: 64px;
        min-width: 742px;
}</style><style>body {transition: opacity ease-in 0.2s; } 
body[unresolved] {opacity: 0; display: block; overflow: hidden; position: relative; } 
</style>
    <title>US8097423B2 - MN/CA IX and breast cancer therapy 
        - Google Patents</title>

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="UTF-8">
    <meta name="referrer" content="origin-when-crossorigin">
    <link rel="canonical" href="https://patents.google.com/patent/US8097423B2/en">
    <meta name="description" content="
     Herein disclosed are methods that are predictive of resistance to endocrine therapy in an estrogen receptor-positive (ER-positive) breast cancer patient. An exemplary method comprises detecting the overexpression of MN/CA9 gene expression product(s) in a sample from an affected subject, wherein if MN/CA9 is overexpressed, then the subject is considered to have a greater probability of resistance to endocrine therapy, particularly tamoxifen, and a corresponding poorer prognosis if undergoing endocrine therapy, than if MN/CA9 is not overexpressed. MN/CA9 gene expression products useful in the predictive/prognostic methods include MN/CA IX, MN proteins/polypeptides, MN nucleic acids and soluble MN/CA IX antigen (s-CA IX). The methods are useful as an aid in the selection of treatment for a patient with an ER-positive breast tumor. The methods of the invention can be used, for example, to identify those patients requiring additional/alternative therapies, preferably, but not necessarily, therapies that are not affected by acidic pH. The methods also comprise the use of diagnostic/prognostic imaging to detect MN/CA IX in a patient tumor, wherein the presence of MN/CA IX in one or more tumors is indicative of probable resistance to antiestrogen therapy, particularly to tamoxifen. 
   
   ">
    <meta name="DC.type" content="patent">
    <meta name="DC.title" content="MN/CA IX and breast cancer therapy 
       ">
    <meta name="DC.date" content="2008-07-29" scheme="dateSubmitted">
    <meta name="DC.description" content="
     Herein disclosed are methods that are predictive of resistance to endocrine therapy in an estrogen receptor-positive (ER-positive) breast cancer patient. An exemplary method comprises detecting the overexpression of MN/CA9 gene expression product(s) in a sample from an affected subject, wherein if MN/CA9 is overexpressed, then the subject is considered to have a greater probability of resistance to endocrine therapy, particularly tamoxifen, and a corresponding poorer prognosis if undergoing endocrine therapy, than if MN/CA9 is not overexpressed. MN/CA9 gene expression products useful in the predictive/prognostic methods include MN/CA IX, MN proteins/polypeptides, MN nucleic acids and soluble MN/CA IX antigen (s-CA IX). The methods are useful as an aid in the selection of treatment for a patient with an ER-positive breast tumor. The methods of the invention can be used, for example, to identify those patients requiring additional/alternative therapies, preferably, but not necessarily, therapies that are not affected by acidic pH. The methods also comprise the use of diagnostic/prognostic imaging to detect MN/CA IX in a patient tumor, wherein the presence of MN/CA IX in one or more tumors is indicative of probable resistance to antiestrogen therapy, particularly to tamoxifen. 
   
   ">
    <meta name="citation_patent_application_number" content="US:12/181,951">
    <meta name="citation_pdf_url" content="https://patentimages.storage.googleapis.com/9e/ce/c9/4d226a3f0713ac/US8097423.pdf">
    <meta name="citation_patent_number" content="US:8097423">
    <meta name="DC.date" content="2012-01-17" scheme="issue">
    <meta name="DC.contributor" content="Adrian L. Harris" scheme="inventor">
    <meta name="DC.contributor" content="Institute of Virology (Slovak Academy of Science)" scheme="assignee">
    <meta name="DC.relation" content="WO:1993018152:A1" scheme="references">
    <meta name="DC.relation" content="US:5387676" scheme="references">
    <meta name="DC.relation" content="US:5989838" scheme="references">
    <meta name="DC.relation" content="US:6004535" scheme="references">
    <meta name="DC.relation" content="WO:1995034650:A2" scheme="references">
    <meta name="DC.relation" content="US:20080138345:A1" scheme="references">
    <meta name="DC.relation" content="WO:2003100029:A2" scheme="references">
    <meta name="citation_reference" content="Bartosova et al., &quot;Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2,&quot; Journal of Pathology, 197: 314-321 (2002)." scheme="references">
    <meta name="citation_reference" content="Bottini et al., &quot;Cytotoxic and antiproliferative activity of the single agent epirubicin versus eprirbicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial ,&quot; Endocrine-Related Cancer, 12: 383-392 (2005)." scheme="references">
    <meta name="citation_reference" content="Bottini et al., &quot;p53 but not bcl-2 Immunostaining Is Predictive of Poor Clinical Complete Response to Primary Chemotherapy in Breast Cancer Patients,&quot; Clinical Cancer Research, 6: 2751-2758 (Jul. 2000)." scheme="references">
    <meta name="citation_reference" content="Brennan et al., &quot;CA IX is an Independent Prognostic Marker in Premenopausal Breast Cancer Patients with One to Three Positive Lymph Nodes and a Putative Marker of Radiation Resistance,&quot; Clinical Cancer Research, 12(21):6412-6431 (Nov. 1, 2006)." scheme="references">
    <meta name="citation_reference" content="Chia et al., &quot;Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma,&quot; Journal of Clinical Oncology, 19(16): 3660-3668 (Aug. 15, 2001)." scheme="references">
    <meta name="citation_reference" content="Chia, et al., &quot;Carbonic anhydrase IX (CA IX) is an independent poor prognostic factor in early stage breast cancer: results from a large population-based tissue microarray (TMA) series,&quot; Breast Cancer Research and Treatment, 88(Supp. 1): S116-S117, Abstract 3015 (2004)." scheme="references">
    <meta name="citation_reference" content="Colpaert et al., &quot;The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis,&quot; Breast Cancer Research and Treatment, 81: 137-147 (2003)." scheme="references">
    <meta name="citation_reference" content="Cooper et al., &quot;Intermittent Hypoxia Induces Proteasome-Dependent Down-Regulation of Estrogen Receptor Alpha in Human Breast Carcinoma,&quot; Clinical Cancer Research, 10: 8720-8727 (Dec. 15, 2004)." scheme="references">
    <meta name="citation_reference" content="Coradini et al., &quot;Hypoxia and estrogen receptor profile influence the responsiveness of human breast cancer cells to estradiol and antiestrogens,&quot; Cellular and Molecular Life Sciences, 61: 76-82 (2004)." scheme="references">
    <meta name="citation_reference" content="Dowsett et al., &quot;Response to specific antioestrogen (IC1182780) in tamoxifen-resistant breast cancer,&quot; Lancet, 345: 525 (Feb. 25, 1995)." scheme="references">
    <meta name="citation_reference" content="Generali et al, &quot;Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer,&quot; Endocrine-Related Cancer, 13(3): 921-930 (Sep. 2006)." scheme="references">
    <meta name="citation_reference" content="Generali et al., &quot;Hypoxia-Inducible Factor-1alpha Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer,&quot; Clin. Cancer Res., 12(15): 4562-4568 (Aug. 1, 2006)." scheme="references">
    <meta name="citation_reference" content="Generali et al., &quot;Regulation of Hepatocyte Growth Factor Activator Inhibitor 2 by Hypoxia in Breast Cancer,&quot; Clin. Cancer Res., 13(2 Pt 1): 550-8 (Jan. 15, 2007)." scheme="references">
    <meta name="citation_reference" content="Gerweck, L.E., &quot;Tumor pH: Implications for Treatment and Novel Drug Design,&quot; Seminars in Radiation Oncology, 8(3): 176-182 (1998)." scheme="references">
    <meta name="citation_reference" content="Harris, A.L., &quot;Hypoxia-A Key Regulatory Factor in Tumour Growth,&quot; Nature Reviews Cancer, 2: 38-47 (Jan. 2002)." scheme="references">
    <meta name="citation_reference" content="Hornberger et al., &quot;Economic Analysis of Targeting Chemotherapy Using a 21-Gene RT-PCT Assay in Lymph-Node-Negative, Estrogen-Receptor-Positive, Early-Stage Breast Cancer,&quot; American Journal of Managed Care, 11(5): 313-324 (2005)." scheme="references">
    <meta name="citation_reference" content="Hussain et al., &quot;Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer,&quot; British Journal of Cancer, 96(1): 104-109 (Jan. 15, 2007)." scheme="references">
    <meta name="citation_reference" content="Leek et al., &quot;Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast,&quot; British Journal of Cancer, 79(5/6): 991-995 (1999)." scheme="references">
    <meta name="citation_reference" content="Lyman et al., &quot;Impact of a 21-Gene RT-PCR Assay on Treatment Decisions in Early-Stage Breast Cancer,&quot; Cancer, 109(6): 1011-1018 (Mar. 15, 2007)." scheme="references">
    <meta name="citation_reference" content="Paik, et al., &quot;Multi-gene RT-PCR assay for Predicting recurrence in node negative breast cancer patients-NSABP studies B-20 and B-14,&quot; Breast Cancer Research Treatment., 82: S10 (2003)." scheme="references">
    <meta name="citation_reference" content="Pastorekova and Zavada, &quot;Carbonic anhydrase IX (CA IX) as a potential target for cancer therapy,&quot; Cancer Therapy, 2: 245-262 (2004)." scheme="references">
    <meta name="citation_reference" content="Pastorekova et al., &quot;A Novel Quasi-Viral Agent, MaTu, Is a Two-Component System,&quot; Virology, 187: 620-626 (1992)." scheme="references">
    <meta name="citation_reference" content="Potter and Harris, &quot;Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer,&quot; British Journal of Cancer, 89: 2-7 (2003)." scheme="references">
    <meta name="citation_reference" content="Raghunand and Gillies, &quot;pH and chemotherapy,&quot; Novartis Foundation Symposium, 240: 199-211 (discussion 265-268) (2001)." scheme="references">
    <meta name="citation_reference" content="Raghunand et al., &quot;Enhancement of chemotherapy by manipulation of tumour pH,&quot; British Journal of Cancer, 80(17): 1005-1011 (1999)." scheme="references">
    <meta name="citation_reference" content="Robertson et al., &quot;Role of Carbonic Anhydrase IX in Human Tumor Cell Growth, Survival, and Invasion,&quot; Cancer Res., 64(17): 6160-6165 (Sep. 1, 2004)." scheme="references">
    <meta name="citation_reference" content="Sargent and Allegra, &quot;Issues in Clinical Trial Design for Tumor Marker Studies,&quot; Seminars in Oncology, 29(3): 222-230 (Jun. 2002)." scheme="references">
    <meta name="citation_reference" content="Span et al., &quot;Carbonic anhydrase IX expression is more predictive than prognostic in breast cancer,&quot; British Journal of Cancer, 96(8): 1309 (Apr. 23, 2007)." scheme="references">
    <meta name="citation_reference" content="Span et al., &quot;Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome,&quot; British Journal of Cancer, 89: 271-276 (2003)." scheme="references">
    <meta name="citation_reference" content="Svastova et al. &quot;Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH,&quot; FEBS Letters, 577: 439-445 (2004)." scheme="references">
    <meta name="citation_reference" content="Tockman et al., &quot;Considerations in Bringing a Cancer Biomarker to Clinical Application &quot; Cancer Research (Suppl.), 52: 2711s-2718s (May 1, 1992)." scheme="references">
    <meta name="citation_reference" content="Tomes et al., &quot;Necrosis and hypoxia in invasive breast carcinoma,&quot; Breast Cancer Research and Treatment, 81(1): 61-69 (Sep. 2003)." scheme="references">
    <meta name="citation_reference" content="Trastour et al., &quot;HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome,&quot; Int. J. Cancer, 120(7): 1451-1458 (Apr. 1, 2007)." scheme="references">
    <meta name="citation_reference" content="Vleugel et al., &quot;Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer,&quot; Journal of Clinical Pathology, 58(2): 172-177 (Feb. 2005)." scheme="references">
    <meta name="citation_reference" content="Wykoff et al., &quot;Expression of the Hypoxia-Inducible and Tumor-Associated Carbonic Anhydrases in Ductal Carcinoma in Situ of the Breast,&quot; American Journal of Pathology, 158(3): 1011-1019 (2001)." scheme="references">
    <meta name="citation_reference" content="Wykoff et al., &quot;Hypoxia-Inducible Expression of Tumor-Associated Carbonic Anhydrases,&quot; Cancer Research, 60: 7075-7083 (Dec. 15. 2000)." scheme="references">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,400italic,500,500italic,700">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Product+Sans">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700">

    <style>
      body { transition: none; }
    </style>

    <script src="https://apis.google.com/_/scs/abc-static/_/js/k=gapi.lb.en.IKZeRvoAYNY.O/m=client/rt=j/sv=1/d=1/ed=1/am=AAAQ/rs=AHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw/cb=gapi.loaded_0?le=scs" async=""></script><script>
      window.version = 'patent-search.search_20240531_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    </script>

    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/webcomponentsjs/webcomponents-lite.min.js"></script>
    <style>[hidden]:not([style-scope]):not(.style-scope) {
  display: none !important;
}

</style><style></style><style></style><style></style><style></style><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,300,300italic,400italic,500,500italic,700,700italic"><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto+Mono:400,700"><style></style><style></style><style>
  html, body {
    min-width: 100%;
    width: 100%;
    min-height: 100%;
    height: 100%;
  }

  body {
    background-color: #fff;
    font-family: 'Roboto', sans-serif;
    color: #333;
    margin: 0;
    padding: 0;
    /*
     * Turn off https://github.com/WICG/ScrollAnchoring/blob/master/explainer.md
     * https://memegen.googleplex.com/5230756293246976
     */
    overflow-anchor: none;
  }

  body h1, body h2, body h3 {
    -webkit-font-smoothing: antialiased;
    -moz-osx-font-smoothing: grayscale;
  }

  body a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  body a:visited {
    color: #3c80f6;
  }

  body a[open-result]:visited {
    color: #7e57c2;
  }

  /* For Firefox */
  a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  a:visited {
    color: #3c80f6;
  }

  a[open-result]:visited {
    color: #7e57c2;
  }

  ::selection , body ::selection {
    background-color: #c6dafc;
    color: #333;
  }
</style><link rel="import" href="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.html">
  <style>[hidden] { display: none !important; }</style><script type="text/javascript" charset="UTF-8" src="https://apis.google.com/js/client.js" gapi_processed="true"></script></head>
  <body>
    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.js"></script><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span>
    <search-app>
    
    <remote-fetch class="style-scope search-app"></remote-fetch>
    <search-state class="style-scope search-app"></search-state>
    <browser-ui class="style-scope search-app"></browser-ui>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    
      <search-result id="result" class="style-scope search-app">
    
    
    <search-ui mode="result" class="style-scope search-result x-scope search-ui-0">
    
    
    
    <div id="content" class="style-scope search-ui" wide="">
      <search-header show-search="" class="style-scope search-ui">
    
    
    <div class="style-scope search-header" wide="">
      <header class="style-scope search-header">
        <div class="layout horizontal headerpad style-scope search-header">
          <div class="layout horizontal leftheader style-scope search-header">
            <h1 class="style-scope search-header">
              <state-modifier inherit="" act="{&quot;type&quot;: &quot;HOME&quot;}" class="style-scope search-header"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                <div class="lockup style-scope search-header">
                  <span class="lockup-logo style-scope search-header"></span>
                  <span class="lockup-text style-scope search-header">
                    <span class="lockup-brand style-scope search-header">&nbsp;Patents</span>
                  </span>
                </div>
              </a></state-modifier>
            </h1>
          </div>
          
            <search-box class="style-scope search-header">
    
    <div class="layout horizontal style-scope search-box" style="position: relative;">
      <div class="inputbox flex layout horizontal style-scope search-box">
        <div class="suggest-bg flex style-scope search-box">
          <input name="q" id="searchInput" data-proto="SEARCH_INPUT" autocomplete="off" class="style-scope search-box">
        </div>
        <div id="corpora" class="style-scope search-box">
          <iron-icon icon="icons:lightbulb-outline" id="patentIcon" class="style-scope search-box x-scope iron-icon-0" active=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M9 21c0 .55.45 1 1 1h4c.55 0 1-.45 1-1v-1H9v1zm3-19C8.14 2 5 5.14 5 9c0 2.38 1.19 4.47 3 5.74V17c0 .55.45 1 1 1h6c.55 0 1-.45 1-1v-2.26c1.81-1.27 3-3.36 3-5.74 0-3.86-3.14-7-7-7zm2.85 11.1l-.85.6V16h-4v-2.3l-.85-.6C7.8 12.16 7 10.63 7 9c0-2.76 2.24-5 5-5s5 2.24 5 5c0 1.63-.8 3.16-2.15 4.1z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#patentIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include patents
    </div>
  </overlay-tooltip>
          <iron-icon icon="social:school" id="nplIcon" class="style-scope search-box x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M5 13.18v4L12 21l7-3.82v-4L12 17l-7-3.82zM12 3L1 9l11 6 9-4.91V17h2V9L12 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#nplIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include non-patent literature
    </div>
  </overlay-tooltip>
          <keyword-wizard id="wizardIcon" class="style-scope search-box">


<div id="wizardContainer" class="style-scope keyword-wizard">
  <iron-icon icon="image:tune" id="wizardIcon" class="style-scope keyword-wizard x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M3 17v2h6v-2H3zM3 5v2h10V5H3zm10 16v-2h8v-2h-8v-2h-2v6h2zM7 9v2H3v2h4v2h2V9H7zm14 4v-2H11v2h10zm-6-4h2V7h4V5h-4V3h-2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
  <paper-material elevation="2" id="wizard" class="style-scope keyword-wizard x-scope paper-material-0" hidden="">
    
    

    
    
    <div class="search-within style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Search within
        <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="within"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="withinHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search within the title, abstract, claims, or full patent document</b>: You can
          restrict your search to a specific field using field names.</p>
        <p class="style-scope keyword-wizard">Use <span class="q style-scope keyword-wizard">TI=</span> to search in the title, <span class="q style-scope keyword-wizard">AB=</span> for the
          abstract, <span class="q style-scope keyword-wizard">CL=</span> for the claims, or <span class="q style-scope keyword-wizard">TAC=</span> for
          all three. For example, <span class="q style-scope keyword-wizard">TI=(safety belt)</span>.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search by Cooperative Patent Classifications (CPCs)</b>: These are commonly used to
          represent ideas in place of keywords, and can also be entered in a search term box. If
          you're searching for<span class="q style-scope keyword-wizard">seat belts</span>, you could also search for
          <span class="q style-scope keyword-wizard">B60R22/00</span> to retrieve documents that mention safety belts or body
          harnesses. <span class="q style-scope keyword-wizard">CPC=B60R22</span> will match documents with exactly this CPC,
          <span class="q style-scope keyword-wizard">CPC=B60R22/low</span> matches documents with this CPC or a child
          classification of this CPC.
        </p>
          <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="filter-chips style-scope keyword-wizard">
        <span class="chip style-scope keyword-wizard" id="title" selected="">Title</span>
        <span class="chip style-scope keyword-wizard" id="abstract" selected="">Abstract</span>
        <span class="chip style-scope keyword-wizard" id="claims" selected="">Claims</span>
        <span class="chip style-scope keyword-wizard" id="fullDoc" selected="">Full Document</span>
      </div>
      
      <div class="cpc-field style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputCPC" class="style-scope keyword-wizard">or CPC</label></span>
        <div class="cpc-inputs style-scope keyword-wizard">
          <input class="keyword-input style-scope keyword-wizard" id="inputCPC" placeholder="Or search with CPC">
          <input type="checkbox" id="childCPC" checked="" class="style-scope keyword-wizard">
          <label class="checkbox-label style-scope keyword-wizard" for="childCPC">
            Include child classifications
          </label>
        </div>
      </div>
    </div>
    
    <div class="find-patents style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Find patents
        <iron-icon class="help-header style-scope keyword-wizard x-scope iron-icon-0" icon="icons:help-outline" id="searchBoolean"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="searchBooleanHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Keywords and boolean syntax (USPTO or EPO format)</b>:
          <span class="q style-scope keyword-wizard">seat belt</span> searches these two words, or their plurals and close
          synonyms. <span class="q style-scope keyword-wizard">"seat belt"</span> searches this exact phrase, in order.
          <span class="q style-scope keyword-wizard">-seat -belt</span> searches for documents not containing either word.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">For searches using boolean logic</b>, the default operator is
          <span class="q style-scope keyword-wizard">AND</span> with left associativity. <i class="style-scope keyword-wizard">Note:</i> this means
          <span class="q style-scope keyword-wizard">safety OR seat belt</span> is searched as <span class="q style-scope keyword-wizard">(safety OR seat)
          AND belt</span>. Each word automatically includes plurals and close synonyms. Adjacent
          words that are implicitly ANDed together, such as <span class="q style-scope keyword-wizard">(safety belt)</span>,
          are treated as a phrase when generating synonyms.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputAnd" class="style-scope keyword-wizard">with ALL of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputAnd" placeholder="with ALL of the words">
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputExact" class="style-scope keyword-wizard">with the EXACT PHRASE</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputExact" placeholder="with the EXACT PHRASE"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputOr" class="style-scope keyword-wizard">with AT LEAST ONE of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputOr" placeholder="with AT LEAST ONE of the words"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputMinus" class="style-scope keyword-wizard">WITHOUT the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputMinus" placeholder="WITHOUT the words"></div>
    </div>
    <div class="search-by style-scope keyword-wizard">
      <div class="wizard-header style-scope keyword-wizard">
          Search by
          <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="chem"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </div>
      
      <div class="help style-scope keyword-wizard" id="chemHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Chemistry searches</b> match terms (trade names, IUPAC names, etc.
          extracted from the entire document, and processed from .MOL files.)
        </p>
        <p class="style-scope keyword-wizard">Substructure (use <span class="q style-scope keyword-wizard">SSS=</span>) and similarity (use
          <span class="q style-scope keyword-wizard">~</span>) searches are limited to one per search at the top-level
          <span class="q style-scope keyword-wizard">AND</span> condition. Exact searches can be used multiple times throughout
          the search query.
        </p>
        <p class="style-scope keyword-wizard">Searching by SMILES or InChi key requires no special syntax. To search by SMARTS, use
          <span class="q style-scope keyword-wizard">SMARTS=</span>.
        </p>
        <p class="style-scope keyword-wizard">To search for multiple molecules, select "Batch" in the "Type" menu. Enter multiple
          molecules separated by whitespace or by comma.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      
      <div class="chemistry-field style-scope keyword-wizard">
          <span class="input-label style-scope keyword-wizard"><label for="inputChem" class="style-scope keyword-wizard">Chemistry</label></span>
          <span class="chem-type-label style-scope keyword-wizard"><label for="chemType" hidden="" class="style-scope keyword-wizard">Type</label></span>
          <select id="chemType" class="style-scope keyword-wizard">
            <option value="identical" class="style-scope keyword-wizard">Identical</option>
            <option value="substructure" class="style-scope keyword-wizard">Substructure</option>
            <option value="smarts" class="style-scope keyword-wizard">SMARTS</option>
            <option value="similarity" class="style-scope keyword-wizard">Similarity</option>
            <option value="batch" class="style-scope keyword-wizard">Batch</option>
          </select>
          <textarea class="keyword-input style-scope keyword-wizard" id="inputChem" placeholder="Trade name, SMILES, InChiKey"></textarea>
      </div>
      <div class="import style-scope keyword-wizard">
        <div class="wizard-header style-scope keyword-wizard">
          Patent numbers
        </div>
        <span class="import-button style-scope keyword-wizard">
          <a href="https://patents.google.com/import" class="style-scope keyword-wizard"><button class="style-scope keyword-wizard">Import</button></a>
        </span>
        <p class="import-text style-scope keyword-wizard">
          Search specific patents by importing a CSV or list of patent publication or application numbers.
        </p>
      </div>
    </div>
    
    <div class="wizard-buttons style-scope keyword-wizard">
      <button type="reset" class="style-scope keyword-wizard">Close</button>
      <button type="button" autofocus="" class="style-scope keyword-wizard">Add</button>
    </div>
  
  </paper-material>
</div>
</keyword-wizard>
          <overlay-tooltip positioning-target="#wizardIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Display advanced search options
    </div>
  </overlay-tooltip>
        </div>
      </div>
      <paper-material id="suggestMenu" class="style-scope search-box x-scope paper-material-0" elevation="1" hidden="">
    
    

    
        <template is="dom-repeat" class="style-scope search-box"></template>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Sorry, we couldn't find this patent number.
        </div>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> 
        </div>
      
  </paper-material>
      <button id="searchButton" class="style-scope search-box"><iron-icon class="style-scope search-box x-scope iron-icon-0" icon="search"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></button>
    </div>
  </search-box>
          <template is="dom-if" class="style-scope search-header"></template>
          <div class="flex style-scope search-header"></div>
          
            <div id="header-container" class="style-scope search-header">
              <result-nav class="style-scope search-header">
    
    <div class="style-scope result-nav" hidden="">
      <state-modifier id="current" act="{&quot;type&quot;: &quot;BACK_TO_RESULTS&quot;}" inherit="" class="style-scope result-nav"><a id="link" href="#" class="style-scope state-modifier" inherit=""><span class="style-scope result-nav"></span> of
      <template is="dom-if" class="style-scope result-nav"></template>
      0<template is="dom-if" class="style-scope result-nav"></template></a></state-modifier>
      <state-modifier id="prevResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-left" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.41 7.41L14 6l-6 6 6 6 1.41-1.41L10.83 12z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier><state-modifier id="nextResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-right" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M10 6L8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier>
      <overlay-tooltip positioning-target="#prevResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Previous result
    </div>
  </overlay-tooltip>
      <overlay-tooltip positioning-target="#nextResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Next result
    </div>
  </overlay-tooltip>
    </div>
  </result-nav>
            </div>
          <template is="dom-if" class="style-scope search-header"></template>
        </div>
      </header>
    </div>
  </search-header>

      <div class="layout horizontal style-scope search-ui">
        <template is="dom-if" class="style-scope search-ui"></template>

        <div id="main" class="style-scope search-ui">
          <search-term-wizard class="style-scope search-ui"><pat-dialog open="" class="style-scope search-term-wizard">
  <span class="header style-scope search-term-wizard">
    <span class="title style-scope search-term-wizard">Search tools</span>
    <span id="language" class="style-scope search-term-wizard">
      <text-button id="textButton" selected="" class="style-scope search-term-wizard">Text
</text-button>
      <text-button id="classificationButton" class="style-scope search-term-wizard">Classification
</text-button>
      <text-button id="chemistryButton" class="style-scope search-term-wizard">Chemistry
</text-button>
      <text-button id="measureButton" class="style-scope search-term-wizard">Measure
</text-button>
      <text-button id="numbersButton" class="style-scope search-term-wizard">Numbers
</text-button>
    </span>
  </span>
  <span id="panels" class="style-scope search-term-wizard">
    <text-search-term-wizard id="textPanel" class="style-scope search-term-wizard" selected=""><span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Type a concept you want to search for here" class="style-scope text-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Type a concept you want to search for here">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="title" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Title</filter-chip>
  <filter-chip id="abstract" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Abstract</filter-chip>
  <filter-chip id="claims" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="all" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
All</filter-chip>
  <filter-chip id="any" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Any</filter-chip>
  <filter-chip id="exact" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="not" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Not</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope text-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope text-search-term-wizard">Add AND condition</span></mat-button></span></text-search-term-wizard>
    <classification-wizard id="classificationPanel" class="style-scope search-term-wizard"><span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope classification-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Enter a CPC here" uppercase="" class="style-scope classification-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Enter a CPC here">
  
</span>
</outlined-text-field>
</span>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope classification-wizard"></path>
  </svg>
  <filter-chip id="notExact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These CPCs and their children
  </filter-chip>
  <filter-chip selected="" id="exact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These exact CPCs
  </filter-chip>
</span>
<span class="style-scope classification-wizard">
  <mat-button id="button" filled="" class="style-scope classification-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope classification-wizard">Add AND condition</span></mat-button>
</span></classification-wizard>
    <chemistry-search-term-wizard id="chemistryPanel" class="style-scope search-term-wizard"><span class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Trade name, SMILES, InChI Key" class="style-scope chemistry-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Trade name, SMILES, InChI Key">
  
</span>
</outlined-text-field>
  <outlined-textarea id="textArea" placeholder="Enter multiple SMILES or InChI Keys, one per line" rows="4" class="style-scope chemistry-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple SMILES or InChI Keys, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
  <a href="https://support.google.com/faqs/answer/7049475#zippy=%2Csearching-by-chemistry" target="_blank" class="style-scope chemistry-search-term-wizard">
    <svg class="help style-scope chemistry-search-term-wizard" xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49">
      <path d="M11.95 18q.525 0 .888-.363.362-.362.362-.887t-.362-.887q-.363-.363-.888-.363t-.888.363q-.362.362-.362.887t.362.887q.363.363.888.363Zm-.9-3.85h1.85q0-.825.188-1.3.187-.475 1.062-1.3.65-.65 1.025-1.238.375-.587.375-1.412 0-1.4-1.025-2.15T12.1 6q-1.425 0-2.312.75-.888.75-1.238 1.8l1.65.65q.125-.45.563-.975Q11.2 7.7 12.1 7.7q.8 0 1.2.437.4.438.4.963 0 .5-.3.937-.3.438-.75.813-1.1.975-1.35 1.475-.25.5-.25 1.825ZM12 22q-2.075 0-3.9-.788-1.825-.787-3.175-2.137-1.35-1.35-2.137-3.175Q2 14.075 2 12t.788-3.9q.787-1.825 2.137-3.175 1.35-1.35 3.175-2.138Q9.925 2 12 2t3.9.787q1.825.788 3.175 2.138 1.35 1.35 2.137 3.175Q22 9.925 22 12t-.788 3.9q-.787 1.825-2.137 3.175-1.35 1.35-3.175 2.137Q14.075 22 12 22Zm0-2q3.35 0 5.675-2.325Q20 15.35 20 12q0-3.35-2.325-5.675Q15.35 4 12 4 8.65 4 6.325 6.325 4 8.65 4 12q0 3.35 2.325 5.675Q8.65 20 12 20Zm0-8Z" class="style-scope chemistry-search-term-wizard"></path>
    </svg>
  </a>
</span>
<span id="chemQuantifiers" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M5 21.2q-1.4 0-2-1.25-.6-1.25.3-2.325l5.5-6.7V5.15h-.825q-.475 0-.8-.338Q6.85 4.475 6.85 4q0-.475.325-.813.325-.337.8-.337h8.05q.475 0 .8.337.325.338.325.813 0 .475-.325.812-.325.338-.8.338H15.2v5.775l5.5 6.7q.9 1.075.3 2.325-.6 1.25-2 1.25Zm2.15-3.275h9.7l-3.275-3.85h-3.15Zm-2 1h13.7l-5.925-7.2V5.15h-1.85v6.575Zm6.85-6.9Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="exact" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="exactBatch" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact Batch</filter-chip>
  <filter-chip id="similar" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Similar</filter-chip>
  <filter-chip id="substructure" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure</filter-chip>
  <filter-chip id="smarts" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure (SMARTS)</filter-chip>
</span>
<span id="location" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="claims" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims only</filter-chip>
</span>
<span class="style-scope chemistry-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope chemistry-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope chemistry-search-term-wizard">Add AND condition</span></mat-button>
</span>
</chemistry-search-term-wizard>
    <measure-search-term-wizard id="measurePanel" class="style-scope search-term-wizard"><span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M4.1 18.15q-.95 0-1.612-.663-.663-.662-.663-1.612v-7.75q0-.95.663-1.613Q3.15 5.85 4.1 5.85h15.8q.95 0 1.613.662.662.663.662 1.613v7.75q0 .95-.662 1.612-.663.663-1.613.663Zm0-2.275h15.8v-7.75H17V12h-2V8.125h-2V12h-2V8.125H9V12H7V8.125H4.1v7.75ZM7 12h2Zm4 0h2Zm4 0h2Zm-3 0Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="measureExpression" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M3.875 20.15V8.85h4.25v11.3Zm6 0V3.85h4.25v16.3Zm6 0v-7.3h4.25v7.3Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="context" placeholder="activity, wavelength, embossing depth, absorption" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="activity, wavelength, embossing depth, absorption">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope measure-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope measure-search-term-wizard">Add AND condition</span></mat-button>
</span>
</measure-search-term-wizard>
    <numerical-search-term-wizard id="numericalPanel" class="style-scope search-term-wizard"><span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-textarea id="batch" placeholder="Enter multiple Patent Application and Publication Numbers, one per line" rows="4" class="style-scope numerical-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple Patent Application and Publication Numbers, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
</span>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="m10.825 23.45-1.6-1.625L10.9 20.15H8q-.35.9-1.162 1.488-.813.587-1.838.587-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.025.588-1.837Q2.95 16.35 3.85 16V8q-.9-.35-1.487-1.163Q1.775 6.025 1.775 5q0-1.35.938-2.288Q3.65 1.775 5 1.775q1.025 0 1.838.587Q7.65 2.95 8 3.85h2.9L9.225 2.175l1.6-1.625L15.275 5l-4.45 4.45-1.6-1.625L10.9 6.15H8q-.25.65-.725 1.125T6.15 8v8q.65.25 1.125.725T8 17.85h2.9l-1.675-1.675 1.6-1.625 4.45 4.45ZM19 22.225q-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.05.588-1.863.587-.812 1.487-1.137V8q-.9-.325-1.487-1.137-.588-.813-.588-1.863 0-1.35.938-2.288.937-.937 2.287-.937 1.35 0 2.288.937.937.938.937 2.288 0 1.05-.587 1.863Q21.05 7.675 20.15 8v8q.9.35 1.488 1.163.587.812.587 1.837 0 1.35-.937 2.288-.938.937-2.288.937ZM5 19.95q.4 0 .675-.275T5.95 19q0-.4-.275-.675T5 18.05q-.4 0-.675.275T4.05 19q0 .4.275.675T5 19.95Zm14 0q.4 0 .675-.275T19.95 19q0-.4-.275-.675T19 18.05q-.4 0-.675.275T18.05 19q0 .4.275.675t.675.275Zm-14-14q.4 0 .675-.275T5.95 5q0-.4-.275-.675T5 4.05q-.4 0-.675.275T4.05 5q0 .4.275.675T5 5.95Zm14 0q.4 0 .675-.275T19.95 5q0-.4-.275-.675T19 4.05q-.4 0-.675.275T18.05 5q0 .4.275.675T19 5.95ZM5 19Zm14 0ZM5 5Zm14 0Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <filter-chip id="applicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Application Numbers</filter-chip>
  <filter-chip id="publicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Publication Numbers</filter-chip>
  <filter-chip id="either" selected="" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Either</filter-chip>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M12 22.2q-2.1 0-3.962-.8-1.863-.8-3.25-2.175Q3.4 17.85 2.6 15.988 1.8 14.125 1.8 12t.8-3.988q.8-1.862 2.188-3.237Q6.175 3.4 8.038 2.6 9.9 1.8 12 1.8q2.125 0 3.988.8 1.862.8 3.237 2.175Q20.6 6.15 21.4 8.012q.8 1.863.8 3.988t-.8 3.988q-.8 1.862-2.175 3.237Q17.85 20.6 15.988 21.4q-1.863.8-3.988.8Zm-1-2.325v-1.95q-.8 0-1.387-.575-.588-.575-.588-1.4v-.975L4.275 10.2q-.075.45-.137.9-.063.45-.063.9 0 3 1.975 5.25T11 19.875Zm6.85-2.525q.5-.55.888-1.175.387-.625.65-1.313.262-.687.4-1.412.137-.725.137-1.45 0-2.425-1.338-4.438-1.337-2.012-3.612-2.887v.375q0 .825-.587 1.4-.588.575-1.388.575h-2v2q0 .4-.287.687-.288.288-.688.288h-2v2h5.95q.425 0 .713.287.287.288.287.688v2.975h1q.65 0 1.163.387.512.388.712 1.013Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryFilter" placeholder="Restrict search to these countries" class="style-scope numerical-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Restrict search to these countries">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M2.85 18.225V15.95h6.3v2.275Zm0-5.075v-2.3h12.3v2.3Zm0-5.1V5.775h18.3V8.05Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryOrder" placeholder="Prefer results from these countries in this order" class="style-scope numerical-search-term-wizard" value="US, EP, WO, JP, CN"><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Prefer results from these countries in this order">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope numerical-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope numerical-search-term-wizard">Add AND condition</span></mat-button>
</span>
</numerical-search-term-wizard>
  </span>

</pat-dialog>
</search-term-wizard>
          
      <div content="" class="style-scope search-result">
        <div id="mainContainer" class="vertical layout style-scope search-result">
          <template is="dom-if" class="style-scope search-result"></template>
          <result-container class="style-scope search-result">
    

    <paper-spinner class="style-scope result-container x-scope paper-spinner-0" aria-hidden="true" hidden=""><div id="spinnerContainer" class="  style-scope paper-spinner"><div class="spinner-layer layer-1 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-2 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-3 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-4 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div></div></paper-spinner>
    
      <patent-result class="style-scope result-container">
    
    
    <div class="layout horizontal style-scope patent-result">
      <div style="width: 1200px; height: auto; overflow: auto;" class="style-scope patent-result">
        <div id="wrapper" tabindex="0" class="style-scope patent-result">
          <result-tags class="style-scope patent-result"></result-tags>
          <h1 id="title" class="scroll-target style-scope patent-result">
            MN/CA IX and breast cancer therapy 
       </h1>
          <div class="horizontal layout style-scope patent-result">
            
            <div class="flex-3 style-scope patent-result" style="margin-top:-20px;overflow:hidden;" marginright="">
              <section id="abstract" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Abstract</div>
                  <div class="righthead style-scope patent-result" hidden="">translated from </div>
                </h3>
                <patent-text name="abstract" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><abstract mxw-id="PA89690777" lang="EN" load-source="patent-office" class="style-scope patent-text">
    <div num="p-0001" class="abstract style-scope patent-text">Herein disclosed are methods that are predictive of resistance to endocrine therapy in an estrogen receptor-positive (ER-positive) breast cancer patient. An exemplary method comprises detecting the overexpression of MN/CA9 gene expression product(s) in a sample from an affected subject, wherein if MN/CA9 is overexpressed, then the subject is considered to have a greater probability of resistance to endocrine therapy, particularly tamoxifen, and a corresponding poorer prognosis if undergoing endocrine therapy, than if MN/CA9 is not overexpressed. MN/CA9 gene expression products useful in the predictive/prognostic methods include MN/CA IX, MN proteins/polypeptides, MN nucleic acids and soluble MN/CA IX antigen (s-CA IX). The methods are useful as an aid in the selection of treatment for a patient with an ER-positive breast tumor. The methods of the invention can be used, for example, to identify those patients requiring additional/alternative therapies, preferably, but not necessarily, therapies that are not affected by acidic pH. The methods also comprise the use of diagnostic/prognostic imaging to detect MN/CA IX in a patient tumor, wherein the presence of MN/CA IX in one or more tumors is indicative of probable resistance to antiestrogen therapy, particularly to tamoxifen.</div>
  </abstract>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
              
              
                <section id="thumbnails" class="style-scope patent-result">
                  <h3 class="style-scope patent-result">Images (<span class="style-scope patent-result">2</span>)</h3>
                  <image-carousel id="figures" class="style-scope patent-result">
    
    
      <div class="thumbnails style-scope image-carousel">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/0a/0c/99/dc681267521481/US08097423-20120117-D00001.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/92/2e/02/638346267d4f57/US08097423-20120117-D00002.png">
        <template is="dom-repeat" as="img" class="style-scope image-carousel"></template>
      </div>
    <template is="dom-if" class="style-scope image-carousel"></template>
  </image-carousel>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <section id="classifications" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Classifications</div>
                  <div id="machineClassifiedWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">machine-classified</div>
                  <div id="machineClassifiedCPCWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">cpc-machine-classified</div>
                  <div id="machineClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-machine-classified</div>
                  <div class="style-scope patent-result" hidden="">&nbsp;</div>
                  <div id="familyClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-family-classified</div>
                </h3>
                <overlay-tooltip positioning-target="#machineClassifiedWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedCPCWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The CPC classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#familyClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned based on a patent family member containing these classification codes.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <classification-viewer class="style-scope patent-result">
    
    <div class="table style-scope classification-viewer">
      
        <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G"><a id="link" href="#" class="style-scope state-modifier">G</a></state-modifier>
                  <span class="description style-scope classification-tree">PHYSICS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01"><a id="link" href="#" class="style-scope state-modifier">G01</a></state-modifier>
                  <span class="description style-scope classification-tree">MEASURING; TESTING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N"><a id="link" href="#" class="style-scope state-modifier">G01N</a></state-modifier>
                  <span class="description style-scope classification-tree">INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/00"><a id="link" href="#" class="style-scope state-modifier">G01N33/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/48"><a id="link" href="#" class="style-scope state-modifier">G01N33/48</a></state-modifier>
                  <span class="description style-scope classification-tree">Biological material, e.g. blood, urine; Haemocytometers</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/50"><a id="link" href="#" class="style-scope state-modifier">G01N33/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/53"><a id="link" href="#" class="style-scope state-modifier">G01N33/53</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoassay; Biospecific binding assay; Materials therefor</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/574"><a id="link" href="#" class="style-scope state-modifier">G01N33/574</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoassay; Biospecific binding assay; Materials therefor for cancer</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/57407"><a id="link" href="#" class="style-scope state-modifier">G01N33/57407</a></state-modifier>
                  <span class="description style-scope classification-tree">Specifically defined cancers</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" first="true" data-cpc="G01N33/57415"><a id="link" href="#" class="style-scope state-modifier">G01N33/57415</a></state-modifier>
                  <span class="description style-scope classification-tree">Specifically defined cancers of breast</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
      <template is="dom-repeat" class="style-scope classification-viewer"></template>
      
      <div class="style-scope classification-viewer">
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12"><a id="link" href="#" class="style-scope state-modifier">C12</a></state-modifier>
                  <span class="description style-scope classification-tree">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12Q"><a id="link" href="#" class="style-scope state-modifier">C12Q</a></state-modifier>
                  <span class="description style-scope classification-tree">MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12Q1/00"><a id="link" href="#" class="style-scope state-modifier">C12Q1/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12Q1/68"><a id="link" href="#" class="style-scope state-modifier">C12Q1/68</a></state-modifier>
                  <span class="description style-scope classification-tree">Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12Q1/6876"><a id="link" href="#" class="style-scope state-modifier">C12Q1/6876</a></state-modifier>
                  <span class="description style-scope classification-tree">Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12Q1/6883"><a id="link" href="#" class="style-scope state-modifier">C12Q1/6883</a></state-modifier>
                  <span class="description style-scope classification-tree">Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12Q1/6886"><a id="link" href="#" class="style-scope state-modifier">C12Q1/6886</a></state-modifier>
                  <span class="description style-scope classification-tree">Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12"><a id="link" href="#" class="style-scope state-modifier">C12</a></state-modifier>
                  <span class="description style-scope classification-tree">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12Q"><a id="link" href="#" class="style-scope state-modifier">C12Q</a></state-modifier>
                  <span class="description style-scope classification-tree">MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12Q2600/00"><a id="link" href="#" class="style-scope state-modifier">C12Q2600/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Oligonucleotides characterized by their use</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="C12Q2600/106"><a id="link" href="#" class="style-scope state-modifier">C12Q2600/106</a></state-modifier>
                  <span class="description style-scope classification-tree">Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12"><a id="link" href="#" class="style-scope state-modifier">C12</a></state-modifier>
                  <span class="description style-scope classification-tree">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12Q"><a id="link" href="#" class="style-scope state-modifier">C12Q</a></state-modifier>
                  <span class="description style-scope classification-tree">MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12Q2600/00"><a id="link" href="#" class="style-scope state-modifier">C12Q2600/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Oligonucleotides characterized by their use</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="C12Q2600/118"><a id="link" href="#" class="style-scope state-modifier">C12Q2600/118</a></state-modifier>
                  <span class="description style-scope classification-tree">Prognosis of disease development</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12"><a id="link" href="#" class="style-scope state-modifier">C12</a></state-modifier>
                  <span class="description style-scope classification-tree">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12Q"><a id="link" href="#" class="style-scope state-modifier">C12Q</a></state-modifier>
                  <span class="description style-scope classification-tree">MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12Q2600/00"><a id="link" href="#" class="style-scope state-modifier">C12Q2600/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Oligonucleotides characterized by their use</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="C12Q2600/158"><a id="link" href="#" class="style-scope state-modifier">C12Q2600/158</a></state-modifier>
                  <span class="description style-scope classification-tree">Expression markers</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G"><a id="link" href="#" class="style-scope state-modifier">G</a></state-modifier>
                  <span class="description style-scope classification-tree">PHYSICS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01"><a id="link" href="#" class="style-scope state-modifier">G01</a></state-modifier>
                  <span class="description style-scope classification-tree">MEASURING; TESTING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N"><a id="link" href="#" class="style-scope state-modifier">G01N</a></state-modifier>
                  <span class="description style-scope classification-tree">INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N2800/00"><a id="link" href="#" class="style-scope state-modifier">G01N2800/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Detection or diagnosis of diseases</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="G01N2800/52"><a id="link" href="#" class="style-scope state-modifier">G01N2800/52</a></state-modifier>
                  <span class="description style-scope classification-tree">Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y"><a id="link" href="#" class="style-scope state-modifier">Y</a></state-modifier>
                  <span class="description style-scope classification-tree">GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y10"><a id="link" href="#" class="style-scope state-modifier">Y10</a></state-modifier>
                  <span class="description style-scope classification-tree">TECHNICAL SUBJECTS COVERED BY FORMER USPC</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y10T"><a id="link" href="#" class="style-scope state-modifier">Y10T</a></state-modifier>
                  <span class="description style-scope classification-tree">TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y10T436/00"><a id="link" href="#" class="style-scope state-modifier">Y10T436/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Chemistry: analytical and immunological testing</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="Y10T436/25"><a id="link" href="#" class="style-scope state-modifier">Y10T436/25</a></state-modifier>
                  <span class="description style-scope classification-tree">Chemistry: analytical and immunological testing including sample preparation</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        <template is="dom-repeat" class="style-scope classification-viewer"></template>
        <div class="more style-scope classification-viewer" style="" hidden="">View 6 more classifications</div>
        <div class="more style-scope classification-viewer">Hide more classifications</div>
      </div>
      <template is="dom-if" class="style-scope classification-viewer"></template>
    </div>
  </classification-viewer>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              
                <section class="style-scope patent-result">
                  <h3 class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Landscapes</div>
                  </h3>
                  <div class="responsive-grid style-scope patent-result">
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Health &amp; Medical Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Health &amp; Medical Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Life Sciences &amp; Earth Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Life Sciences &amp; Earth Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    <template is="dom-repeat" class="style-scope patent-result"></template>
                  </div>
                  <s-more-inline class="style-scope patent-result"><hr aria-hidden="true" class="style-scope s-more-inline">

<div class="button style-scope s-more-inline">
  <span slot="expand_text" class="style-scope patent-result">Show more</span>
  <span class="expand more style-scope s-more-inline"></span>
</div>
<div class="button style-scope s-more-inline" hidden="">
  <span slot="collapse_text" class="style-scope patent-result">Show less</span>
  <span class="expand less style-scope s-more-inline"></span>
</div>
</s-more-inline>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
            <div class="flex-2 style-scope patent-result">
              <section class="knowledge-card style-scope patent-result">
                <header class="style-scope patent-result">
                  <h2 id="pubnum" class="style-scope patent-result">US8097423B2</h2>
                  <p class="tagline style-scope patent-result">United States</p>
                  <overlay-tooltip positioning-target="#pubnum" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                    <div style="max-width: 300px;" class="style-scope patent-result">Patent ( having previously published pre-grant publication)</div>
                  
    </div>
  </overlay-tooltip>

                  <div class="knowledge-card-action-bar style-scope patent-result">
                    <a target="_blank" class="style-scope patent-result" href="https://patentimages.storage.googleapis.com/9e/ce/c9/4d226a3f0713ac/US8097423.pdf"><iron-icon icon="description" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download PDF</a>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_FIND_PRIOR_ART&quot;, &quot;keywords&quot;: $keywords, &quot;before&quot;: &quot;$before&quot;}" class="style-scope patent-result" data-keywords="[&quot;tumor&quot;,&quot;positive&quot;,&quot;breast cancer&quot;,&quot;therapy&quot;,&quot;sample&quot;]" data-before="20070730"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="find-in-page" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 19.59V8l-6-6H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c.45 0 .85-.15 1.19-.4l-4.43-4.43c-.8.52-1.74.83-2.76.83-2.76 0-5-2.24-5-5s2.24-5 5-5 5 2.24 5 5c0 1.02-.31 1.96-.83 2.75L20 19.59zM9 13c0 1.66 1.34 3 3 3s3-1.34 3-3-1.34-3-3-3-3 1.34-3 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Find Prior Art
                    </a></state-modifier>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_SIMILAR_DOCUMENTS&quot;, &quot;id&quot;: &quot;$id&quot;}" class="style-scope patent-result" data-id="patent/US8097423B2"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="editor:functions" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M18 4H6v2l6.5 6L6 18v2h12v-3h-7l5-5-5-5h7z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Similar
                    </a></state-modifier>
                  </div>
                </header>

                <dl class="important-people style-scope patent-result">
                  <template is="dom-if" class="style-scope patent-result"></template>
                  
                  <dt class="style-scope patent-result">Inventor</dt>
                  <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Adrian L. Harris"><a id="link" href="#" class="style-scope state-modifier">Adrian L. Harris</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>

                  
                  <dt class="style-scope patent-result">
                    <span class="tooltip-hint style-scope patent-result" id="assigneeWarning">Current Assignee</span>
                    <overlay-tooltip positioning-target="#assigneeWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                      The listed assignees may be inaccurate.<br class="style-scope patent-result">
                      Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.
                    
    </div>
  </overlay-tooltip>
                  </dt>
                  <dd class="style-scope patent-result">
                    
    Biomedical Research Centre Of Slovak Academy Of Sciences
  
                  </dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                </dl>

                <hr class="style-scope patent-result">

                <application-timeline class="style-scope patent-result">
    
    
    <div class="wrap style-scope application-timeline">
      <div class="header style-scope application-timeline">Worldwide applications</div>
      <div class="event style-scope application-timeline">
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2008</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US8097423B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline" this="">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US12/181,951</div>
                <div class="style-scope application-timeline">Filing date: 2008-07-29</div>
                <div class="style-scope application-timeline">Legal status: Expired - Fee Related</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        <template is="dom-repeat" class="style-scope application-timeline"></template>
      </div>
      <hr class="style-scope application-timeline">
      <div class="header style-scope application-timeline">Application US12/181,951 events <iron-icon id="legal" icon="icons:help-outline" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        <overlay-tooltip positioning-target="#legal" direction="right" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
          <div style="max-width: 300px;" class="style-scope application-timeline">
            A timeline of key events for this patent application, including priority claims, publications, legal status, reassignments, and litigation.<br class="style-scope application-timeline"><br class="style-scope application-timeline">
            Google has not performed a legal analysis and makes no representation as to the accuracy or completeness of the events listed.
          </div>
        
    </div>
  </overlay-tooltip>
      </div>
      <div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="filed style-scope application-timeline">2008-07-29</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_ASSIGNEE&quot;, &quot;assignee&quot;: &quot;$assignee&quot;}" class="style-scope application-timeline" data-assignee="Institute of Virology (Slovak Academy of Science)"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Application filed by Institute of Virology (Slovak Academy of Science)</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="priority style-scope application-timeline">2008-07-29</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US8097423B2/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Priority to US12/181,951</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline"><div date="" class="reassignment style-scope application-timeline">2008-09-02</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_ASSIGNEE&quot;, &quot;assignee&quot;: &quot;$assignee&quot;}" class="style-scope application-timeline" data-assignee="INSTITUTE OF VIROLOGY"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Assigned to INSTITUTE OF VIROLOGY</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><iron-icon id="icon" icon="icons:help-outline" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><overlay-tooltip positioning-target="#icon" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      <div class="description-item style-scope application-timeline">ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).</div><div class="description-item style-scope application-timeline">Assignors: HARRIS, ADRIAN L.</div><template is="dom-repeat" class="style-scope application-timeline"></template>
    </div>
  </overlay-tooltip><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2009-02-19</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US20090047215A1/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of US20090047215A1</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="granted style-scope application-timeline">2012-01-17</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Application granted</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2012-01-17</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US8097423B2/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of US8097423B2</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline"><div date="" class="reassignment style-scope application-timeline">2018-06-05</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_ASSIGNEE&quot;, &quot;assignee&quot;: &quot;$assignee&quot;}" class="style-scope application-timeline" data-assignee="BIOMEDICAL RESEARCH CENTRE OF THE SLOVAK ACADEMY OF SCIENCES"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Assigned to BIOMEDICAL RESEARCH CENTRE OF THE SLOVAK ACADEMY OF SCIENCES</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><iron-icon id="icon" icon="icons:help-outline" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><overlay-tooltip positioning-target="#icon" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      <div class="description-item style-scope application-timeline">ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).</div><div class="description-item style-scope application-timeline">Assignors: INSTITUTE OF VIROLOGY OF THE SLOVAK ACADEMY OF SCIENCES</div><template is="dom-repeat" class="style-scope application-timeline"></template>
    </div>
  </overlay-tooltip><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" current="" critical=""><div date="" class="legal-status style-scope application-timeline">Status</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Expired - Fee Related</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="legal-status style-scope application-timeline">2028-07-29</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Anticipated expiration</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><template is="dom-repeat" strip-whitespace="" class="style-scope application-timeline"></template>
      <template is="dom-if" class="style-scope application-timeline"></template>
    </div>
  </application-timeline>
                <hr class="style-scope patent-result">

                <dl class="links style-scope patent-result">
                  <dt class="style-scope patent-result">Info</dt>

                  
                  <dd class="style-scope patent-result"><a href="#patentCitations" class="style-scope patent-result">Patent citations (5)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#nplCitations" class="style-scope patent-result">Non-patent citations (36)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#citedBy" class="style-scope patent-result">Cited by (6)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#legalEvents" class="style-scope patent-result">Legal events</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#similarDocuments" class="style-scope patent-result">Similar documents</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#relatedApplications" class="style-scope patent-result">Priority and Related Applications</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <dt class="style-scope patent-result">External links</dt>

                  <dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&amp;Sect2=HITOFF&amp;p=1&amp;u=/netahtml/PTO/srchnum.html&amp;r=1&amp;f=G&amp;l=50&amp;d=PALL&amp;s1=8097423.PN.">USPTO</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patentcenter.uspto.gov/applications/12181951">USPTO PatentCenter</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://assignment.uspto.gov/patent/index.html#/patent/search/resultFilter?searchInput=8097423">USPTO Assignment</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://worldwide.espacenet.com/publicationDetails/biblio?CC=US&amp;NR=8097423B2&amp;KC=B2&amp;FT=D">Espacenet</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://globaldossier.uspto.gov/#/result/patent/US/8097423/1">Global Dossier</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patents.stackexchange.com/questions/tagged/US8097423">Discuss</a></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                </dl>
              </section>
            </div>
          </div>

          <div id="text" class="horizontal layout style-scope patent-result">
            <div class="flex flex-width style-scope patent-result" marginright="">
              <section id="description" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Description</div>
                  <div class="righthead style-scope patent-result" hidden="">translated from </div>
                </h3>
                <patent-text name="description" id="descriptionText" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><div mxw-id="PDES44179561" lang="EN" load-source="patent-office" class="description style-scope patent-text">
    
    <heading class="style-scope patent-text">FIELD OF THE INVENTION</heading>
    <div num="p-0002" class="description-paragraph style-scope patent-text">The present invention is in the general area of medical genetics and in the fields of biochemical engineering, immunochemistry and oncology. More specifically, it relates to the MN genea cellular gene considered to be an oncogene, known alternatively as MN/CA9, CA9, or carbonic anhydrase 9, which gene encodes the oncoprotein now known alternatively as the MN protein, the MN/CA IX isoenzyme, MN/CA IX, carbonic anhydrase IX, CA IX, the MN/G250 or the G250 protein.</div>
    <div num="p-0003" class="description-paragraph style-scope patent-text">More specifically, the instant invention concerns methods of detecting, or detecting and quantitating, MN antigen and/or MN gene expression in tumors, tumor samples or body fluids, of estrogen receptor-positive (ER-positive) breast cancer patients, wherein said methods provide the basis for predicting patient resistance to endocrine therapy for breast cancer, and for making clinical decisions concerning cancer treatment. The methods in one aspect are particularly directed to predicting the resistance of ER-positive breast cancer patients to antiestrogens, such as tamoxifen.</div>
    <heading class="style-scope patent-text">REFERENCE TO SEQUENCE LISTING</heading>
    <div num="p-0004" class="description-paragraph style-scope patent-text">The Sequence Listing, filed electronically herewith and identified as MST-5298-1-SEQ-LISTING, was created on Jul. 24, 2008, is 32.4 kb in size and is hereby incorporated by reference.</div>
    <heading class="style-scope patent-text">BACKGROUND OF THE INVENTION</heading>
    <div num="p-0005" class="description-paragraph style-scope patent-text">As indicated above, the MN gene and protein are known by a number of alternative names, which names are used herein interchangeably. The MN protein was found to bind zinc and have carbonic anhydrase (CA) activity and is now considered to be the ninth carbonic anhydrase isoenzymeMN/CA IX or CA IX [Opavsky et al., Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships, <i class="style-scope patent-text">Genomics. </i>33: 480-487 (1996)]. According to the carbonic anhydrase nomenclature, human CA isoenzymes are written in capital Roman letters and numbers, whereas their genes are written in italic letters and Arabic numbers. Alternatively, MN is used herein to refer either to carbonic anhydrase isoenzyme IX (CA IX) proteins/polypeptides, or carbonic anhydrase isoenzyme 9 (CA9) gene, nucleic acids, cDNA, mRNA etc. as indicated by the context.</div>
    <div num="p-0006" class="description-paragraph style-scope patent-text">The MN protein has also been identified with the G250 antigen. Uemura et al. [Expression of Tumor-Associated Antigen MN/G250 in Urologic Carcinoma: Potential Therapeutic Target, <i class="style-scope patent-text">J. Urol. </i>157 (4 Suppl.): 377 (Abstract 1475; 1997)] states: Sequence analysis and database searching revealed that G250 antigen is identical to MN, a human tumor-associated antigen identified in cervical carcinoma (Pastorek et al., 1994).</div>
    <div num="p-0007" class="description-paragraph style-scope patent-text">Zavada et al., International Publication No. WO 93/18152 (published Sep. 16, 1993) and U.S. Pat. No. 5,387,676 (issued Feb. 7, 1995) describe the discovery of the MN gene and protein. The MN gene was found to be present in the chromosomal DNA of all vertebrates tested, and its expression to be strongly correlated with tumorigenicity. In general, oncogenesis may be signified by the abnormal expression of CA IX protein. For example, oncogenesis may be signified: (1) when CA IX protein is present in a tissue which normally does not express CA IX protein to any significant degree; (2) when CA IX protein is absent from a tissue that normally expresses it; (3) when CA9 gene expression is at a significantly increased level, or at a significantly reduced level from that normally expressed in a tissue; or (4) when CA IX protein is expressed in an abnormal location. WO 93/18152 further discloses, among other MN-related inventions, MN/CA IX-specific monoclonal antibodies (MAbs), including the M75 MAb and the VU-M75 hybridoma that secretes the M75 MAb. The M75 MAb specifically binds to immunodominant epitopes on the proteoglycan (PG) domain of MN/CA IX.</div>
    <div num="p-0008" class="description-paragraph style-scope patent-text">Zavada et al., International Publication No. WO 95/34650 (published Dec. 21, 1995) provides in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 1</figref> the nucleotide sequence for a full-length MN cDNA [SEQ ID NO: 1] clone isolated as described therein, and the amino acid sequence [SEQ ID NO: 2] encoded by that MN cDNA. WO 95/34650 also provides in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 3A-F</figref> a 10,898 base pair (bp) complete genomic sequence of MN [SEQ ID NO: 3], and in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 6</figref> the nucleotide sequence for the MN promoter [SEQ ID NO: 4]. Those MN cDNA, amino acid, genomic, and promoter sequences are incorporated by reference herein.</div>
    <div num="p-0009" class="description-paragraph style-scope patent-text">Zavada et al., International Publication No. WO 03/100029 (published Dec. 4, 2003) discloses among other MN-related inventions, MN/CA IX-specific MAbs that are directed to non-immunodominant epitopes, including those on the carbonic anhydrase (CA) domain of MN/CA IX. An example of such a MN/CA IX-specific MAb is the V/10 MAb, secreted from the V/10-VU hybridoma.</div>
    <div num="p-0010" class="description-paragraph style-scope patent-text">The MN protein is now considered to be the first tumor-associated carbonic anhydrase isoenzyme that has been described. The carbonic anhydrase family (CA) includes twelve catalytically active zinc metalloenzymes involved in the reversible hydration-dehydration of carbon dioxide: CO<sub class="style-scope patent-text">2</sub>+<figure-callout id="0" label="H" filenames="US08097423-20120117-D00001.png,US08097423-20120117-D00002.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">H<sub class="style-scope patent-text"> </sub> </a></figure-callout> <sub class="style-scope patent-text">2</sub>0<div class="patent-image small-patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/af/8c/6d/fa681e801529a2/US08097423-20120117-P00001.png" class="style-scope patent-text"><img id="CUSTOM-CHARACTER-00001" he="2.79mm" wi="3.56mm" file="US08097423-20120117-P00001.TIF" alt="Figure US08097423-20120117-P00001" img-content="character" img-format="tif" orientation="portrait" inline="no" width="14" height="11" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/af/8c/6d/fa681e801529a2/US08097423-20120117-P00001.png"></a></div>HCO<sub class="style-scope patent-text">3</sub> <sup class="style-scope patent-text"></sup>+H<sup class="style-scope patent-text">+</sup>. CAs are widely distributed in different living organisms. The CAs participate in a variety of physiological and biological processes and show remarkable diversity in tissue distribution, subcellular localization, and biological functions, including pH regulation, CO<sub class="style-scope patent-text">2 </sub>and HCO<sub class="style-scope patent-text">3 </sub>transport, and water and electrolyte balance. [Parkkila and Parkkila, <i class="style-scope patent-text">Scand J Gastroenterol., </i>31: 305-317 (1996); Potter and Harris, <i class="style-scope patent-text">Br J Cancer, </i>89: 2-7 (2003); Wingo et al., <i class="style-scope patent-text">Biochem Biophys Res Commun, </i>288: 666-669 (2001); Christianson and Cox, <i class="style-scope patent-text">Ann Rev Biochem, </i>68: 33-57 (1999); Supuran et al., <i class="style-scope patent-text">Curr Med Chem Cardiov Hemat Agents, </i>2: 51-70 (2004).] CA IX is a glycosylated transmembrane CA isoform with a unique N-terminal proteoglycan-like extension [Opavsky et al. (1996)]. Through transfection studies it has been demonstrated that CA IX can induce the transformation of 3T3 cells [Opavsky et al. (1996)].</div>
    <div num="p-0011" class="description-paragraph style-scope patent-text">Many studies, using the MN-specific monoclonal antibody (MAb) M75, have confirmed the diagnostic/prognostic utility of MN in diagnosing/prognosing precancerous and cancerous cervical lesions [Liao et al., <i class="style-scope patent-text">Am. J. Pathol., </i>145: 598-609 (1994); Liao and Stanbridge, <i class="style-scope patent-text">Cancer Epidemiology, Biomarkers </i>&amp; <i class="style-scope patent-text">Prevention, </i>5: 549-557 (1996); Brewer et al., <i class="style-scope patent-text">Gynecologic Oncology </i>63: 337-344 (1996)]. Immunohistochemical studies with the M75 MAb of cervical carcinomas and a PCR-based (RT-PCR) survey of renal cell carcinomas have identified MN expression as closely associated with those cancers and confirm MN's utility as a tumor biomarker [Liao et al. (1994); Liao and Stanbridge (1996); McKiernan et al., <i class="style-scope patent-text">Cancer Res. </i>57: 2362-2365 (1997)]. In various cancers (notably uterine cervical, ovarian, endometrial, renal, bladder, breast, colorectal, lung, esophageal, head and neck and prostate cancers, among others), CA IX expression is increased and has been correlated with the microvessel density and the levels of hypoxia in some tumors [Koukourakis et al. (2001); Giatromanolaki et al. (2001)].</div>
    <div num="p-0012" class="description-paragraph style-scope patent-text">In tissues that normally do not express MN protein, CA IX positivity is considered to be diagnostic for preneoplastic/neoplastic diseases, such as, lung, breast and cervical precancers/cancers [Swinson et al. (2003); Chia et al. (2001); Loncaster et al. (2001)], among other precancers/cancers. Very few normal tissues have been found to express MN protein to any significant degree; those MN-expressing normal tissues include the human gastric mucosa and gallbladder epithelium, and some other normal tissues of the alimentary tract [Pastorekova and Zavada, Carbonic anhydrase IX (CA IX) as a potential target for cancer therapy, <i class="style-scope patent-text">Cancer Therapy, </i>2: 245-262 (2004); Pastorekova et al., Carbonic Anhydrase IX: Analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts, <i class="style-scope patent-text">Gastroenterology, </i>112: 398-408 (1997); Leppilampi et al., Carbonic anhydrase isozymes IX and XII in gastric tumors, <i class="style-scope patent-text">World J Gastroenterol, </i>9: 1398-1403 (2003)].</div>
    <div num="h-0004" class="description-paragraph style-scope patent-text">MN/CA IX and Hypoxia</div>
    <div num="p-0013" class="description-paragraph style-scope patent-text">Recent studies have revealed that CA IX not only participates in cell adhesion and pH regulation, but also can be induced in hypoxia via the HIF-1 protein binding to the hypoxia-responsive element of the MN promoter [Svastova et al., <i class="style-scope patent-text">Exp Cell Res, </i>290: 332-345 (2003); Wykoff et al., <i class="style-scope patent-text">Cancer Res, </i>60: 7075-7083 (2000)]. Hypoxia is a common feature in solid tumors. It is a pathophysiologic consequence of a structurally and functionally disturbed microcirculation and the deterioration of oxygen diffusion conditions [Hckel and Vaupel (2001)]. Tumor hypoxia has long been known to be associated with poor survival in cancer patients, since it may contribute to the development of more malignant tumor phenotypes and increase tumor invasiveness and metastatic potential [Harris (2002)]. Hypoxia also has an important role in the development of resistance to chemotherapy and radiotherapy [Hckel et al. (1996)].</div>
    <div num="p-0014" class="description-paragraph style-scope patent-text">It is recognized that tumor cells under hypoxic conditions maintain a low extracellular pH (pHe) and a high intracellular pH [Svastova et al. (2004)]. This confers a survival advantage by possible prevention of tumor cell apoptosis and facilitates the local invasiveness of the tumor by breakdown of the extracellular matrix [Svastova et al. (2004)]. In addition, the acidic tumor microenvironment may reduce the uptake of drugs which are weak bases and hence ionized at acid pH [Gerweck and Seetharaman (1996); Raghunand et al., (1999); Raghunand and Gillies (2001)]. For example, under some circumstances, an acidic tumor environment may indicate against the use of anthracyclines.</div>
    <div num="h-0005" class="description-paragraph style-scope patent-text">MN/CA IX Hypoxic Regulation</div>
    <div num="p-0015" class="description-paragraph style-scope patent-text">The transcription of the MN gene is negatively regulated by wild-type von Hippel-Lindau tumor suppressor gene in transfected renal cell carcinoma cells [Ivanov et al., <i class="style-scope patent-text">Proc Natl Acad Sci </i>(USA), 95: 12596-12601 (1998)]. The protein product of the von Hippel-Lindau tumor suppressor gene interacts with the ubiquitin ligase complex that is responsible for targeting HIF-1 for oxygen-dependent proteolysis [Maxwell et al., <i class="style-scope patent-text">Nature, </i>399: 271-275 (1999); Jaakkola et al., <i class="style-scope patent-text">Science, </i>292: 468-472 (2001)]. Thus, low levels of oxygen lead to stabilization of HIF-1, which in turn leads to the increased expression of MN [Wykoff et al. (2000)]. Areas of high expression of MN in cancers are linked to tumor hypoxia as reported in many cancers, and incubation of tumor cells under hypoxic conditions leads to the induction of MN expression [Wykoff et al. (2000); Koukourakis et al., <i class="style-scope patent-text">Clin Cancer Res, </i>7: 3399-3403 (2001); Giatromanolaki et al., <i class="style-scope patent-text">Cancer Res, </i>61: 7992-7998 (2001); Swinson et al., <i class="style-scope patent-text">J Clin Oncoli, </i>21: 473-482 (2003); Chia et al., <i class="style-scope patent-text">J Clin Oncol, </i>19: 3660-3668 (2001); Loncaster et al., <i class="style-scope patent-text">Cancer Res, </i>61: 6394-6399 (2001)]. Expression of MN/CA IX is localized to the perinecrotic area of tumors and has been observed to start at a median distance of 80 m from a blood vessel, where the oxygen tension drops to 1%, in head and neck squamous cell carcinoma [Beasley et al. (2001)].</div>
    <div num="h-0006" class="description-paragraph style-scope patent-text">MN/CA IX and Breast Cancer Therapy</div>
    <div num="p-0016" class="description-paragraph style-scope patent-text">It has been shown that MN/CA IX can acidify the pHe of tumor cells in a culture medium and downregulation reduces the survival of breast tumor cells under hypoxic conditions [Potter and Harris (2003)]. In three studies, the expression of MN/CA IX was associated with poor prognosis independent of the other commonly recognized prognostic parameters such as tumor (T) status, node (N) status, tumor grade, estrogen receptor (ER), and c-erbB2 expression in breast cancer patients [Chia et al. (2001); Bartosova et al. (2002); Span et al. (2003)]. All those studies involved heterogeneous patient populations submitted postoperatively to different treatment strategies (radiotherapy, chemotherapy, and endocrine therapy) or no therapy.</div>
    <div num="p-0017" class="description-paragraph style-scope patent-text">Primary chemotherapy administered to the breast cancer patients is a useful model to identify baseline features able to predict which patients are most likely to benefit from the cytotoxic treatment and is a way to study new biological markers in relation to the predictive information they provide. In addition, tumor biopsy specimens obtained in matched pair cases at diagnosis and definitive surgery provide valuable information on the interaction between biological markers and treatment.</div>
    <div num="p-0018" class="description-paragraph style-scope patent-text">For example, breast cancer patients are routinely tested for the presence or absence of the estrogen receptor in an attempt to predict whether the patients will be resistant or responsive to tamoxifen [Nolvadex; AstraZeneca], a nonsteroidal antiestrogen that is currently the most widely used breast cancer treatment. Based on the current test, cancer patients who test positive for the presence of estrogen receptors (ER positive) are typically prescribed tamoxifen. However, a significant number of ER positive patients are in fact resistant to tamoxifen. Therefore, administration of tamoxifen to a patient who is resistant to its benefits may cause delay by preventing the patient from undergoing more effective treatments. Further, tamoxifen administration has been associated with an increased risk of endometrial cancer. An accurate determination of whether a patient will be susceptible or resistant to the antineoplastic effects of tamoxifen administration, before embarking on such a treatment course, would be a valuable diagnostic tool. Due in large part to the limited ability of clinical criteria to assess accurately an individual's risk, many patients continue to be overtreated or undertreated [Lyman et al. (2007)].</div>
    <div num="p-0019" class="description-paragraph style-scope patent-text">Commercialized multigene assays have been developed to predict clinical outcome for breast cancer. For example, the Oncotype DX diagnostic assay was recently developed by Genomic Health, and tests for 21 genes, including genes associated with proliferation, estrogen and HER-2 activity, invasion, as well as five control genes. This assay provides a recurrence score for lymph node negative breast cancer patients with estrogen receptor positive tumors that have received adjuvant tamoxifen [Paik et al., <i class="style-scope patent-text">Breast Cancer Res. Treat., </i>82: S10 (2003)]. However, such a multigene test is expensive: the cost of Oncotype DX patient testing was estimated in 2005 as $3,450 per patient [Hornberger et al., <i class="style-scope patent-text">Am J Manag Care, </i>11(5): 317 (2005)]. It would be useful to have an assay to predict clinical outcome for tamoxifen treatment of patients with breast cancer, that was relatively inexpensive and could be performed routinely, based on the detection of expression of only one gene, and which could be also performed by immunohistochemistry.</div>
    <div num="p-0020" class="description-paragraph style-scope patent-text">Disclosed herein are methods wherein MN overexpression is shown to be useful as a prognostic marker for estrogen receptor (ER) positive breast cancer, particularly for those patients who are treated with, or under consideration for treatment with, endocrine therapy, particularly tamoxifen therapy. MN positive expression in ER-positive breast cancer patients treated with tamoxifen was found to be a poor prognostic factor, and conversely MN negative expression was found to be a good prognostic factor. The prognostic methods disclosed herein detect MN overexpression, and can identify high-risk estrogen receptor positive breast cancer patients who could benefit from additional and/or alternative therapies, such as adjuvant chemotherapy or immunotherapy and MN-targeted therapies, among other appropriate therapies.</div>
    <heading class="style-scope patent-text">SUMMARY OF THE INVENTION</heading>
    <div num="p-0021" class="description-paragraph style-scope patent-text">The present invention relates to methods of predicting resistance to endocrine therapy, particularly tamoxifen therapy, in a patient afflicted with estrogen receptor (ER) positive breast cancer, comprising detecting, or detecting and quantitating, MN/CA9 overexpression in a sample taken from said patient. The breast cancer patient can be a vertebrate, preferably a mammal, and more preferably a human.</div>
    <div num="p-0022" class="description-paragraph style-scope patent-text">The methods comprise detecting, or detecting and quantitating, MN/CA9 gene expression product(s) in a sample taken from the breast cancer patient, and determining that the patient has greater probability of resistance to endocrine therapy, and/or a poorer prognosis if undergoing endocrine therapy, if the presence, level, intensity and/or extent of MN/CA9 gene expression product(s) indicates that MN/CA9 is overexpressed in said patient sample, than if said MN/CA9 product is not overexpressed in said patient sample. In addition to predicting clinical outcome, the methods of the present invention can also identify high-risk ER-positive breast cancer patients in need of adjuvant chemotherapy, and/or identify candidates for MN-targeted therapies, among other courses of treatment.</div>
    <div num="p-0023" class="description-paragraph style-scope patent-text">In a preferred embodiment of the invention, the MN/CA9 gene expression product is MN antigen, and the methods comprise immunologically detecting MN antigen in a breast tumor tissue sample taken from an ER-positive breast cancer patient. In an alternate preferred embodiment of the invention, the MN/CA9 gene expression product is soluble MN/CA IX antigen (s-CA IX), and the methods comprise immunologically detecting s-CA IX in a body fluid sample, preferably a blood, serum, or breast exudate sample, taken from an ER-positive breast cancer patient.</div>
    <div num="p-0024" class="description-paragraph style-scope patent-text">Preferably, said sample is taken from said breast cancer, or from a metastatic lesion derived from said breast cancer. Such samples can be, for example, tissue specimens, tissue extracts, body fluids, cells, cell lysates and cell extracts, among other samples. Preferred tissue specimens to assay by immunohistochemical staining, for example, include cell smears, histological sections from biopsied tissues or organs, and imprint preparations among other tissue samples. Such tissue specimens can be variously maintained, for example, they can be fresh, frozen, or formalin-, alcohol- or acetone- or otherwise fixed and/or paraffin-embedded and deparaffinized. Preferred tissue samples are formalin-fixed, paraffin-embedded tissue samples.</div>
    <div num="p-0025" class="description-paragraph style-scope patent-text">A poorer prognosis can be measured, for example, in terms of shortened disease-free survival (DFS), shortened overall survival (OS), increased risk of recurrence, and/or increased risk of metastasis, among other clinical endpoints. Preferably, said poorer prognosis is measured in terms of shortened disease-free survival (DFS) or shortened overall survival (OS).</div>
    <div num="p-0026" class="description-paragraph style-scope patent-text">Said endocrine therapy comprises or consists of the use of an antiestrogen or estrogen lowering drug, or drug that modifies endocrine environment. Preferably, said endocrine therapy is a selective estrogen receptor modulator (SERM), a pure antiestrogen, a steroidal aromatase inhibitor, a nonsteroidal aromatase inhibitor, or estrogen. Preferably, said endocrine therapy is selected from the group consisting of tamoxifen, raloxifene, toremifene, fulvestrant, exemestane, letrozole or anastrozole. More preferably, said antiestrogen is tamoxifen.</div>
    <div num="p-0027" class="description-paragraph style-scope patent-text">In one aspect, the invention concerns methods of predicting resistance to endocrine therapy in a breast cancer patient with an ER-positive breast tumor, wherein an exemplary method comprises:</div>
    <div num="p-0028" class="description-paragraph style-scope patent-text">(a) obtaining a breast tumor tissue sample from said patient; and</div>
    <div num="p-0029" class="description-paragraph style-scope patent-text">(b) detecting MN/CA9 gene product overexpression in said sample, wherein said MN/CA9 gene product overexpression is indicative of a greater probability of resistance in said patient to said endocrine therapy, than if said MN/CA9 gene product is not overexpressed;</div>
    <div num="p-0030" class="description-paragraph style-scope patent-text">wherein said MN/CA9 gene product is encoded by a nucleotide sequence selected from the group consisting of:</div>
    <div num="p-0031" class="description-paragraph style-scope patent-text">(1) SEQ ID NO: 1's coding region;</div>
    <div num="p-0032" class="description-paragraph style-scope patent-text">(2) nucleotide sequences that hybridize under stringent hybridization conditions of 50% formamide at 42 degree C. to complement of SEQ ID NO: 1's coding region; and</div>
    <div num="p-0033" class="description-paragraph style-scope patent-text">(3) nucleotide sequences that differ from SEQ ID NO: 1's coding region or from the nucleotide sequences of (2) in codon sequence due to the degeneracy of the genetic code. SEQ ID NO: 1 is the full-length MN cDNA as disclosed in Zavada et al. WO 95/34650, supra.</div>
    <div num="p-0034" class="description-paragraph style-scope patent-text">Preferred assays to be used according to the methods of the invention to detect said MN/CA9 gene product overexpression in detecting step (b) are those wherein said MN/CA9 gene product comprises MN/CA IX or a MN protein, and said assays are selected from the group consisting of Western blots, enzyme-linked immunosorbent assays, radioimmunoassays, competition immunoassays, dual antibody sandwich assays, immunohistochemical staining assays, agglutination assays, and fluorescent immunoassays. More preferably, said MN/CA9 gene product detecting step (b) comprises the use of immunohistochemical staining of tumor cells in a patient sample, wherein if any cells in said sample are immunoreactive, concluding that said patient has a poorer prognosis than if no cells in said sample are immunoreactive. Preferably, the detecting step (b) comprises determining the intensity of MN/CA IX staining, wherein any conventionally detectable MN/CA IX staining is considered to represent MN/CA IX overexpression. Still more preferably, said detecting step (b) comprises the use of a MN/CA IX-specific monoclonal antibody, preferably the M75 MAb secreted by the hybridoma VU-M75 which has Accession No. ATCC HB 11128.</div>
    <div num="p-0035" class="description-paragraph style-scope patent-text">In an alternative preferred embodiment, preferred assays to be used according to the methods of the invention in said MN/CA9 gene overexpression detecting step (b) are nucleic acid-based assays, wherein said MN/CA9 gene expression product comprises a mRNA encoding MN/CA IX, a MN protein, or a MN polypeptide or a cDNA complementary to mRNA encoding MN/CA IX, a MN protein, or a MN polypeptide. Preferably, said detecting step (b) is by in situ hybridization, Northern blotting, PCR, RT-PCR, real-time PCR, or by quantitative real-time RT-PCR. Nucleic acid-based assays for detecting, or detecting and quantitating, MN/CA9 gene overexpression in vertebrate samples are described in greater detail elsewhere, for example, in Zavada et al., U.S. Pat. No. 7,186,514.</div>
    <div num="p-0036" class="description-paragraph style-scope patent-text">An exemplary and preferred method of predicting resistance to endocrine therapy in a breast cancer patient with an ER-positive breast tumor comprises:</div>
    <div num="p-0037" class="description-paragraph style-scope patent-text">(a) obtaining a breast tumor tissue sample from said patient; and</div>
    <div num="p-0038" class="description-paragraph style-scope patent-text">(b) determining MN/CA IX positivity or MN/CA IX negativity in said sample, wherein MN/CA IX positivity is indicative of a greater probability of resistance to said endocrine therapy than MN/CA IX negativity; and wherein MN/CA IX positivity indicates MN/CA IX overexpression. Said endocrine therapy comprises or consists of the use of an antiestrogen or estrogen lowering drug, or drug that modifies the endocrine environment. Preferably, said endocrine therapy is a selective estrogen receptor modulator (SERM), a pure antiestrogen, a steroidal aromatase inhibitor, a nonsteroidal aromatase inhibitor, or estrogen. Preferably, said endocrine therapy is selected from the group consisting of tamoxifen, raloxifene, toremifene, fulvestrant, exemestane, letrozole or anastrozole. More preferably, said antiestrogen is tamoxifen.</div>
    <div num="p-0039" class="description-paragraph style-scope patent-text">An exemplary and particularly preferred method which is predictive of resistance to endocrine therapy, and/or prognostic if undergoing endocrine therapy, for ER-positive breast cancer afflicting a patient comprises:</div>
    <div num="p-0040" class="description-paragraph style-scope patent-text">(a) obtaining a neoplastic sample from said patient;</div>
    <div num="p-0041" class="description-paragraph style-scope patent-text">(b) detecting MN/CA IX in said sample, comprising the use of immunohistochemical staining with MN/CA IX-specific antibody;</div>
    <div num="p-0042" class="description-paragraph style-scope patent-text">(c) determining an MN/CA IX immunoreactivity score of cells in said sample, wherein said sample is assigned an immunoreactivity score with</div>
    <div num="p-0043" class="description-paragraph style-scope patent-text">a value of 0 (zero) if no staining,</div>
    <div num="p-0044" class="description-paragraph style-scope patent-text">a value of 1 if weak staining, or</div>
    <div num="p-0045" class="description-paragraph style-scope patent-text">a value of 2 if strong staining;</div>
    <div num="p-0046" class="description-paragraph style-scope patent-text">and</div>
    <div num="p-0047" class="description-paragraph style-scope patent-text">wherein if the immunoreactivity score of the sample is greater than 0 (zero), concluding in step (d) that said patient has a greater probability of resistance to said endocrine therapy, and/or has a poorer prognosis if undergoing endocrine therapy, than if said immunoreactivity score is 0 (zero).</div>
    <div num="p-0048" class="description-paragraph style-scope patent-text">In another aspect, this invention is directed to a method of predicting resistance to endocrine therapy in an ER-positive breast cancer patient, comprising the use of assays to detect or to detect and quantify soluble MN/CA IX antigen (s-CA IX). An exemplary and preferred method which is predictive of resistance to endocrine therapy for ER-positive breast cancer afflicting a patient comprises:</div>
    <div num="p-0049" class="description-paragraph style-scope patent-text">(a) obtaining a body fluid sample from said patient; and</div>
    <div num="p-0050" class="description-paragraph style-scope patent-text">(b) immunologically detecting s-CA IX in said sample,</div>
    <div num="p-0051" class="description-paragraph style-scope patent-text">wherein s-CA IX in said sample is indicative of a greater probability of resistance of said patient to said endocrine therapy, than if s-CA IX is not detected in said sample. Preferably, said endocrine therapy comprises or consists of the use of an antiestrogen. More preferably, said antiestrogen is tamoxifen. Exemplary assays for detecting, or detecting and quantitating, s-CA IX overexpression in vertebrate body fluid samples are described in greater detail elsewhere [e.g., Pastorek et al., US Patent Application No. US2005031623 A1; Zavada et al., <i class="style-scope patent-text">Br J Cancer, </i>89(6): 1067-71 (2003)].</div>
    <div num="p-0052" class="description-paragraph style-scope patent-text">Further, this invention concerns the coexpression of MN/CA IX and HER-2/neu/c-erbB-2 (HER-2), and diagnostic/prognostic and therapeutic methods in parallel with and/or alternative to those targeting MN/CA IX/CA9. Particularly preferred are assays to detect both s-CA IX [the predominant species being the MN/CA IX extracellular domain (50/54 kilodaltons)] and the HER-2 ectodomain (p100) in the same body fluid sample from an ER-positive breast cancer patient. Backup therapeutic methods targeting MN/CA IX/CA9 and/or HER-2 can be used for patients not responding to, or having low probability of responding to, endocrine therapy. Such integrated diagnostic/prognostic and therapeutic methods with MN/CA IX/CA9 and HER-2 as targets can provide clinicians with more comprehensive resources to help ER-positive breast cancer patients.</div>
    <div num="p-0053" class="description-paragraph style-scope patent-text">The invention also concerns a method of predicting resistance to an endocrine therapy, preferably an antiestrogen therapy, in a breast cancer patient with an ER-positive breast tumor, comprising the use of diagnostic/prognostic imaging to detect the presence or absence of MN/CA IX in one or more tumors in said patient, wherein the presence of MN/CA IX in said one or more tumors is indicative that said patient has a greater probability of resistance to said endrocine therapy, preferably said antiestrogen therapy, than if MN/CA IX is absent in said one or more tumors. Said one or more tumors may be primary breast tumor(s) and/or metastatic tumor(s). Preferably, said diagnostic/prognostic imaging comprises the use of labeled MN/CA IX-specific antibodies or labeled MN/CA IX-specific inhibitors, such as MN/CA IX-specific sulfonamide inhibitors, preferably aromatic and heterocyclic sulfonamides.</div>
    <div num="p-0054" class="description-paragraph style-scope patent-text">Further, the methods of the invention can be used as an aid in the selection of treatment for an ER-positive breast cancer patient. The methods of the invention can be used, for example, to identify those subsets of patients with a higher than average probability of resistance to one or more endocrine therapies, in order to establish additional or alternative therapy regimens. In one embodiment of the invention, if MN/CA9 gene product overexpression is detected in a tumor, or in a metastasis of said tumor, obtained from an ER-positive breast cancer patient, said MN/CA9 gene product overexpression is indicative of greater resistance to antiestrogen therapy, preferably tamoxifen, than if said MN/CA9 gene product is not overexpressed, and therefore indicates that said patient should be administered additional or alternative therapy, preferably a therapy that is not substantially inhibited by acidic pH. Said MN/CA9 gene expression product may comprise, for example, MN/CA IX, a MN protein or a MN polypeptide, an mRNA encoding MN/CA IX, a MN protein or a MN/polypeptide, or a cDNA encoding MN/CA IX, a MN protein or a MN polypeptide. Preferably, said additional or alternative therapy is selected from adjuvant chemotherapy, alternative endocrine therapy, or MN-targeted therapy. More preferably, said adjuvant chemotherapy is a taxane, preferably paclitaxel or docetaxel. Alternatively, said additional or alternative therapy is an anthracycline, preferably epirubicin or doxorubicin. It may be preferred under certain circumstances that the additional or alternative therapy is one that is not affected by acidic pH, whether the effect is on uptake, activity or any other mechanism.</div>
    <div num="p-0055" class="description-paragraph style-scope patent-text">Aspects of the instant invention disclosed herein are described in more detail below.</div>
    <heading class="style-scope patent-text">REFERENCES</heading>
    <div num="p-0056" class="description-paragraph style-scope patent-text">
      </div> <ul class="style-scope patent-text">
        <li id="ul0001-0001" num="0055" class="style-scope patent-text">1. Bartosova et al., Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2<i class="style-scope patent-text">, Journal of Pathology, </i>197: 314-321 (2002).</li>
        <li id="ul0001-0002" num="0056" class="style-scope patent-text">2. Beasley et al., Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density, <i class="style-scope patent-text">Cancer Research, </i>61: 5262-5267 (2001).</li>
        <li id="ul0001-0003" num="0057" class="style-scope patent-text">3. Bottini et al., p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients, <i class="style-scope patent-text">Clinical Cancer Research, </i>6: 2751-2758 (2000).</li>
        <li id="ul0001-0004" num="0058" class="style-scope patent-text">4. Bottini et al., Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial, <i class="style-scope patent-text">Endocrine</i>-<i class="style-scope patent-text">Related Cancer, </i>12: 383-392 (2005).</li>
        <li id="ul0001-0005" num="0059" class="style-scope patent-text">5. Bui et al., Prognostic value of carbonic anhydrase IX and K67 as predictors of survival for renal clear cell carcinoma, <i class="style-scope patent-text">Journal of Urology, </i>171: 2461-2466 (2004).</li>
        <li id="ul0001-0006" num="0060" class="style-scope patent-text">6. Chia and Yorida, Carbonic anhydrase IX (CaIX) is an independent poor prognostic factor in early stage breast cancer: results from a large population-based tissue microarray (TMA) series, <i class="style-scope patent-text">Proceedings of the </i>27<i class="style-scope patent-text">th San Antonio Breast Cancer Symposium</i>, Abstract 3015 (2004).</li>
        <li id="ul0001-0007" num="0061" class="style-scope patent-text">7. Chia et al., Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma, <i class="style-scope patent-text">Journal of Clinical Oncology, </i>19: 3660-3668 (2001).</li>
        <li id="ul0001-0008" num="0062" class="style-scope patent-text">8. Christianson and Cox, Catalysis by metal-activated hydroxide in zinc and manganese metalloenzymes, <i class="style-scope patent-text">Annual Reviews in Biochemistry, </i>68: 33-57 (1999).</li>
        <li id="ul0001-0009" num="0063" class="style-scope patent-text">9. Colpaert et al., The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis, <i class="style-scope patent-text">Breast Cancer Research and Treatment, </i>81: 137-147 (2003).</li>
        <li id="ul0001-0010" num="0064" class="style-scope patent-text">10. Cooper et al., Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor alpha in human breast carcinoma, <i class="style-scope patent-text">Clinical Cancer Research, </i>10: 8720-8727 (2004).</li>
        <li id="ul0001-0011" num="0065" class="style-scope patent-text">11. Coradini et al., Hypoxia and estrogen receptor profile influence the responsiveness of human breast cancer cells to estradiol and antiestrogens, <i class="style-scope patent-text">Cellular and Molecular Life Sciences, </i>61: 76-82 (2004).</li>
        <li id="ul0001-0012" num="0066" class="style-scope patent-text">12. Dowsett et al., Response to specific antioestrogen (ICI182780) in tamoxifen-resistant breast cancer, <i class="style-scope patent-text">Lancet, </i>345: 525 (1995).</li>
        <li id="ul0001-0013" num="0067" class="style-scope patent-text">13. Elston and Ellis, Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, <i class="style-scope patent-text">Histopathology </i>19: 403-410 (1991).</li>
        <li id="ul0001-0014" num="0068" class="style-scope patent-text">14. Gerweck and Seetharaman, Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer, <i class="style-scope patent-text">Cancer Research, </i>56: 1194-1198 (1996).</li>
        <li id="ul0001-0015" num="0069" class="style-scope patent-text">15. Gillies and Deamer, Intracellular pH: methods and applications, <i class="style-scope patent-text">Current Topics in Bioenergetics, </i>9: 63-87 (1978).</li>
        <li id="ul0001-0016" num="0070" class="style-scope patent-text">16. Harris, A. L., Hypoxiaa key regulatory factor in tumour growth, <i class="style-scope patent-text">Nature Reviews Cancer, </i>2: 38-47 (2002).</li>
        <li id="ul0001-0017" num="0071" class="style-scope patent-text">17. Hckel and Vaupel, Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects, <i class="style-scope patent-text">Journal of the National Cancer Institute, </i>93: 266-276 (2001).</li>
        <li id="ul0001-0018" num="0072" class="style-scope patent-text">18. Hckel et al., Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix, <i class="style-scope patent-text">Cancer Research, </i>56: 4509-4515 (1996).</li>
        <li id="ul0001-0019" num="0073" class="style-scope patent-text">19. Hui et al., Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival, <i class="style-scope patent-text">Clinical Cancer Research, </i>8: 2595-2604 (2002).</li>
        <li id="ul0001-0020" num="0074" class="style-scope patent-text">20. Hussain et al., Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder, <i class="style-scope patent-text">Oncology Reports, </i>11: 1005-1010 (2004).</li>
        <li id="ul0001-0021" num="0075" class="style-scope patent-text">21. Kaluzova et al., DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and down-regulation of the hypoxia marker carbonic anhydrase IX, <i class="style-scope patent-text">Molecular and Cellular Biology, </i>24: 5757-5766 (2004).</li>
        <li id="ul0001-0022" num="0076" class="style-scope patent-text">22. Koukourakis et al., Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy, <i class="style-scope patent-text">Clinical Cancer Research, </i>7: 3399-3403 (2001).</li>
        <li id="ul0001-0023" num="0077" class="style-scope patent-text">23. Leek et al., Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast, <i class="style-scope patent-text">British Journal of Cancer, </i>79: 991-995 (1999).</li>
        <li id="ul0001-0024" num="0078" class="style-scope patent-text">24. Loncaster et al., Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix, <i class="style-scope patent-text">Cancer Research, </i>61: 6394-6399 (2001).</li>
        <li id="ul0001-0025" num="0079" class="style-scope patent-text">25. Lyman et al., Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer, <i class="style-scope patent-text">Cancer, </i>109(6): 1011-1018 (2007).</li>
        <li id="ul0001-0026" num="0080" class="style-scope patent-text">26. McCarty et al., Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies, <i class="style-scope patent-text">Archives in Pathology and Laboratory Medicine, </i>109: 716-721 (1985).</li>
        <li id="ul0001-0027" num="0081" class="style-scope patent-text">27. Pastorekova et al., A novel quasi-viral agent, MaTu, is a two-component system, <i class="style-scope patent-text">Virology, </i>187: 620-626 (1992).</li>
        <li id="ul0001-0028" num="0082" class="style-scope patent-text">28. Potter and Harris, Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer, <i class="style-scope patent-text">British Journal of Cancer, </i>89: 2-7 (2003).</li>
        <li id="ul0001-0029" num="0083" class="style-scope patent-text">29. Raghunand and Gillies, pH and chemotherapy, <i class="style-scope patent-text">Novartis Foundation Symposium, </i>240: 199-211 (discussion 265-268) (2001).</li>
        <li id="ul0001-0030" num="0084" class="style-scope patent-text">30. Raghunand et al., Enhancement of chemotherapy by manipulation of tumour pH, <i class="style-scope patent-text">British Journal of Cancer, </i>80: 1005-1011 (1999).</li>
        <li id="ul0001-0031" num="0085" class="style-scope patent-text">31. Roos, A., Weak acids, weak bases and intracellular pH, <i class="style-scope patent-text">Respiratory Physiology, </i>33: 27-30 (1978).</li>
        <li id="ul0001-0032" num="0086" class="style-scope patent-text">32. Schmid et al., HIF-1 and p53: communication of transcription factors under hypoxia, <i class="style-scope patent-text">Journal of Cellular and Molecular Medicine, </i>8: 423-431 (2004).</li>
        <li id="ul0001-0033" num="0087" class="style-scope patent-text">33. Span et al., Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome, <i class="style-scope patent-text">British Journal of Cancer, </i>89: 271-276 (2003).</li>
        <li id="ul0001-0034" num="0088" class="style-scope patent-text">34. Supuran et al., Designing of novel carbonic anhydrase inhibitors and activators, <i class="style-scope patent-text">Current Medicinal Chemistry Cardiovascular and Hematological Agents, </i>2: 51-70 (2004).</li>
        <li id="ul0001-0035" num="0089" class="style-scope patent-text">35. Svastova et al., Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH, <i class="style-scope patent-text">FEBS Letters, </i>577: 439-445 (2004).</li>
        <li id="ul0001-0036" num="0090" class="style-scope patent-text">36. Swinson et al., Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer, <i class="style-scope patent-text">Journal of Clinical Oncology, </i>21: 473-482 (2003).</li>
        <li id="ul0001-0037" num="0091" class="style-scope patent-text">37. Wykoff et al., Hypoxia-inducible expression of tumor-associated carbonic anhydrases, <i class="style-scope patent-text">Cancer Research, </i>60: 7075-7083 (2000).</li>
        <li id="ul0001-0038" num="0092" class="style-scope patent-text">38. Zambetti et al., Sequential adriamycin and CMF in metastatic breast cancer, <i class="style-scope patent-text">Oncologist, </i>2: 223-227 (1997).</li>
      </ul>
    
    <div num="p-0057" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00001" num="00001" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="1"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Abbreviations</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">The following abbreviations are used herein:</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="1"> </td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">aa</td>
                <td class="description-td style-scope patent-text">amino acid</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">ANOVA</td>
                <td class="description-td style-scope patent-text">analysis of variance</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">ATCC</td>
                <td class="description-td style-scope patent-text">American Type Culture Collection</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">bp</td>
                <td class="description-td style-scope patent-text">base pairs</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">CA</td>
                <td class="description-td style-scope patent-text">carbonic anhydrase</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">CAI</td>
                <td class="description-td style-scope patent-text">carbonic anhydrase inhibitor</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">X<sup class="style-scope patent-text">2</sup> </td>
                <td class="description-td style-scope patent-text">Chi-squared</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Ci</td>
                <td class="description-td style-scope patent-text">curie</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Cl</td>
                <td class="description-td style-scope patent-text">confidence interval</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">cm</td>
                <td class="description-td style-scope patent-text">centimeter</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">CMF</td>
                <td class="description-td style-scope patent-text">regimen of cyclophosphamide (600 mg/m<sup class="style-scope patent-text">2</sup>), methotrex-</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">ate (40 mg/m<sup class="style-scope patent-text">2</sup>), and 5-fluorouracil (600 mg/m<sup class="style-scope patent-text">2</sup>)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">CR</td>
                <td class="description-td style-scope patent-text">complete response</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">CS</td>
                <td class="description-td style-scope patent-text">cumulative survival</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">C-terminus</td>
                <td class="description-td style-scope patent-text">carboxyl-terminus</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> C.</td>
                <td class="description-td style-scope patent-text">degrees centigrade</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">DAB</td>
                <td class="description-td style-scope patent-text">diaminobenzidine tetrahydrochloride</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">DFS</td>
                <td class="description-td style-scope patent-text">disease-free survival</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">ds</td>
                <td class="description-td style-scope patent-text">double-stranded</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">EDTA</td>
                <td class="description-td style-scope patent-text">ethylenediaminetetraacetate</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">ELISA</td>
                <td class="description-td style-scope patent-text">enzyme-linked immunosorbent assay</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">EPI</td>
                <td class="description-td style-scope patent-text">epirubicin</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">ER</td>
                <td class="description-td style-scope patent-text">estrogen receptor</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Gr</td>
                <td class="description-td style-scope patent-text">Grade</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">H&amp;E</td>
                <td class="description-td style-scope patent-text">haepatoxylin and eosin</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">HR</td>
                <td class="description-td style-scope patent-text">hazard ratio</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">HRP</td>
                <td class="description-td style-scope patent-text">horseradish peroxidase</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">IC</td>
                <td class="description-td style-scope patent-text">intracellular</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">IFN</td>
                <td class="description-td style-scope patent-text">interferon (exemplary cytokine)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">IL-2</td>
                <td class="description-td style-scope patent-text">interleukin-2 (exemplary cytokine)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">i.v.</td>
                <td class="description-td style-scope patent-text">intravenous</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">kb</td>
                <td class="description-td style-scope patent-text">kilobase</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">kbp</td>
                <td class="description-td style-scope patent-text">kilobase pairs</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">kd or kDa</td>
                <td class="description-td style-scope patent-text">kilodaltons</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">m</td>
                <td class="description-td style-scope patent-text">meter</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">M</td>
                <td class="description-td style-scope patent-text">molar</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">MAb</td>
                <td class="description-td style-scope patent-text">monoclonal antibody</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">min.</td>
                <td class="description-td style-scope patent-text">minute(s)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">mg</td>
                <td class="description-td style-scope patent-text">milligram</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">ml</td>
                <td class="description-td style-scope patent-text">milliliter</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">mM</td>
                <td class="description-td style-scope patent-text">millimolar</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">mmol</td>
                <td class="description-td style-scope patent-text">millimole</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">n</td>
                <td class="description-td style-scope patent-text">number of cases</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">N</td>
                <td class="description-td style-scope patent-text">node status</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">ng</td>
                <td class="description-td style-scope patent-text">nanogram</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">nm</td>
                <td class="description-td style-scope patent-text">nanometer</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">nM</td>
                <td class="description-td style-scope patent-text">nanomolar</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">nt</td>
                <td class="description-td style-scope patent-text">nucleotide</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">N-terminus</td>
                <td class="description-td style-scope patent-text">amino terminus</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">OR</td>
                <td class="description-td style-scope patent-text">odds ratio</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">ORF</td>
                <td class="description-td style-scope patent-text">open reading frame</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">OS</td>
                <td class="description-td style-scope patent-text">overall survival</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">PBS</td>
                <td class="description-td style-scope patent-text">phosphate buffered saline</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">pCR</td>
                <td class="description-td style-scope patent-text">pathological complete response</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">PCR</td>
                <td class="description-td style-scope patent-text">polymerase chain reaction</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">PD</td>
                <td class="description-td style-scope patent-text">tumor progression</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">PG</td>
                <td class="description-td style-scope patent-text">proteoglycan</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">PgR</td>
                <td class="description-td style-scope patent-text">progesterone receptor</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">pHe</td>
                <td class="description-td style-scope patent-text">extracellular pH</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">pI</td>
                <td class="description-td style-scope patent-text">isoelectric point</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">PR</td>
                <td class="description-td style-scope patent-text">partial response</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">RCC</td>
                <td class="description-td style-scope patent-text">renal cell carcinoma</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">RT-PCR</td>
                <td class="description-td style-scope patent-text">reverse transcription polymerase chain reaction</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">SD</td>
                <td class="description-td style-scope patent-text">standard deviation</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">SDS</td>
                <td class="description-td style-scope patent-text">sodium dodecyl sulfate</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">SPSS</td>
                <td class="description-td style-scope patent-text">Statistical Package for the Social Sciences</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">SSPE</td>
                <td class="description-td style-scope patent-text">NaCl (0.18 M), sodium phosphate (0.01 M), EDTA</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">(0.001 M)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Stg</td>
                <td class="description-td style-scope patent-text">stage</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">T</td>
                <td class="description-td style-scope patent-text">tumor stage</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Tam/TAM</td>
                <td class="description-td style-scope patent-text">tamoxifen</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">TM</td>
                <td class="description-td style-scope patent-text">transmembrane</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Tris</td>
                <td class="description-td style-scope patent-text">tris (hydroxymethyl) aminomethane</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Ci</td>
                <td class="description-td style-scope patent-text">microcurie</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">g</td>
                <td class="description-td style-scope patent-text">microgram</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">l</td>
                <td class="description-td style-scope patent-text">microliter</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">M</td>
                <td class="description-td style-scope patent-text">micromolar</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    
    
    <description-of-drawings class="style-scope patent-text">
      <heading class="style-scope patent-text">BRIEF DESCRIPTION OF THE FIGURES</heading>
      <div num="p-0058" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 1</figref> graphically shows disease-free (A) and overall survival (B) of breast cancer patients according to CA IX status.</div>
      <div num="p-0059" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 2</figref> graphically depicts disease-free survival of breast cancer patient subgroups stratified according to CA IX and estrogen receptor (ER) status.</div>
    </description-of-drawings>
    
    
    <heading class="style-scope patent-text">NUCLEOTIDE AND AMINO ACID SEQUENCE SYMBOLS</heading>
    <div num="p-0060" class="description-paragraph style-scope patent-text">The following symbols are used to represent nucleotides herein:</div>
    <div num="p-0061" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00002" num="00002" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Base</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Symbol</td>
                <td class="description-td style-scope patent-text">Meaning</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">A</td>
                <td class="description-td style-scope patent-text">adenine</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">C</td>
                <td class="description-td style-scope patent-text">cytosine</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">G</td>
                <td class="description-td style-scope patent-text">guanine</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">T</td>
                <td class="description-td style-scope patent-text">thymine</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">U</td>
                <td class="description-td style-scope patent-text">uracil</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">I</td>
                <td class="description-td style-scope patent-text">inosine</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">M</td>
                <td class="description-td style-scope patent-text">A or C</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">R</td>
                <td class="description-td style-scope patent-text">A or G</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">W</td>
                <td class="description-td style-scope patent-text">A or T/U</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">S</td>
                <td class="description-td style-scope patent-text">C or G</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Y</td>
                <td class="description-td style-scope patent-text">C or T/U</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">K</td>
                <td class="description-td style-scope patent-text">G or T/U</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">V</td>
                <td class="description-td style-scope patent-text">A or C or G</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">H</td>
                <td class="description-td style-scope patent-text">A or C or T/U</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">D</td>
                <td class="description-td style-scope patent-text">A or G or T/U</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">B</td>
                <td class="description-td style-scope patent-text">C or G or T/U</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">N/X</td>
                <td class="description-td style-scope patent-text">A or C or G or T/U</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <div num="p-0062" class="description-paragraph style-scope patent-text">There are twenty main amino acids, each of which is specified by a different arrangement of three adjacent nucleotides (triplet code or codon), and which are linked together in a specific order to form a characteristic protein. A three-letter or one-letter convention may be used herein to identify said amino acids as follows:</div>
    <div num="p-0063" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00003" num="00003" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="3" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="4"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">3 Ltr.</td>
                <td class="description-td style-scope patent-text">1 Ltr.</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Amino acid name</td>
                <td class="description-td style-scope patent-text">Abbrev.</td>
                <td class="description-td style-scope patent-text">Abbrev.</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="3" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="4"> </td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Alanine</td>
                <td class="description-td style-scope patent-text">Ala</td>
                <td class="description-td style-scope patent-text">A</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Arginine</td>
                <td class="description-td style-scope patent-text">Arg</td>
                <td class="description-td style-scope patent-text">R</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Asparagine</td>
                <td class="description-td style-scope patent-text">Asn</td>
                <td class="description-td style-scope patent-text">N</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Aspartic Acid</td>
                <td class="description-td style-scope patent-text">Asp</td>
                <td class="description-td style-scope patent-text">D</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Cysteine</td>
                <td class="description-td style-scope patent-text">Cys</td>
                <td class="description-td style-scope patent-text">C</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Glutamic Acid</td>
                <td class="description-td style-scope patent-text">Glu</td>
                <td class="description-td style-scope patent-text">E</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Glutamine</td>
                <td class="description-td style-scope patent-text">Gln</td>
                <td class="description-td style-scope patent-text">Q</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Glycine</td>
                <td class="description-td style-scope patent-text">Gly</td>
                <td class="description-td style-scope patent-text">G</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Histidine</td>
                <td class="description-td style-scope patent-text">His</td>
                <td class="description-td style-scope patent-text">H</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Isoleucine</td>
                <td class="description-td style-scope patent-text">Ile</td>
                <td class="description-td style-scope patent-text">I</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Leucine</td>
                <td class="description-td style-scope patent-text">Leu</td>
                <td class="description-td style-scope patent-text">L</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Lysine</td>
                <td class="description-td style-scope patent-text">Lys</td>
                <td class="description-td style-scope patent-text">K</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Methionine</td>
                <td class="description-td style-scope patent-text">Met</td>
                <td class="description-td style-scope patent-text">M</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Phenylalanine</td>
                <td class="description-td style-scope patent-text">Phe</td>
                <td class="description-td style-scope patent-text">F</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Proline</td>
                <td class="description-td style-scope patent-text">Pro</td>
                <td class="description-td style-scope patent-text">P</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Serine</td>
                <td class="description-td style-scope patent-text">Ser</td>
                <td class="description-td style-scope patent-text">S</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Threonine</td>
                <td class="description-td style-scope patent-text">Thr</td>
                <td class="description-td style-scope patent-text">T</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Tryptophan</td>
                <td class="description-td style-scope patent-text">Trp</td>
                <td class="description-td style-scope patent-text">W</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Tyrosine</td>
                <td class="description-td style-scope patent-text">Tyr</td>
                <td class="description-td style-scope patent-text">Y</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Valine</td>
                <td class="description-td style-scope patent-text">Val</td>
                <td class="description-td style-scope patent-text">V</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Unknown or other</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">X</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="3" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="4"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <heading class="style-scope patent-text">DETAILED DESCRIPTION</heading>
    <div num="p-0064" class="description-paragraph style-scope patent-text">The invention provides methods for predicting resistance to endocrine therapy in a patient with an estrogen receptor (ER) positive breast tumor. The methods comprise detecting the presence, level, intensity and/or extent of MN/CA9 gene expression product, if any, in a sample taken from a patient that has been diagnosed with ER-positive breast cancer, particularly a patient being considered for, or undergoing, endocrine therapy. The MN/CA9 gene expression product can be MN/CA IX, a MN protein, a MN polypeptide, soluble MN/CA IX antigen (s-CA IX), MN/CA9 nucleic acids, particularly mRNA encoding MN/CA IX, a MN protein or a MN polypeptide, a cDNA corresponding to an mRNA encoding MN/CA IX, a MN protein or a MN polypeptide, or the like.</div>
    <div num="p-0065" class="description-paragraph style-scope patent-text">As used herein, endocrine therapy refers broadly to any therapy that is considered to modify (at least potentially) the effect of the endocrine environment to reduce growth of a preneoplastic/neoplastic cell or tumor. All endocrine treatment is systemic therapy, and may be medical (eg., through the use of drugs) or surgical (usually by ovariectomy). Types of endocrine therapies include antiestrogens, selective estrogen receptor modulators (SERMs), progesterone, antiprogesterone, estrogen or androgens, among other therapies. Exemplary endocrine therapies include raloxifene, steroidal and nonsteroidal aromatase inhibitors [e.g., Arimidex (anastrozole); Femara (letrozole)], and Faslodex [fulvestrant; ICI 182,780; AstraZeneca]. Endocrine therapies targeting estrogen may inhibit or reduce the amount of estrogen available. For example, aromatase inhibitors prevent the conversion of androgen into estrogen, thereby reducing the amount of estrogen available. Estrogen receptor downregulators inhibit or reduce the number of estrogen receptors on the cell. As used herein, antiestrogen refers to those drugs that antagonize the estrogen receptor, such as tamoxifen, but does not include drugs that primarily act to lower estrogen levels in the body, such as aromatase inhibitors (AIs).</div>
    <div num="p-0066" class="description-paragraph style-scope patent-text">As used herein, chemotherapy refers to any chemical administered to kill, or inhibit the growth of, preneoplastic/neoplastic cells in a patient. Chemotherapy may comprise or consist of one or more alkylating agents, antimetabolites, anthracyclines, plant alkaloids, topoisomerase inhibitors, monoclonal antibodies, tyrosine kinase inhibitors, multikinase inhibitors, and alternative endocrine therapies (i.e., alternative to the endocrine therapy for which patient resistance is predicted).</div>
    <div num="p-0067" class="description-paragraph style-scope patent-text">In one embodiment of the invention, the MN/CA9 gene expression product levels are quantified in the ER-positive breast cancer patient sample, and said levels, including absence of MN/CA9 gene expression product, are correlated with a better or worse prognosis for the patient. Said MN/CA9 gene expression product is preferably MN/CA IX quantitated in a sample taken from the patient. The methods can be used, for example, to predict ER-positive breast cancer patient response to endocrine therapy, and to aid in the selection of therapies. In particular, elevated levels of MN/CA9 gene expression products (above levels found in normal breast cells) can be used to identify high risk ER-positive breast cancer patients in need of adjuvant therapies, particularly those in need of adjuvant therapies from the outset.</div>
    <div num="p-0068" class="description-paragraph style-scope patent-text">A preferred method of detecting, or detecting and quantitating MN/CA9 gene expression product in a patient sample is by immunohistochemical staining of MN/CA IX. More preferably, said MN/CA9 gene expression product detection is by immunohistochemical staining, and said quantitating comprises determining the percentage of immunoreactive cells, the intensity and/or extent of immunostaining of immunoreactive cells. Still more preferably, said detection comprises the use of a MN/CA IX-specific monoclonal antibody, preferably the M75 MAb secreted by the hybridoma VU-M75 which has Accession No. ATCC HB 11128 and has been deposited under the Budapest Treaty at the American Type Culture Collection. In one preferred embodiment of the invention, the immunostaining is quantified in carcinoma cells by semi-quantitative scoring as previously described [Colpaert et al. (2003)], in which a score of 0-2 is given for the intensity of staining (0, no staining; 1, weak staining; 2, moderate to strong staining), and for all comparisons with survival and response, wherein any staining is counted as positive.</div>
    <div num="p-0069" class="description-paragraph style-scope patent-text">In an alternative preferred embodiment, preferred assays to be used according to the methods of the invention in detecting and quantitating overexpression of said MN/CA9 gene expression product in breast cancer cells, are nucleic acid-based assays, wherein said MN/CA9 gene expression product comprises a mRNA encoding MN/CA IX, a MN protein or a MN polypeptide, or a cDNA complementary to mRNA encoding MN/CA IX, a MN protein or a MN polypeptide. Preferably, said detecting and quantitating are by in situ hybridization or by Northern blotting.</div>
    <div num="p-0070" class="description-paragraph style-scope patent-text">Suitable detection means include the use of labels such as radionuclides, enzymes, coenzymes, fluorescers, chemiluminescers, chromogens, enzyme substrates or co-factors, enzyme inhibitors, free radicals, particles, dyes and the like. Such labeled reagents may be used in a variety of well known assays, such as radioimmunoassays, enzyme immunoassays, e.g., ELISA, fluorescent immunoassays, and the like. See for example, U.S. Pat. Nos. 3,766,162; 3,791,932; 3,817,837; and 4,233,402.</div>
    <div num="p-0071" class="description-paragraph style-scope patent-text">It can be appreciated by those of skill in the art that various other preneoplastic/neoplastic samples can be used to quantify the MN/CA9 gene expression products. For example, in the case of a patient afflicted with a breast tumor, the sample may be taken from the tumor or from a metastatic lesion derived from the tumor, or from the extracellular fluid within or immediately surrounding the tumor or metastatic lesion.</div>
    <div num="h-0012" class="description-paragraph style-scope patent-text">Neoplastic Cells/Tissues</div>
    <div num="p-0072" class="description-paragraph style-scope patent-text">As used herein, cancerous and neoplastic have equivalent meanings, as well as precancerous and preneoplastic.</div>
    <div num="p-0073" class="description-paragraph style-scope patent-text">In a preferred embodiment of the invention, the MN/CA9 gene expression product is MN/CA IX antigen, and the MN/CA IX antigen is detected and quantitated in vertebrate samples, preferably mammalian samples, more preferably human samples, comprising preneoplastic/neoplastic cells, particularly, neoplastic cells. Such samples can be tissue specimens, tissue extracts, body fluids, cells, cell lysates and cell extracts, among other samples. Preferred tissue specimens to assay by immunohistochemical staining, for example, include cell smears, histological sections from biopsied tissues or organs, and imprint preparations among other tissue samples. An exemplary immunohistochemical staining protocol is described below in the <i class="style-scope patent-text">Materials and Methods </i>section (infra). Such tissue specimens can be variously maintained; for example, they can be fresh, frozen, or formalin-, alcohol- or acetone- or otherwise fixed and/or paraffin-embedded and deparaffinized. Biopsied tissue samples can be, for example, those samples removed by aspiration, bite, brush, cone, chorionic villus, endoscopic, excisional, incisional, needle, fine needle, percutaneous punch, and surface biopsies, among other biopsy techniques. Preferred tissue samples are formalin-fixed, paraffin-embedded tissue samples.</div>
    <div num="h-0013" class="description-paragraph style-scope patent-text">Tumor Stage and Grade</div>
    <div num="p-0074" class="description-paragraph style-scope patent-text">The TNM classification devised by the International Union Against Cancer (UICC) and accepted by the American Joint Commission on Cancer Staging is a world standard [Greene et al, eds. <i class="style-scope patent-text">American Joint Committee on Cancer </i>(<i class="style-scope patent-text">AJCC</i>) <i class="style-scope patent-text">Cancer Staging Manual. </i>6th ed. New York: Springer-Verlag, (2002)]. The TNM is based on the clinical features of tumor (T), the regional lymph nodes (N), and the presence or absence of distant metastases (M). The tumor is characterized by its size, so that a T1 is a tumor less than 2 cm, a T2 is 2 to 5 cm, and a T3 is over 5 cm. Similarly, N0 represents negative, or normal, regional lymph nodes, and so on [see, e.g., Kufe et al. (eds.), <i class="style-scope patent-text">Cancer Medicine </i>6, London: B. C. Decker, Inc., (2003), Section 31, Subsection 121].</div>
    <div num="p-0075" class="description-paragraph style-scope patent-text">Tumor grade indicates the degree of tumor differentiation. In general, a low grade indicates a well differentiated tumor, and a high grade indicates an undifferentiated tumor. In the Examples described below, the Nottingham system [Elston and Ellis (1991)] was used to determine tumor grade.</div>
    <div num="p-0076" class="description-paragraph style-scope patent-text">Other methods of determining tumor stage and grade are known in the art and could be adapted to be used according to the methods of the invention.</div>
    <div num="h-0014" class="description-paragraph style-scope patent-text">Assays</div>
    <div num="p-0077" class="description-paragraph style-scope patent-text">According to the methods of the instant invention, many assays can be used to determine MN/CA9 gene overexpression in a sample taken from a breast cancer patient. Many formats can be adapted for use with the methods of the present invention. For example, the detection and quantitation of MN/CA IX can be performed by Western blots, enzyme-linked immunosorbent assays, radioimmunoassays, competition immunoassays, dual antibody sandwich assays, immunohistochemical staining assays, agglutination assays, fluorescent immunoassays, immunoelectron and scanning microscopy using immunogold, among other assays commonly known in the art. The quantitation of MN/CA9 gene expression products in such assays can be adapted by conventional methods known in the art; for example, if the detection method is by immunohistochemical staining, the determination of MN/CA IX overexpression can be performed by determining the percentage of immunoreactive cells and/or the intensity or extent of immunostaining of immunoreactive cells, and can additionally comprise addition or multiplication of these values, or other mathematical calculations using these values.</div>
    <div num="p-0078" class="description-paragraph style-scope patent-text">The monoclonal antibodies useful according to this invention to identify MN proteins/polypeptides can be labeled in any conventional manner, for example, with enzymes such as horseradish peroxidase (HRP), fluorescent compounds, or with radioactive isotopes such as, <sup class="style-scope patent-text">125</sup>I, among other labels. A preferred label according to this invention is the method of labeling the antibodies using peroxidase. Also preferred is <sup class="style-scope patent-text">125</sup>I, and a preferred method of labeling the antibodies is by using chloramine-T [Dalbadie-McFarland et al., <i class="style-scope patent-text">PNAS </i>(USA), 79(21): 6409-6413 (November 1982)]. Many other means of visualizing the MN/CA9 gene expression products known to those of skill in the art can also be used.</div>
    <div num="p-0079" class="description-paragraph style-scope patent-text">It can further be appreciated that alternate methods, in addition to those disclosed herein, can be used to detect and quantify the MN/CA9 gene expression products. For example, immunological assays for detecting, or detecting and quantitating, s-CA IX overexpression in human body fluid samples are described in Pastorek et al., US Patent Application No. US2005031623 A1, and Zavada et al., <i class="style-scope patent-text">Br J Cancer, </i>89(6): 1067-71 (2003). Body fluids which can be assayed for the presence of s-CA IX can include any of the following: blood, serum, plasma, semen, breast exudate, gastric secretions, fecal suspensions, bile, saliva, tears, sputum, mucous, urine, lymph, cytosols, ascites, pleural effusions, amniotic fluid, bladder washes, bronchioalveolar lavages and cerebrospinal fluid, among other fluids. It is preferred that the MN antigen be concentrated from a larger volume of body fluid before testing. A preferred body fluid to assay for breast cancer would be breast exudate or serum.</div>
    <div num="h-0015" class="description-paragraph style-scope patent-text">Exemplary Immunohistochemical Assays</div>
    <div num="p-0080" class="description-paragraph style-scope patent-text">An exemplary semiquantitative immunohistochemical assay described in Example 1 below uses antibody staining to investigate the expression of MN/CA IX. Two core tissue biopsies are taken from the paraffin-embedded tissue section of an ER-positive breast cancer patient, and stained with the MN/CA IX-specific monoclonal antibody M75. The sections are then reacted with a secondary rabbit anti-mouse antibody labeled with HRP (horseradish peroxidase). The immunoperoxidase complexes are then visualized with a chromogen, such as diaminobenzidine tetrahydrochloride (DAB) or 3-amino-9-ethyl carbazole (AEC). The immunostaining of breast cancer patient samples was quantified by semi-quantitative scoring as previously described (Colpaert et al. 2003).</div>
    <div num="h-0016" class="description-paragraph style-scope patent-text">Nucleic Acid-Based Assays</div>
    <div num="p-0081" class="description-paragraph style-scope patent-text">In certain embodiments of the invention, overexpression of mRNA or cDNA that encodes MN/CA IX, a MN protein or a MN polypeptide is detected and correlated with a prediction of endocrine therapy resistance, preferably tamoxifen resistance, and/or prognosis for an ER-positive breast cancer patient. Nucleic acid-based assays for detecting, or detecting and quantitating, MN/CA9 gene overexpression in vertebrate samples are described in greater detail elsewhere, for example, in Zavada et al., U.S. Pat. No. 7,186,514. An exemplary nucleic acid-based method is Northern blotting, where the nucleic acid sequence used as a probe for detecting MN/CA9-specific mRNA expression is complementary to all or part of the MN/CA9 cDNA sequence. A preparation of RNA is run on a denaturing agarose gel, and transferred to a suitable support, such as activated cellulose, nitrocellulose or glass or nylon membranes. The nucleic acids used to detect the MN/CA9 mRNA or cDNA may be radiolabelled and analyzed by autoradiography. Non-radioactive labels, for example, such as fluorophores or reporter groups such as digoxigenin may also be used to detect the MN/CA9 mRNA or cDNA.</div>
    <div num="p-0082" class="description-paragraph style-scope patent-text">An alternate preferred method for measuring MN-specific mRNA expression is the detection of CA9 mRNA expression via hybridization of a nucleic acid probe derived from MN/CA9 cDNA sequence to RT-PCR products generated from RNA isolated from a biological sample. Exemplary PCR primers designed to amplify a 240 bp cDNA fragment of the CA9 gene are <figure-callout id="5" label="sense" filenames="US08097423-20120117-D00002.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">sense</a></figure-callout> 5-AGGAGGATCTGCC CAGTGA-3 [SEQ ID NO: 11]; antisense 5-GCCAATGACTCTGGTCATC-3) [SEQ ID NO: 12]. Murakami et al. and Uemura et al. have reported that MN detection by RT-PCR in renal cell carcinoma (RCC) patient samples correlate well with immunohistochemistry [Murakami et al., <i class="style-scope patent-text">BJU Int., </i>83: 743-747 (1999); Uemura et al., <i class="style-scope patent-text">Br. J. Cancer, </i>81: 741-746 (1999)].</div>
    <div num="p-0083" class="description-paragraph style-scope patent-text">According to the methods of the invention, the MN/CA9 mRNA or cDNA that is detected in the nucleic-acid based assays represents nucleic acid sequences that are unique to the MN gene. Said MN/CA9 mRNA or cDNA that is detected in the nucleic-acid based assays is preferably at least 16 nucleotides in length, but may be considerably longer. Preferably, said MN/CA9 mRNA (or cDNA) encodes (or hybridizes under stringent hybridization conditions to nucleic acids that encode) MN proteins or polypeptides that are specifically bound by monoclonal antibodies designated M75 that are produced by the hybridoma VU-M75 deposited at the American Type Culture Collection (ATCC) at 10801 University Blvd., Manassas, Va. 20110-2209 (USA) under ATCC No. HB 11128, and/or by monoclonal antibodies designated V/10 produced by the hybridoma V/10-VU deposited at the International Depository Authority (IDA) of the Belgian Coordinated Collections of Microorganisms (BCCM) at the Laboratorium voor Moleculaire Blologie-Plasmidencollectie (LMPB) at the Universeit Gent, K. L. Ledeganckstraat 35, B-9000 Gent, Belgium [BCCM/LMBP] under the Accession No. LMBP 6009CB.</div>
    <div num="h-0017" class="description-paragraph style-scope patent-text">MN Gene and Protein</div>
    <div num="p-0084" class="description-paragraph style-scope patent-text">The terms MN/CA IX and MN/CA9 are herein considered to be synonyms for MN. Also, the G250 antigen is considered to refer to MN protein/polypeptide [Uemura et al., <i class="style-scope patent-text">J. Urol. </i>157 (4 Suppl.): 377 (Abstract 1475; 1997)].</div>
    <div num="p-0085" class="description-paragraph style-scope patent-text">Zavada et al., WO 93/18152 and/or WO 95/34650 disclose the MN cDNA sequence [SEQ ID NO: 1], the MN amino acid sequence [SEQ ID NO: 2], and the MN genomic sequence [SEQ ID NO: 3]. The MN gene is organized into 11 exons and 10 introns.</div>
    <div num="p-0086" class="description-paragraph style-scope patent-text">The ORF of the MN cDNA [SEQ ID NO: 1] has the coding capacity for a 459 amino acid protein with a calculated molecular weight of 49.7 kd. The overall amino acid composition of MN/CA IX is rather acidic, and predicted to have a pI of 4.3. Analysis of native MN/CA IX from CGL3 cells by two-dimensional electrophoresis followed by immunoblotting has shown that in agreement with computer prediction, MN/CA IX is an acidic protein existing in several isoelectric forms with pIs ranging from 4.7 to 6.3. [CGL3 cells are hybrid HeLa fibroblast cells that are tumorigenic, derived from HeLa D98/AH.2 (also known as HeLa S), a mutant HeLa clone that is hypoxanthine guanine phosphoribosyl transferase-deficient (HGPRT<sup class="style-scope patent-text"></sup>) reported in Stanbridge et al., <i class="style-scope patent-text">Science, </i>215: 252-259 (15 Jan. 1982).]</div>
    <div num="p-0087" class="description-paragraph style-scope patent-text">The first thirty seven amino acids of MN/CA IX is the putative MN signal peptide [SEQ ID NO: 7]. MN/CA IX has an extracellular domain [amino acids (aa) 38-414; SEQ ID NO: 8], a transmembrane domain [aa 415-434; SEQ ID NO: 9] and an intracellular domain [aa 435-459; SEQ ID NO: 10]. The extracellular domain contains the proteoglycan-like domain [aa 53-111: SEQ ID NO: 5] and the carbonic anhydrase (CA) domain [aa 135-391; SEQ ID NO: 6].</div>
    <div num="p-0088" class="description-paragraph style-scope patent-text">The CA domain is essential for induction of anchorage independence, whereas the TM anchor and IC tail are dispensable for that biological effect. The MN protein is also capable of causing plasma membrane ruffling in the transfected cells and appears to participate in their attachment to the solid support. The data evince the involvement of MN in the regulation of cell proliferation, adhesion and intercellular communication.</div>
    <div num="h-0018" class="description-paragraph style-scope patent-text">MN Proteins and Polypeptides</div>
    <div num="p-0089" class="description-paragraph style-scope patent-text">The phrase MN proteins and/or polypeptides (MN proteins/polypeptides) is herein defined to mean proteins and/or polypeptides encoded by an MN gene or fragments thereof. An exemplary and preferred MN protein according to this invention has the deduced amino acid sequence represented by SEQ ID NO: 2. Preferred MN proteins/polypeptides are those proteins and/or polypeptides that have substantial homology with the MN protein [SEQ ID NO: 2]. For example, such substantially homologous MN proteins/polypeptides are those that are reactive with MN-specific antibodies, preferably the Mab M75 or its equivalent. The VU-M75 hybridoma that secretes the M75 Mab was deposited at the ATCC under HB 11128 on Sep. 17, 1992.</div>
    <div num="p-0090" class="description-paragraph style-scope patent-text">A polypeptide or peptide is a chain of amino acids covalently bound by peptide linkages and is herein considered to be composed of 50 or less amino acids. A protein is herein defined to be a polypeptide composed of more than 50 amino acids. The term polypeptide encompasses the terms peptide and oligopeptide.</div>
    <div num="p-0091" class="description-paragraph style-scope patent-text">As used herein, MNCA IX positivity or presence of MN/CA9 gene expression product refers to a determination that the cells in a preneoplastic/neoplastic sample taken from an ER-positive breast cancer patient overexpress the MN/CA9 gene. Correspondingly, MN/CA IX negativity or absence of MN/CA9 gene expression product refers to a determination that cells in a preneoplastic/neoplastic sample taken from an ER-positive breast cancer patient do not overexpress the MN/CA9 gene.</div>
    <div num="p-0092" class="description-paragraph style-scope patent-text">It can be appreciated that a protein or polypeptide produced by a preneoplastic/neoplastic cell in vivo could be altered in sequence from that produced by a tumor cell in cell culture or by a transformed cell. Thus, MN proteins and/or polypeptides which have varying amino acid sequences including without limitation, amino acid substitutions, extensions, deletions, truncations, interpolations and combinations thereof, fall within the contemplated scope of this invention, provided the protein or polypeptide containing them is immunogenic, and antibodies elicited by such a polypeptide or protein cross-react with naturally occurring MN proteins and polypeptides to a sufficient extent to provide protective immunity and/or anti-tumorigenic activity when administered as a vaccine. It can also be appreciated that a protein extant within body fluids is subject to degradative processes, such as, proteolytic processes; thus, MN proteins that are significantly truncated and MN polypeptides may be found in body fluids, such as, sera. The phrase MN antigen is used herein to encompass MN proteins and/or polypeptides.</div>
    <div num="p-0093" class="description-paragraph style-scope patent-text">It will further be appreciated that the amino acid sequence of MN proteins and polypeptides can be modified by genetic techniques. One or more amino acids can be deleted or substituted. Such amino acid changes may not cause any measurable change in the biological activity of the protein or polypeptide and result in proteins or polypeptides which are within the scope of this invention, as well as, MN muteins.</div>
    <div num="h-0019" class="description-paragraph style-scope patent-text">Nucleic Acid Probes</div>
    <div num="p-0094" class="description-paragraph style-scope patent-text">Nucleic acid probes of this invention are those comprising sequences that are complementary or substantially complementary to the MN cDNA sequence [SEQ ID NO: 1] or to other MN gene sequences, such as, the complete genomic sequence [SEQ ID NO: 3]. The phrase substantially complementary is defined herein to have the meaning as it is well understood in the art and, thus, used in the context of standard hybridization conditions. The stringency of hybridization conditions can be adjusted to control the precision of complementarity. Two nucleic acids are, for example, substantially complementary to each other, if they hybridize to each other under stringent hybridization conditions.</div>
    <div num="h-0020" class="description-paragraph style-scope patent-text">Stringent Hybridization Conditions</div>
    <div num="p-0095" class="description-paragraph style-scope patent-text">Stringent hybridization conditions are considered herein to conform to standard hybridization conditions understood in the art to be stringent. Only very closely related nt sequences having a homology of at least 80-90%, preferably at least 90%, would hybridize to each other under stringent hybridization conditions.</div>
    <div num="p-0096" class="description-paragraph style-scope patent-text">For example, it is generally understood that stringent conditions encompass relatively low salt and/or high temperature conditions, such as provided by 0.02 M to 0.15 M NaCl at temperatures of 50 C. to 70 C. such as, 0.15 M to 0.9 M salt at temperatures ranging from 20 C. to 55 C. Less stringent conditions can be made more stringent by adding increasing amounts of formamide, which serves to destabilize hybrid duplexes as does increased temperature, such as provided by 0.15 M to 0.9 M NaCl in the presence of 50% formamide at 42 C. with a final wash of 0.1% SSPE and 0.1% SDS at 65 C.</div>
    <div num="p-0097" class="description-paragraph style-scope patent-text">Exemplary stringent hybridization conditions are described in Sambrook et al., <i class="style-scope patent-text">Molecular Cloning: A Laboratory Manual</i>, pages 1.91 and 9.47-9.51 (Second Edition, Cold Spring Harbor Laboratory Press; Cold Spring Harbor, N.Y.; 1989); Maniatis et al., <i class="style-scope patent-text">Molecular Cloning: A Laboratory Manual</i>, pages 387-389 (Cold Spring Harbor Laboratory; Cold Spring Harbor, N.Y.; 1982); Tsuchiya et al., <i class="style-scope patent-text">Oral Surgery, Oral Medicine, Oral Pathology. </i>71(6): 721-725 (June 1991); and in U.S. Pat. No. 5,989,838, U.S. Pat. No. 5,972,353, U.S. Pat. No. 5,981,711, and U.S. Pat. No. 6,051,226.</div>
    <div num="h-0021" class="description-paragraph style-scope patent-text">Antibodies</div>
    <div num="p-0098" class="description-paragraph style-scope patent-text">The term antibodies is defined herein to include not only whole antibodies but also biologically active fragments of antibodies, preferably fragments containing the antigen binding regions. Further included in the definition of antibodies are bispecific antibodies that are specific for MN protein and to another tissue-specific antigen.</div>
    <div num="p-0099" class="description-paragraph style-scope patent-text">Antibodies useful according to the methods of the invention may be prepared by conventional methodology and/or by genetic engineering. Antibody fragments may be genetically engineered, preferably from the variable regions of the light and/or heavy chains (V<sub class="style-scope patent-text">H </sub>and V<sub class="style-scope patent-text">L</sub>), including the hypervariable regions, and still more preferably from both the V<sub class="style-scope patent-text">H </sub>and V<sub class="style-scope patent-text">L </sub>regions. For example, the term antibodies as used herein includes polyclonal and monoclonal antibodies and biologically active fragments thereof including among other possibilities univalent antibodies [Glennie et al., <i class="style-scope patent-text">Nature, </i>295: 712-714 (1982)]. Fab proteins including Fab and F(ab)<sub class="style-scope patent-text">2 </sub>fragments whether covalently or non-covalently aggregated; light or heavy chains alone, preferably variable heavy and light chain regions (V<sub class="style-scope patent-text">H </sub>and V<sub class="style-scope patent-text">L </sub>regions), and more preferably including the hypervariable regions [otherwise known as the complementarity determining regions (CDRs) of the V<sub class="style-scope patent-text">H </sub>and V<sub class="style-scope patent-text">L </sub>regions]; Fc proteins; hybrid antibodies capable of binding more than one antigen; constant-variable region chimeras; composite immunoglobulins with heavy and light chains of different origins; bispecific antibodies, preferably bispecific MAbs; altered antibodies with improved specificity and other characteristics as prepared by standard recombinant techniques and also oligonucleotide-directed mutagenesis techniques [Dalbadie-McFarland et al., <i class="style-scope patent-text">PNAS </i>(USA), 79(21): 6409-6413 (1982)]. Particularly preferred antibodies, particularly for therapeutic use, are humanized, preferably fully humanized antibodies, preferably fully humanized MN/CA IX-specific monoclonal antibodies or biologically active fragments thereof.</div>
    <div num="p-0100" class="description-paragraph style-scope patent-text">The antibodies useful according to this invention to identify MN proteins/polypeptides can be labeled in any conventional manner, for example, with enzymes such as horseradish peroxidase (HRP), fluorescent compounds, or with radioactive isotopes such as, <sup class="style-scope patent-text">125</sup>I, among other labels. A preferred label according to this invention is <sup class="style-scope patent-text">125</sup>I, and a preferred method of labeling the antibodies is by using chloramine-T [Hunter, W. M., Radioimmunoassay, <i class="style-scope patent-text">In: Handbook of Experimental Immunology</i>, pp. 14.1-14.40 (D. W. Weir ed.; Blackwell, Oxford/London/Edinburgh/Melbourne; 1978)].</div>
    <div num="p-0101" class="description-paragraph style-scope patent-text">Representative monoclonal antibodies useful according to this invention include Mabs M75, MN9, MN12 and MN7 described in earlier Zavada et al. patents and patent applications. [U.S. Pat. No. 6,297,041; U.S. Pat. No. 6,204,370; U.S. Pat. No. 6,093,548; U.S. Pat. No. 6,051,226; U.S. Pat. No. 6,004,535; U.S. Pat. No. 5,989,838; U.S. Pat. No. 5,981,711; U.S. Pat. No. 5,972,353; U.S. Pat. No. 5,955,075; U.S. Pat. No. 5,387,676; US App. Nos: 20030049828 and 20020137910; and Int'l. Pub. No. WO 03/100029]. Monoclonal antibodies useful according to this invention serve to identify MN proteins/polypeptides in various laboratory diagnostic/prognostic tests, for example, in clinical samples. For example, monoclonal antibody M75 (Mab M75) is produced by mouse lymphocytic hybridoma VU-M75, which was deposited under ATCC designation HB 11128 on Sep. 17, 1992 at the American Tissue Type Culture Collection [ATCC]. The production of hybridoma VU-M75 is described in Zavada et al., International Publication No. WO 93/18152. Mab M75 recognizes both the nonglycosylated GST-MN fusion protein and native MN protein as expressed in CGL3 cells equally well. The M75 Mab recognizes both native and denatured forms of MN protein [Pastorekova et al., <i class="style-scope patent-text">Virology, </i>187: 620-626 (1992)].</div>
    <div num="p-0102" class="description-paragraph style-scope patent-text">General texts describing additional molecular biological techniques useful herein, including the preparation of antibodies include Berger and Kimmel, <i class="style-scope patent-text">Guide to Molecular Cloning Techniques, Methods in Enzymology</i>, Vol. 152, Academic Press, Inc., Sambrook et al., <i class="style-scope patent-text">Molecular Cloning: A Laboratory Manual</i>, (Second Edition, Cold Spring Harbor Laboratory Press; Cold Spring Harbor, N.Y.; 1989) Vol. 1-3<i class="style-scope patent-text">; Current Protocols in Molecular Biology</i>, F. M. Ausabel et al. [Eds.], Current Protocols, a joint venture between Green Publishing Associates, Inc. and John Wiley &amp; Sons, Inc. (supplemented through 2000), Harlow et al., <i class="style-scope patent-text">Monoclonal Antibodies: A Laboratory Manual</i>, Cold Spring Harbor Laboratory Press (1988), Paul [Ed.]; <i class="style-scope patent-text">Fundamental Immunology</i>, Lippincott Williams &amp; Wilkins (1998), and Harlow et al., <i class="style-scope patent-text">Using Antibodies: A Laboratory Manual</i>, Cold Spring Harbor Laboratory Press (1998).</div>
    <div num="h-0022" class="description-paragraph style-scope patent-text">MN/CA IX and Prognosis: Use in Breast Cancer Therapy Selection</div>
    <div num="p-0103" class="description-paragraph style-scope patent-text">As MN/CA IX positive staining correlated with worse outcome and tamoxifen resistance (Example 1), detection and quantitation of CA IX can be used to identify high-risk patients in need of therapies other than tamoxifen, or in need of adjuvant therapies, including adjuvant chemotherapy and MN-targeted therapies. Careful patient selection and stratification to various adjuvant therapies may delineate those patients most likely to respond to treatment. For example, resistance to tamoxifen does not necessarily imply resistance to other endocrine therapies, including other antiestrogens. Conventional treatment options for women who are resistant to tamoxifen may include discontinuation of tamoxifen, an alternative endocrine therapy, or systemic chemotherapy; however, resistance to tamoxifen does not necessarily indicate against the use of tamoxifen, if clinical factors indicate that its continued use may have some benefit. Similarly, therapies based on monoclonal antibodies to CA IX or immunotherapy with CA IX-based vaccine, or CA9-directed gene therapies can also be considered according to CA IX detection and quantitation.</div>
    <div num="h-0023" class="description-paragraph style-scope patent-text">Selection of Additional/Alternative Therapies</div>
    <div num="p-0104" class="description-paragraph style-scope patent-text">In one aspect of the invention, the presence of MN/CA9 gene expression product in a sample from a breast cancer patient with an ER-positive tumor is indicative of probable resistance to endocrine therapy, particularly antiestrogen therapy, more particularly tamoxifen, and of selection and administration of additional or alternative therapies. Such additional or alternative therapies may comprise adjuvant chemotherapy, alternative endocrine therapy, MN-targeted therapy, and therapies targeting additional oncogenes or oncoproteins, preferably oncoproteins such as Her-2 whose overexpression has been correlated with MN/CA9 overexpression. In general, if a tumor appears to be rapidly progressing, adjuvant non-endocrine chemotherapy would be preferred over alternative endocrine therapy. A finding of probable resistance to an endocrine therapy, particularly tamoxifen, may still indicate that there can be a clinical benefit to administering that therapy, depending upon clinically approved protocols. For example, tamoxifen may still be administered to breast cancer patients that have ER-positive, MN-positive tumors. However, the finding of an ER-positive, MN-positive tumor in a breast cancer patient is an indication that the patient should be treated more aggressively (with additional therapy or therapies) from the outset.</div>
    <div num="p-0105" class="description-paragraph style-scope patent-text">In view of a prediction of probable resistance to antiestrogens, patient therapy selection will depend upon many additional factors, such as a woman's menopausal status, and the grade, progress, and stage of the breast cancer (e.g., low or high grade, rapid or slow progression, early stage or metastatic). In general, however, the presence of MN/CA9 gene expression in an ER-positive breast cancer patient sample would point to selection of an additional/alternate therapy, preferably in certain cases, those unaffected by low pH, as MN/CA9 is associated with acidification of the extracellular environment.</div>
    <div num="p-0106" class="description-paragraph style-scope patent-text">The mechanism for the correlation of CA IX positivity and tamoxifen resistance in ER-positive breast cancer is not clearly understood. For example, one fairly probable underlying mechanism is that wherein CA IX is a marker for biochemical pathways that bypass the estrogen receptor. Under that understanding, the presence of CA IX in a tumor derived from an ER-positive breast cancer patient would be considered to indicate that the patient would be resistant to endocrine therapies in general, and other therapeutic options may be preferably indicated instead (nonendocrine chemotherapies such as, e.g., taxols and MN-targeted therapies, among others). However, it could be that CA IX is acting more predominantly as a marker of acidic inhibition of tamoxifen uptake, under which understanding it would be considered likely that other endocrine therapies could be used with clinical benefit.</div>
    <div num="p-0107" class="description-paragraph style-scope patent-text">I. Additional/Alternative Chemotherapy</div>
    <div num="p-0108" class="description-paragraph style-scope patent-text">In the case of CA IX-positive expression and consequent prediction of probable resistance to endocrine treatment, particularly tamoxifen resistance, in ER-positive breast cancer, additional/alternative therapies that can be considered include adjuvant chemotherapy. Preferred adjuvant chemotherapy would comprise a taxane, preferably paclitaxel [Taxol], protein-bound paclitaxel [Abraxane] or docetaxel [Taxotere]. Other adjuvant chemotherapy that can be considered for use includes Gemcitabine [Gemzar; Eli Lilly and Co.], a nucleoside analog; vinorelbine [Navelbine]; capecitabine [Xeloda], ixabepilone [Ixempra], mitoxantrone [Novantrone]; and leucovorin. Depending on the clinical context, in certain cases the anthracyclines epirubicin and doxorubicin would be preferably used. Other preferred chemotherapy based on the presence of CA IX in breast tumors would comprise prodrugs that are activated by hypoxia.</div>
    <div num="p-0109" class="description-paragraph style-scope patent-text">On the other hand, in certain cases depending on clinical factors, weakly basic chemotherapeutic agents would not be preferred alternative chemotherapy for CA IX-expressing ER-positive breast cancers. Such weakly basic chemotherapeutic agents prescribed for breast cancer include, for example, the vinca alkaloids. Vinca alkaloids (VAs) such as vincristine, vinblastine, vindesine and vinorelbine are antineoplastic drugs that inhibit tubulin polymerisation into microtubules, induce mitotic G2/M arrest, activate c-Jun N-terminal kinase (JNK) and induce apoptosis. [Martinez-Campa et al., <i class="style-scope patent-text">Breast Cancer Res Treat., </i>98(1): 81-9 (2006).] However, therapy selection requires balancing many considerations. For example, although anthracyclines have been reported as having reduced cellular uptake and toxicity to MCF-7 cells at pH 6.8 compared to pH 7.4 [Raghunand et al. (1999)], it may still be desirable to use an anthracycline, because there may be beneficial effects of an anthracycline used in combination with other drugs that overcome any inhibitory effects caused by acid conditions.</div>
    <div num="p-0110" class="description-paragraph style-scope patent-text">II. Alternative/Additional Endocrine Therapy</div>
    <div num="p-0111" class="description-paragraph style-scope patent-text">Based on CA IX overexpression in an ER-positive breast cancer patient sample, the choice of an alternative/additional endocrine therapy depends in large part upon whether the ER-positive breast cancer patient is premenopausal or postmenopausal. Such preferred alternative/additional endocrine therapy may comprise therapy selected from any of the following therapies, or combinations thereof: antiestrogens, preferably other than tamoxifen, such as fulvestrant [Faslodex], estrogen deprivation therapies, including gonadotropin releasing hormone agonists [GnRH], such as goserelin [Zoladex] or leuprolide [Lupron]; sex steroid hormones (progestins, androgens, and/or estrogen); and ovariectomy.</div>
    <div num="p-0112" class="description-paragraph style-scope patent-text">III. MN-Targeted Therapies</div>
    <div num="p-0113" class="description-paragraph style-scope patent-text">Because of MN's unique characteristics, it is an attractive candidate target for cancer therapy. In comparison to other tumor-related molecules (e.g. growth factors and their receptors), MN has the unique property of being differentially expressed in preneoplastic/neoplastic and normal tissues. Because of the extremely limited expression of MN protein in normal tissues, chemotherapeutic agents that target its expression would be expected to have reduced side effects, relative to agents that target proteins more extensively found in normal tissues (e.g., tamoxifen which binds the estrogen receptor). Furthermore, Phase I and II clinical trials of an MN-specific drug, Rencarex, have shown that at least one MN-specific agent is well-tolerated, with no serious drug-related side effects, further supporting MN as a possible target for cancer chemotherapy.</div>
    <div num="p-0114" class="description-paragraph style-scope patent-text">Many MN-directed therapies may be useful according to the methods of the present invention, alone or in combination with other therapies to treat ER-positive breast cancers associated with abnormal MN expression. As used herein, MN-targeted therapy refers to either CA9-targeted therapy and CA IX-targeted therapy, or both; that is, any therapy targeting either CA9 nucleic acids or MN protein. Preferred therapies comprise therapies selected from the group consisting of MN-specific antibodies, MN-specific carbonic anhydrase inhibitors, MN antisense therapies, MN RNA interference, and MN gene therapy vectors; some of which preferred therapies are described in greater detail below. The therapeutic use of MN-specific anti-idiotype antibodies and MN gene therapy vectors is described in greater detail elsewhere, for example, in Soyupak and Erdogan, US Patent Application No. 20070224606 A1, which reference is hereby incorporated by reference.</div>
    <div num="p-0115" class="description-paragraph style-scope patent-text">MN-Specific Antibodies: The MN-specific antibodies, monoclonal and/or polyclonal, preferably monoclonal, may be used therapeutically in the treatment of CA9-expressing breast cancer, either alone or in combination with chemotherapeutic drugs or toxic agents, such as ricin A. Further preferred for therapeutic use would be biologically active antibody fragments. Also preferred MN-specific antibodies for such therapeutic uses would be MN-specific humanized monoclonal antibodies, fully human monoclonal antibodies, and/or bispecific antibodies.</div>
    <div num="p-0116" class="description-paragraph style-scope patent-text">MN-specific antibodies can be administered in a therapeutically effective amount, preferably dispersed in a physiologically acceptable, nontoxic liquid vehicle, to patients afflicted with breast cancer expressing MN/CA IX. The MN-specific antibody can be given alone or as a carrier of an anti-tumor drug. Among the various antiproliferative, antineoplastic or cytotoxic agents that may be linked to the MN-specific antibodies are antimetabolites, such as the antifolate, methotrexate, or the purine or pyrimidine analogs mercaptopurine and fluorouracil. Others include antibiotics, lectins such as ricin and abrin, toxins such as the subunit of diphtheria toxin, radionuclides such as <sup class="style-scope patent-text">211</sup>Astatine and <sup class="style-scope patent-text">131</sup>Iodine, radiosensitizers such as misanidazole or neutron sensitizers such as boron containing organics. Such agents may be attached to the antibody by conventional techniques such as glutaraldehyde cross-linking.</div>
    <div num="p-0117" class="description-paragraph style-scope patent-text">MN-specific antibodies can be used to target cytotoxic cells (e.g. human T cells, monocytes or NK cells). Cytotoxic cells can be attached to MN-expressing tumor cells through Fc receptors on the cytotoxic cells, which bind the Fc portion of a MN-specific antibody, or via a bridging antibody of dual specificity, that is, a bispecific antibody specific for MN protein and for the cytotoxic cell.</div>
    <div num="p-0118" class="description-paragraph style-scope patent-text">The cytotoxic cell can be targeted by allowing the bispecific antibody to bind the cell. After targeting, the cells can be administered to the patient. Therapy with targeted cells can be used as an adjunct to surgical therapy, radiation therapy, or chemotherapy.</div>
    <div num="p-0119" class="description-paragraph style-scope patent-text">MN-Specific Carbonic Anhydrase Inhibitors</div>
    <div num="p-0120" class="description-paragraph style-scope patent-text">The novel methods of the present invention comprise inhibiting the growth of preneoplastic/neoplastic cells with compounds that preferentially inhibit the enzymatic activity of MN protein. Said compounds are organic or inorganic, preferably organic, more preferably sulfonamides. More preferably, said compounds are aromatic or heterocyclic sulfonamides, or pyridinium derivatives of aromatic or heterocyclic sulfonamides. These preferred pyridinium derivatives of sulfonamides are likely to have fewer side effects than other compounds in three respects: they are small molecules, they are membrane-impermeant, and they are specific potent inhibitors of the enzymatic activity of the tumor-associated MN protein. The pyridinium derivatives of sulfonamides useful according to the present invention can be formed, for example, by creating bonds between pyrylium salts and aromatic or heterocyclic sulfonamide reagents, as described in U.S. Patent Application No. 2004/0146955, which is hereby incorporated by reference. The aromatic or heterocyclic sulfonamide portion of a pyridinium salt of a sulfonamide compound can be called the head, and the pyridinium portion can be called the tail.</div>
    <div num="p-0121" class="description-paragraph style-scope patent-text">It can be appreciated by those of skill in the art that various other MN-preferential sulfonamide carbonic anhydrase inhibitors can be useful according to the present invention.</div>
    <div num="p-0122" class="description-paragraph style-scope patent-text">IV. Therapies Targeting Additional Oncogenes</div>
    <div num="p-0123" class="description-paragraph style-scope patent-text">Additional or alternative therapies that may be selected on the basis of MN/CA9 overexpression in an ER-positive breast cancer patient, are therapies targeting oncogenes found to be co-expressed with MN/CA9 in breast cancer, such as c-erbB-2/HER-2. As reported in Bartosova et al., (2002) and in Example 1 below, a significant correlation of expression of the two genes has been observed in breast cancer patients. Trastuzumab or Herceptin is a humanized mab to HER-2 used to treat HER-2-positive cancers, particularly breast cancers, more particularly metastastic breast cancer [Horton, M. B., <i class="style-scope patent-text">Cancer Control, </i>9(6): 499-507 (2002)]. Herceptin can be given alone to a patient but can enhance the effectiveness of several chemotherapeutic agents. It would be advantageous to test ER-positive breast cancer patients for both HER-2 and MN/CA IX expression to enlarge the clinical perspective, therapeutic resources and diagnostic/prognostic parameters to pick the optimal therapeutic combinations for the most promising treatment outcomes.</div>
    <div num="h-0024" class="description-paragraph style-scope patent-text">Diagnostic/Prognostic Imaging</div>
    <div num="p-0124" class="description-paragraph style-scope patent-text">Positron emission tomography [PET] imaging in assessment of endocrine tumors has been until recently restricted to the use of <sup class="style-scope patent-text">18</sup>F-fluoro-deoxy-D-glucose (18F-FDG). Being a marker of metabologically active lesions that show high grading and low differentiation, FDG is not ideal for this purpose since the majority of endocrine tumors are slow growing and highly differentiated [Khan et al., <i class="style-scope patent-text">Minerva Endocrinol</i>., Feb. 15, 2008 Epub ahead of print].</div>
    <div num="p-0125" class="description-paragraph style-scope patent-text">For the diagnostic/prognostic imaging methods of the invention, wherein MN/CA IX presence is detected and used to indicate resistance to endocrine therapy, preferably resistance to antiestrogen therapy, the methods preferably comprise the use of labeled MN/CA IX-specific antibodies or labeled MN/CA IX-specific inhibitors, such as MN/CA IX-specific aromatic or heterocyclic sulfonamides. A preferred imaging method is PET imaging, and a preferred tracer for PET imaging purposes using MN/CA IX-specific inhibitors is the fluorine isotope <sup class="style-scope patent-text">18</sup>F, which may be incorporated, for example, in a CF<sub class="style-scope patent-text">3 </sub>moiety.</div>
    <div num="h-0025" class="description-paragraph style-scope patent-text">Computerized MN/CA IX Data Analysis</div>
    <div num="p-0126" class="description-paragraph style-scope patent-text">The correlation of MN/CA9 expression (for example, level and/or extent) and breast cancer prognosis can be analyzed by any number of methods known to one of skill in the art, for example, by computer program. Such a computer program could comprise algorithms for correlating CA9 expression data derived from a breast cancer patient with a probable prognosis.</div>
    <div num="p-0127" class="description-paragraph style-scope patent-text">The following examples are for purposes of illustration only and are not meant to limit the invention in any way.</div>
    <heading class="style-scope patent-text">MATERIALS AND METHODS</heading>
    <div num="p-0128" class="description-paragraph style-scope patent-text">In Examples 1-6 (infra), MN/CA IX expression was evaluated in a series of breast cancer specimens obtained before and after primary anthracycline and tamoxifen therapy from breast cancer patients enrolled in a randomized trial of primary therapy, with the aim to: (1) assess the relationship between MN/CA IX expression and disease-free survival (DFS), (2) evaluate expression in relation to response to the therapy with a single cytotoxic agent, where acid pH could contribute to drug resistance, and (3) assess changes in MN/CA IX expression after treatment and their relation to the outcome.</div>
    <div num="p-0129" class="description-paragraph style-scope patent-text">Patients: Patients with T2-4 N0-1 breast cancer [TNM staging system] were recruited in a randomized trial comparing single agent epirubicin (EPI arm) versus epirubicin+tamoxifen (EPI-Tam arm) as primary systemic treatment. The results of this trial have recently been published [Bottini et al., (2005)]. Two hundred and eleven patients were enrolled in which one hundred and five were randomized to receive epirubicin alone and one hundred and six were randomized to receive epirubicin+tamoxifen. In first presentation, an incision biopsy was performed on each patient and a small tissue sample (0.5-0.8 cm) was removed. Chemotherapy was started within 2 days of diagnosis. Patients in the EPI arm received 60 mg/m<sup class="style-scope patent-text">2 </sup>epirubicin (Farmorubicine, Pharmacia Italia S.p.A., Via Roberto Koch 1.2, 1-20100 Milan, Italy) by slow i.v. push on days 1 and 2, while patients in the EPI-TAM arm received 60 mg/m<sup class="style-scope patent-text">2 </sup>epirubicin by slow i.v. push on <figure-callout id="30" label="days" filenames="US08097423-20120117-D00001.png,US08097423-20120117-D00002.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">days</a></figure-callout> 1 and 2, and 30 mg tamoxifen (Kessar, Pharmacia Italia S.p.A.) daily. Epirubicin injections were repeated every 21 days for four cycles before definitive surgery, whereas tamoxifen was given continuously until definitive surgery. Surgery was planned after complete clinical reassessment. Quadrantectomy or modified radical mastectomy was performed when indicated in association with complete axillary node dissection. All patients subjected to quadrantectomy underwent irradiation of the residual breast (60 Gy delivered over 6 weeks). All patients received four cycles of cyclophosphamide (600 mg/m<sup class="style-scope patent-text">2</sup>), methotrexate (40 mg/m<sup class="style-scope patent-text">2</sup>), and 5-fluorouracil (600 mg/m<sup class="style-scope patent-text">2</sup>) intravenously on <figure-callout id="8" label="days" filenames="US08097423-20120117-D00001.png,US08097423-20120117-D00002.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">days</a></figure-callout> 1 and 8 every 28 days (CMF regimen) [Zambetti et al., (1997)] postoperatively. Patients with ER-positive primary tumor in both arms received tamoxifen (20 mg, i.e. lower than the primary dose) starting after surgery, up to progression or for a maximum of 5 years.</div>
    <div num="p-0130" class="description-paragraph style-scope patent-text">Treatment evaluation: Each month, the size of the primary tumor and axillary lymph nodes, when appreciable, were measured with a caliper by the same clinician. Response was assessed by the clinical measurement of the changes in the product of the two largest diameters recorded in two successive evaluations. According to the World Health Organization criteria, tumor progression (PD) was defined as an increase of at least 25% in tumor size; stable disease as an increase of less than 25%, or a reduction of less than 50%; partial response (PR) as a tumor shrinkage greater than 50%; and complete response (CR) as the complete disappearance of all clinical signs of the disease.</div>
    <div num="p-0131" class="description-paragraph style-scope patent-text">Pathological CR (pCR) was defined as the absence of neoplastic cells in the breast and in the axillary lymph nodes.</div>
    <div num="p-0132" class="description-paragraph style-scope patent-text">Histopathologic grade and immunohistochemistry: Tumor grade was evaluated using the Nottingham system [Elston and Ellis, (1991)]. Immunohistochemical evaluation was performed on paraffin-embedded tumor samples obtained at diagnosis and at definitive surgery. Staining of bcl2, p53, ER, progesterone receptor (PgR), and Ki67 were performed at the Pathology Unit of the Azienda Ospedaliera Istituti Ospitalieri of Cremona (Italy), and MN/CA IX staining was assessed at the John Radcliffe Hospital in Oxford, UK.</div>
    <div num="p-0133" class="description-paragraph style-scope patent-text">The immunohistochemical methodology used in Cremona for routine markers is completely described elsewhere [Bottini et al., (2000)]. Briefly, an antigen retrieval step was performed by heating a tissue section in a citrate buffer. The primary antibodies applied were: ER [mouse monoclonal 6F11 (Novocastra Lab., UK), dilution 1:50, 1 h incubation at room temperature], PgR [mouse monoclonal 1A6 (Novocastra Lab.), dilution 1:20, 1 h incubation at room temperature], Ki67 [mouse monoclonal Mib-1 (Dako, Glostrup, Denmark), dilution 1:30, 1 h incubation at room temperature], p53 [mouse monoclonal D07 (Novocastra Lab.), dilution 1:100, 1 h incubation at room temperature], bcl2 [mouse monoclonal 124 (Dako), dilution 1:40, overnight incubation at 4 C.], and c-erbB2 [mouse monoclonal CB11 (Novocastra Lab.), overnight incubation at 4 C.].</div>
    <div num="p-0134" class="description-paragraph style-scope patent-text">Biotinylated horse anti-mouse IgG and avidin-biotin-peroxidase complex were applied as a staining method (Vectastatin ABC kit; Vector Laboratories, Inc., Burlingame, Calif., USA). A solution containing hydrogen peroxide (0.06% v/v) and diamino-benzidine-4 HCl (DAB; 0.05 v/v) was used as chromogen.</div>
    <div num="p-0135" class="description-paragraph style-scope patent-text">All samples had a negative control slide (no primary antibody) of an adjacent section to assess the degree of non-specific staining. Positive controls included breast carcinomas known to exhibit high levels of each marker.</div>
    <div num="p-0136" class="description-paragraph style-scope patent-text">All staining was scored by counting the number of positive-stained cells and was expressed as a percentage of the total tumor cells (at least 1000) counted across several representative fields of the section using a standard light microscope equipped with a 1010 square graticule. Reproducibility of counting was assessed by a second investigator re-scoring ten slides.</div>
    <div num="p-0137" class="description-paragraph style-scope patent-text">The relative intensity of ER and PgR staining was assessed in a semi-quantitative fashion as previously described by McCarty et al. (1985), incorporating both the intensity and distribution of specific staining. A value (HSCORE) was derived from the sum of the percentages of positive-stained epithelial cells multiplied by the weighted intensity of staining. Specimens were deemed receptor positive if the HSCORE was greater than 100.</div>
    <div num="p-0138" class="description-paragraph style-scope patent-text">Immunohistochemistry for MN/CA IX was performed on tissues retrieved from the histopathology archives at the Pathology Unit of Cremona, Italy. Two core tissue biopsies, 0.6 mm in diameter, were taken from selected morphologically representative regions of each paraffin-embedded breast tumor and sections of 5 m thickness of each tissue array block were transferred to the glass slides. Quality control was assessed on each block by haepatoxylin and eosin (H&amp;E) staining.</div>
    <div num="p-0139" class="description-paragraph style-scope patent-text">Immunohistochemical staining for the endogenous hypoxia marker CA IX was performed with the murine monoclonal antibody M75, supra at a dilution of 1:50 for 30 min [Pastorekova et al., (1992); ATCC deposited VU-M75 hybridoma, supra]. Secondary antibody, an anti-rabbit anti-mouse antibody complex from the EnVision HRP kit (Dako) was allowed to incubate for 30 min. Slides were then stained with DAB and counterstained with hematoxylin and mounted. The immunostaining was quantified in carcinoma cells by semi-quantitative scoring as previously described [Colpaert et al., (2003)]. In brief, a score of 0-2 for the intensity of staining was given (0, no staining; 1, weak staining; 2, moderate to strong staining). For all comparisons with survival and response, any staining was counted as positive.</div>
    <div num="p-0140" class="description-paragraph style-scope patent-text">The pathologists performing the immunohistochemical evaluations both in the Pathology Unit of Cremona, Italy and John Radcliffe Hospital in Oxford, UK worked in blinded conditions, that is, they did not know the patient outcome and whether the samples they examined were obtained from incisional biopsy or definitive surgery.</div>
    <div num="p-0141" class="description-paragraph style-scope patent-text">Statistical methodology: The x<sup class="style-scope patent-text">2</sup>-test for trend and Fisher's exact test were used when indicated to perform comparisons of proportions. Kruskal-Wallis ANOVA was performed to compare continuous variables. Multivariate logistic regression was used to identify covariates independently associated with MN/CA IX expression. In this analysis, MN/CA IX expression was dichotomized in two classes, 0 (no immunostaining) and 1 (presence of immunostaining). DFS was calculated from randomization to the occurrence of disease relapse or death, whichever was first. Overall survival (OS) was calculated from randomization to the date of death. The last follow-up date was considered for DFS and OS (censored), if patients were free from recurrence and alive respectively. The DFS and OS curves were estimated using the Kaplan-Meier method. Unadjusted differences in these estimates were assessed with the log rank test. The Cox proportional hazard model was used to assess the independent predictive role of the clinical-pathological factors in multivariate analysis, and the treatment undergone for disease recurrence. The analysis was conducted in two steps: initially, MN/CA IX expression and all classical clinical and pathological factors were included in the multivariate model. Variables not significantly associated with the outcome were then removed from the model in a stepwise backward procedure based on the likelihood ratio (P&lt;0.10). In the second step, the presence of interactions between MN/CA IX and each of the clinical and pathological factors and the treatment undergone was investigated by introducing the appropriate terms describing the interaction between the MN/CA IX and the covariates of interest, one at a time, in the final model obtained in the preceding step. Due to the small sample size and the number of interactions that were evaluated, these analyses must be considered as exploratory, and no attempt was made to build a complete model, where all the significant interaction terms and the associated main effects were included and evaluated simultaneously. All variables included in multivariate analyses were dichotomized and coded 0 in negative cases and 1 in positive cases with the exception of Ki67. This latter variable had a left skewed distribution and was modeled using the log transformation. The assumption of proportional hazards was verified by visual inspection of the plots of the log-estimated cumulative hazards in the various strata defined by the covariates, and no major violation of the assumption was observed. All P values reported were two sided; values less than 0.05 were considered statistically significant.</div>
    <div num="p-0142" class="description-paragraph style-scope patent-text">Statistical analyses were performed using the STATISTICA for Windows (Tulsa, Okla., USA) and SPSS for Windows software packages.</div>
    <heading class="style-scope patent-text">EXAMPLE 1</heading>
    <heading class="style-scope patent-text">Patient Characteristics and MN/CA IX Expression</heading>
    <div num="p-0143" class="description-paragraph style-scope patent-text">The purpose of this study is to investigate the role of carbonic anhydrase IX (MN/CA IX) expression in predicting the response to epirubicin and disease-free survival (DFS) in breast cancer patients enrolled in a single institution trial of primary anthracycline and tamoxifen therapy. MN/CA IX expression was assessed in 183 patients with T2-4 N0-1 breast cancer enrolled in a randomized trial comparing four cycles of single agent epirubicin versus epirubicin+tamoxifen as primary systemic treatment. All patients received postoperatively four cycles of the four weekly i.v. cyclophosphamide, methotrexate, 5-fluorouracil regimen. Patients with estrogen receptor (ER)-positive primary tumors received 5 years of adjuvant tamoxifen. Pretreatment, p53 (P=0.007), c-erbB2 (P&lt;0.01), and Ki67 (P=0.02) were directly associated with MN/CA IX expression, while bcl2 (P&lt;0.000) and ER (P=0.000) and progesterone receptor (PgR; P&lt;0.01) were inversely correlated. In multivariate analysis, only high p53 and low bcl2 were independently associated with MN/CA IX positivity. MN/CA IX immunostaining was significantly associated with poor outcomefor DFS (P&lt;0.002) and overall survival (P=0.001). In multivariate analysis, a significant interaction was found between MN/CA IX and markers of hormone sensitivity, bcl2 (P=0.01), ER (P=0.02), PgR (P=0.02), and lymph node involvement (P=0.04), in predicting DFS.</div>
    <div num="p-0144" class="description-paragraph style-scope patent-text">Presently, there are few clinical markers of resistance to tamoxifen treatment in ER-positive tumors. MN/CA IX expression in breast cancer patients shows a negative predictive role of treatment efficacy in ER-positive patients on the adjuvant tamoxifen after primary chemo-endocrine therapy.</div>
    <div num="p-0145" class="description-paragraph style-scope patent-text">Out of 211, 183 patients prospectively enrolled in the trial (86.7%) had MN/CA IX assessed. For the remaining 28 patients, the blocks had been discarded due to insufficient material. Characteristics of the 183 patients included in this study are shown in Table 1. Eighty-nine patients were randomized in the EPI arm, ninety-four were randomized in the EPI-TAM arm. One hundred and sixty-nine patients had MN/CA IX evaluated at the baseline, one hundred and forty had MN/CA IX assessed in residual tumor, one hundred and twenty-six had MN/CA IX assessed both before and after treatment, while fourteen patients had MN/CA IX assessed in the residual tumor histology only. MN/CA IX immunostaining was detected in 41/169 tumor samples collected before treatment (24.2%) and in 30/140 tumor samples collected afterwards (21.4%).</div>
    <div num="p-0146" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00004" num="00004" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="1" rowsep="1" class="description-td style-scope patent-text" colspan="1">TABLE 1</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="1"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Patient characteristics</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="1"> </td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">No. of randomized</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">183</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">EPI</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">89</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">EPI-TAM</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">94</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Premenopause</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">61</td>
                <td class="description-td style-scope patent-text">(33.9%)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Postmenopause</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">119</td>
                <td class="description-td style-scope patent-text">(66.1%)</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Grading</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">1</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">0</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">2</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">47</td>
                <td class="description-td style-scope patent-text">(26.5%)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">3</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">131</td>
                <td class="description-td style-scope patent-text">(73.5%)</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Missing</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">5</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">T stage</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">T2</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">138</td>
                <td class="description-td style-scope patent-text">(75.4%)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">T3</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">26</td>
                <td class="description-td style-scope patent-text">(14.2%)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">T4</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">19</td>
                <td class="description-td style-scope patent-text">(10.4%)</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">N status</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">N0</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">104</td>
                <td class="description-td style-scope patent-text">(56.8%)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">N1</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">79</td>
                <td class="description-td style-scope patent-text">(43.2%)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">ER</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">38</td>
                <td class="description-td style-scope patent-text">(20.7%)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">ER+</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">145</td>
                <td class="description-td style-scope patent-text">(79.2%)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">PgR</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">92</td>
                <td class="description-td style-scope patent-text">(50.3%)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">PgR+</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">91</td>
                <td class="description-td style-scope patent-text">(49.7%)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">p53</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">91</td>
                <td class="description-td style-scope patent-text">(50.0%)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">p53+</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">91</td>
                <td class="description-td style-scope patent-text">(50.0%)</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Missing</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">1</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">c-erbB2</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">134</td>
                <td class="description-td style-scope patent-text">(73.2%)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">c-erbB2+</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">49</td>
                <td class="description-td style-scope patent-text">(26.8%)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">bcl2</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">50</td>
                <td class="description-td style-scope patent-text">(27.5%)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">bcl2+</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">132</td>
                <td class="description-td style-scope patent-text">(72.5%)</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Missing</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">1</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Response to treatment (clinical)</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Complete response</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">32</td>
                <td class="description-td style-scope patent-text">(17.6%)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Partial response</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">108</td>
                <td class="description-td style-scope patent-text">(59.3%)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">No response</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">42</td>
                <td class="description-td style-scope patent-text">(23.1%)</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Not evaluable</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">1</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Pathological complete response</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">6</td>
                <td class="description-td style-scope patent-text">(3.3%)</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Baseline</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">CA IX (n = 169)</td>
                <td class="description-td style-scope patent-text">0</td>
                <td class="description-td style-scope patent-text">128</td>
                <td class="description-td style-scope patent-text">(75.7%)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">1</td>
                <td class="description-td style-scope patent-text">20</td>
                <td class="description-td style-scope patent-text">(11.8%)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">2</td>
                <td class="description-td style-scope patent-text">21</td>
                <td class="description-td style-scope patent-text">(12.5%)</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">After treatment</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">CA IX (n = 140)</td>
                <td class="description-td style-scope patent-text">0</td>
                <td class="description-td style-scope patent-text">110</td>
                <td class="description-td style-scope patent-text">(78.6%)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">1</td>
                <td class="description-td style-scope patent-text">17</td>
                <td class="description-td style-scope patent-text">(12.1%)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">2</td>
                <td class="description-td style-scope patent-text">13</td>
                <td class="description-td style-scope patent-text">(9.3%)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <heading class="style-scope patent-text">EXAMPLE 2</heading>
    <heading class="style-scope patent-text">Relationship Between MN/CA IX Expression and Clinical and Immunohistochemical Prognostic Parameters</heading>
    <div num="p-0147" class="description-paragraph style-scope patent-text">As shown in Table 2, MN/CA IX expression at baseline conditions did not correlate with T status and N status in univariate analysis. An association of borderline significance (0.08) between MN/CA IX intensity and grade was observed. MN/CA IX expression was directly associated with p53, c-erbB2, and Ki67 expression, while it was inversely associated with bcl2 and steroid hormone receptor status.</div>
    <div num="p-0148" class="description-paragraph style-scope patent-text">In multivariate analysis, however, the only two variables independently associated with MN/CA IX positivity were bcl2 expression, [odds ratio (OR) 0.2; 95% confidence interval (CI): 0.1-0.5, P=0.0001], and p53 expression [OR 2; 95% CI: 0.9-4.8, P=0.05].</div>
    <div num="p-0149" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00005" num="00005" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="1" rowsep="1" class="description-td style-scope patent-text" colspan="1">TABLE 2</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="1"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Relationship between baseline MN/CA IX expression</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">and clinical and immunohistochemical parameters</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="1"> </td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">CA IX intensity</td>
                <td class="description-td style-scope patent-text">Univariate analysis</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Grading</td>
                <td class="description-td style-scope patent-text">0</td>
                <td class="description-td style-scope patent-text">1</td>
                <td class="description-td style-scope patent-text">2</td>
                <td class="description-td style-scope patent-text">P</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="8" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">2</td>
                <td class="description-td style-scope patent-text">36/125</td>
                <td class="description-td style-scope patent-text">(28.8%)</td>
                <td class="description-td style-scope patent-text">7/20</td>
                <td class="description-td style-scope patent-text">(35.0%)</td>
                <td class="description-td style-scope patent-text">1/19</td>
                <td class="description-td style-scope patent-text">(5.3%)</td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">3</td>
                <td class="description-td style-scope patent-text">89/125</td>
                <td class="description-td style-scope patent-text">(71.2%)</td>
                <td class="description-td style-scope patent-text">13/20</td>
                <td class="description-td style-scope patent-text">(65.0%)</td>
                <td class="description-td style-scope patent-text">18/19</td>
                <td class="description-td style-scope patent-text">(94.7%)</td>
                <td class="description-td style-scope patent-text">0.08*</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">p53</td>
                <td class="description-td style-scope patent-text">56/128</td>
                <td class="description-td style-scope patent-text">(43.7%)</td>
                <td class="description-td style-scope patent-text">14/20</td>
                <td class="description-td style-scope patent-text">(70.0%)</td>
                <td class="description-td style-scope patent-text">14/20</td>
                <td class="description-td style-scope patent-text">(70.0%)</td>
                <td class="description-td style-scope patent-text">0.007*</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">c-erbB2</td>
                <td class="description-td style-scope patent-text">48/128</td>
                <td class="description-td style-scope patent-text">(37.5%)</td>
                <td class="description-td style-scope patent-text">13/20</td>
                <td class="description-td style-scope patent-text">(65.0%)</td>
                <td class="description-td style-scope patent-text">13/21</td>
                <td class="description-td style-scope patent-text">(61.9%)</td>
                <td class="description-td style-scope patent-text">&lt;0.01*</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">bcl2</td>
                <td class="description-td style-scope patent-text">105/127</td>
                <td class="description-td style-scope patent-text">(82.6%)</td>
                <td class="description-td style-scope patent-text">14/20</td>
                <td class="description-td style-scope patent-text">(70.0%)</td>
                <td class="description-td style-scope patent-text">6/21</td>
                <td class="description-td style-scope patent-text">(28.6%)</td>
                <td class="description-td style-scope patent-text">0.000*</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">ER</td>
                <td class="description-td style-scope patent-text">111/128</td>
                <td class="description-td style-scope patent-text">(86.7%)</td>
                <td class="description-td style-scope patent-text">15/20</td>
                <td class="description-td style-scope patent-text">(75.0%)</td>
                <td class="description-td style-scope patent-text">11/21</td>
                <td class="description-td style-scope patent-text">(52.4%)</td>
                <td class="description-td style-scope patent-text">0.000*</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">PgR</td>
                <td class="description-td style-scope patent-text">71/128</td>
                <td class="description-td style-scope patent-text">(55.5%)</td>
                <td class="description-td style-scope patent-text">7/20</td>
                <td class="description-td style-scope patent-text">(35.0%)</td>
                <td class="description-td style-scope patent-text">6/21</td>
                <td class="description-td style-scope patent-text">(28.6%)</td>
                <td class="description-td style-scope patent-text">&lt;0.01*</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Ki67 mean</td>
                <td class="description-td style-scope patent-text">19.8</td>
                <td class="description-td style-scope patent-text">(17.1-22.5)</td>
                <td class="description-td style-scope patent-text">26.0</td>
                <td class="description-td style-scope patent-text">(13.6-38.5)</td>
                <td class="description-td style-scope patent-text">35.8</td>
                <td class="description-td style-scope patent-text">(23.2-48.5)</td>
                <td class="description-td style-scope patent-text">0.02</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">(95% CI)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">T2</td>
                <td class="description-td style-scope patent-text">98/128</td>
                <td class="description-td style-scope patent-text">(76.5%)</td>
                <td class="description-td style-scope patent-text">13/20</td>
                <td class="description-td style-scope patent-text">(65.0%)</td>
                <td class="description-td style-scope patent-text">16/21</td>
                <td class="description-td style-scope patent-text">(76.2%)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">T3-4</td>
                <td class="description-td style-scope patent-text">30/128</td>
                <td class="description-td style-scope patent-text">(23.5%)</td>
                <td class="description-td style-scope patent-text">7/20</td>
                <td class="description-td style-scope patent-text">(35.0%)</td>
                <td class="description-td style-scope patent-text">5/21</td>
                <td class="description-td style-scope patent-text">(23.8%)</td>
                <td class="description-td style-scope patent-text">0.68</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">N+</td>
                <td class="description-td style-scope patent-text">53/128</td>
                <td class="description-td style-scope patent-text">(41.4%)</td>
                <td class="description-td style-scope patent-text">10/20</td>
                <td class="description-td style-scope patent-text">(50.0%)</td>
                <td class="description-td style-scope patent-text">11/21</td>
                <td class="description-td style-scope patent-text">(52.4%)</td>
                <td class="description-td style-scope patent-text">0.12*</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="8" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="8"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Multivariate analysis<sup class="style-scope patent-text"></sup> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Odds ratio</td>
                <td class="description-td style-scope patent-text">95% confidence intervals</td>
                <td class="description-td style-scope patent-text">P</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="4" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="4"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Variables in the model</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">p53</td>
                <td class="description-td style-scope patent-text">2</td>
                <td class="description-td style-scope patent-text">0.9-4.8</td>
                <td class="description-td style-scope patent-text">0.05</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">bc12</td>
                <td class="description-td style-scope patent-text">0.2</td>
                <td class="description-td style-scope patent-text">0.1-0.5</td>
                <td class="description-td style-scope patent-text">0.0001</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Variables failing to enter the model</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">ER</td>
                <td class="description-td style-scope patent-text">0.9</td>
                <td class="description-td style-scope patent-text">0.2-3.1</td>
                <td class="description-td style-scope patent-text">0.6</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Tumor grade</td>
                <td class="description-td style-scope patent-text">0.9</td>
                <td class="description-td style-scope patent-text">0.3-2.4</td>
                <td class="description-td style-scope patent-text">0.9</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">PgR</td>
                <td class="description-td style-scope patent-text">0.6</td>
                <td class="description-td style-scope patent-text">0.2-1.6</td>
                <td class="description-td style-scope patent-text">0.2</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Log Ki67</td>
                <td class="description-td style-scope patent-text">1</td>
                <td class="description-td style-scope patent-text">0.5-1.9</td>
                <td class="description-td style-scope patent-text">0.7</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">c-erbB2</td>
                <td class="description-td style-scope patent-text">1.7</td>
                <td class="description-td style-scope patent-text">0.7-4.1</td>
                <td class="description-td style-scope patent-text">0.17</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="4" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="4"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="4" align="left" id="FOO-00001" class="description-td style-scope patent-text" colspan="4">*X<sup class="style-scope patent-text">2 </sup>for trend;</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="4" align="left" id="FOO-00002" class="description-td style-scope patent-text" colspan="4"> <sup class="style-scope patent-text"></sup>CA IX was dichotomized and coded as 0 (no expression) and 1 (expression).</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <heading class="style-scope patent-text">EXAMPLE 3</heading>
    <heading class="style-scope patent-text">Effect of Treatment on MN/CA IX Immunostaining</heading>
    <div num="p-0150" class="description-paragraph style-scope patent-text">In 126 patients with MN/CA IX assessed in matched samples before and after treatments, MN/CA IX positivity was found in 32 baseline tumor samples (25.4%) and 27 residual tumor samples to chemotherapy (21.4%), respectively. MN/CA IX-positive tumors (21/32) at the baseline showed reduction in marker expression (Table 3), and 18 of these became negative at the end of treatment, while MN/CA IX-negative tumors (13/94) at the baseline became positive at the end of treatment. MN/CA IX variation did not differ according to the treatment received (EPI or EPI-Tam; data not shown).</div>
    <div num="p-0151" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00006" num="00006" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="1" rowsep="1" class="description-td style-scope patent-text" colspan="1">TABLE 3</td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="1"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">MN/CA IX individual changes and MN/CA IX</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">expression before and after treatment</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Overall</td>
                <td class="description-td style-scope patent-text">No variation</td>
                <td class="description-td style-scope patent-text">Increase</td>
                <td class="description-td style-scope patent-text">Decrease</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">CA IX + ve</td>
                <td class="description-td style-scope patent-text">32</td>
                <td class="description-td style-scope patent-text">11 (34.4%)</td>
                <td class="description-td style-scope patent-text">n.a.</td>
                <td class="description-td style-scope patent-text">21 (65.6%)</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">CA IX  ve</td>
                <td class="description-td style-scope patent-text">94</td>
                <td class="description-td style-scope patent-text">81 (86.2.%)</td>
                <td class="description-td style-scope patent-text">13 (13.8%)</td>
                <td class="description-td style-scope patent-text">n.a.</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <heading class="style-scope patent-text">EXAMPLE 4</heading>
    <heading class="style-scope patent-text">MN/CA IX Expression and Response to Treatment</heading>
    <div num="p-0152" class="description-paragraph style-scope patent-text">Among 169 patients with MN/CA IX assessed at baseline, one patient refused to continue the treatment after the first cycle and was not assessable for response; 129 (76.7%) out of 168 assessable cases attained a clinical response (complete+partial), 30 (17.8%) cases showed a CR, and 99 (58.9%) had a PR. At postchemotherapy residual histology, six patients (3.6%) had a pCR. As previously published, there was no significant difference in treatment responses between the epirubicin and epirubicin+tamoxifen arms (76 vs 82% respectively) [Bottini et al., (2005)]. According to the MN/CA IX status, overall response was observed in 100 out of 127 patients (78.7%) with MN/CA IX-negative tumors and 29 out of 41 patients (70.7%) with MN/CA IX-positive tumors, and CR was observed in 25/127 (19.7%) MN/CA IX-negative and in 5/41 (12.2%) MN/CA IX-positive patients respectively. None of these differences was statistically significant. All the six pCRs were confined to patients with MN/CA IX negative primary tumor (P=0.33, Fisher's exact test).</div>
    <heading class="style-scope patent-text">EXAMPLE 5</heading>
    <heading class="style-scope patent-text">MN/CA IX Expression and Disease Outcome</heading>
    <div num="p-0153" class="description-paragraph style-scope patent-text">Out of 183, 45 patients relapsed (24.6%), and 21 (11.5%) died of disease. As shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIGS. 1A</figref> and B, MN/CA IX expression was significantly associated with poor outcome both in terms of DFS and OS. In univariate analysis, tumor grade (P=0.04), T (P=0.0001) and N status (P=0.000), ER (P=0.003), PgR (P=0.03), and bcl-2 expression (P=0.002), in addition to MN/CA IX expression, were significantly associated with disease recurrence, while the correlation with disease recurrence of Ki67 (P=0.10), p53 (P=0.06), and c-erbB2 expression (P=0.07) just failed to attain statistical significance. Menopausal status was not associated with disease recurrence (P=0.29).</div>
    <div num="p-0154" class="description-paragraph style-scope patent-text">In multivariate analysis, MN/CA IX expression was not an independent predictor of DFS (Table 4). Tumor size [hazard ratio (HR) 2.7; 95% CI: 1.4-5.4, P=0.003], lymph node involvement (HR 2.8; 95% CI: 1.4-5.7, P=0.004), and bcl2 status (HR 0.4; 95% CI: 0.2-0.8, P=0.008) were retained in the final model. Treatment-induced changes in MN/CA IX were not correlated with DFS in univariate analysis (data not shown).</div>
    <div num="p-0155" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00007" num="00007" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="1" rowsep="1" class="description-td style-scope patent-text" colspan="1">TABLE 4</td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="1"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Multivariate Cox analysis for independent</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">factors predictive for disease recurrence</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Hazard ratio</td>
                <td class="description-td style-scope patent-text">95% confidence intervals</td>
                <td class="description-td style-scope patent-text">P</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="3" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="4"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Variables in the final model</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Nodal status</td>
                <td class="description-td style-scope patent-text">3.0</td>
                <td class="description-td style-scope patent-text">1.5-6.0</td>
                <td class="description-td style-scope patent-text">0.002</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">T</td>
                <td class="description-td style-scope patent-text">2.6</td>
                <td class="description-td style-scope patent-text">1.3-5.0</td>
                <td class="description-td style-scope patent-text">0.007</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">bcl2</td>
                <td class="description-td style-scope patent-text">0.4</td>
                <td class="description-td style-scope patent-text">0.2-0.8</td>
                <td class="description-td style-scope patent-text">0.008</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Variables failing to enter the model</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">c-erbB2</td>
                <td class="description-td style-scope patent-text">0.7</td>
                <td class="description-td style-scope patent-text">0.3-1.5</td>
                <td class="description-td style-scope patent-text">0.4</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">PgR</td>
                <td class="description-td style-scope patent-text">1.1</td>
                <td class="description-td style-scope patent-text">0.5-2.6</td>
                <td class="description-td style-scope patent-text">0.8</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">ER</td>
                <td class="description-td style-scope patent-text">0.7</td>
                <td class="description-td style-scope patent-text">0.3-1.9</td>
                <td class="description-td style-scope patent-text">0.5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Grading</td>
                <td class="description-td style-scope patent-text">1.4</td>
                <td class="description-td style-scope patent-text">0.5-3.8</td>
                <td class="description-td style-scope patent-text">0.4</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Log Ki67</td>
                <td class="description-td style-scope patent-text">2.5</td>
                <td class="description-td style-scope patent-text">0.8-8.0</td>
                <td class="description-td style-scope patent-text">0.1</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">CA IX</td>
                <td class="description-td style-scope patent-text">1.6</td>
                <td class="description-td style-scope patent-text">0.8-3.2</td>
                <td class="description-td style-scope patent-text">0.2</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">p53</td>
                <td class="description-td style-scope patent-text">1.2</td>
                <td class="description-td style-scope patent-text">0.6-2.4</td>
                <td class="description-td style-scope patent-text">0.5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="4" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="4"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <heading class="style-scope patent-text">EXAMPLE 6</heading>
    <heading class="style-scope patent-text">Effect of MN/CA IX on DFS in Different Subgroups According to Clinical and Pathological Parameters</heading>
    <div num="p-0156" class="description-paragraph style-scope patent-text">In the exploratory analyses aimed at evaluating the interactions on DFS between MN/CA IX and each of the clinical and pathological parameters, a significant positive interaction was found between MN/CA IX and bcl2 (P=0.01), ER (P=0.02), PgR (P=0.02), and lymph node involvement (P=0.04). The interaction between MN/CA IX and the various factors in predicting DFS is depicted in Table 5. As shown, MN/CA IX positivity was clearly associated with a two- to threefold increased risk of relapse in patients with tumors positive for markers of responsiveness to endocrine therapy, such as ER, PgR and bcl2, and in node-positive patients, whereas no association was seen in patients negative for these markers and in node-negative patients (Table 5). No variation in the prognostic effect of MN/CA IX was seen across subgroups of the other factors. The interaction between MN/CA IX and ER status is shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 2</figref> in which the predictive role of MN/CA IX for DFS in univariate analysis is confined to ER-positive patients.</div>
    <div num="p-0157" class="description-paragraph style-scope patent-text"> <tables id="TABLE-US-00008" num="00008" class="style-scope patent-text"> <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text"> <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%"> <thead class="style-scope patent-text"> <tr class="description-tr style-scope patent-text"> <td namest="1" nameend="1" rowsep="1" class="description-td style-scope patent-text" colspan="1">TABLE 5</td> </tr> </thead>  <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text"> <td namest="1" nameend="1" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="1"> </td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">Subgroup analysis of disease-free survival of MN/CA</td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">IX-positive patients versus MN/CA IX negative ones</td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">within strata formed by each prognostic factor</td> </tr>  </tbody></table> <table align="left" colsep="0" rowsep="0" cols="4" class="description-table style-scope patent-text" width="100%"> <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text"> </td> <td class="description-td style-scope patent-text">Hazard ratio*</td> <td class="description-td style-scope patent-text">95% confidence interval</td> <td class="description-td style-scope patent-text">P</td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text"> </td> <td namest="offset" nameend="3" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="4"> </td> </tr>  </tbody></table> <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%"> <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">Estrogen receptor</td> </tr>  </tbody></table> <table align="left" colsep="0" rowsep="0" cols="4" class="description-table style-scope patent-text" width="100%"> <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">Positive</td> <td class="description-td style-scope patent-text">3.2</td> <td class="description-td style-scope patent-text">1.4-7.4</td> <td class="description-td style-scope patent-text">0.02<sup class="style-scope patent-text"></sup> </td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">Negative</td> <td class="description-td style-scope patent-text">0.7</td> <td class="description-td style-scope patent-text">0.2-3.1</td> </tr>  </tbody></table> <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%"> <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">Progesterone receptor</td> </tr>  </tbody></table> <table align="left" colsep="0" rowsep="0" cols="4" class="description-table style-scope patent-text" width="100%"> <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">Positive</td> <td class="description-td style-scope patent-text">17.1</td> <td class="description-td style-scope patent-text">3.2-90.5</td> <td class="description-td style-scope patent-text">0.02<sup class="style-scope patent-text"></sup> </td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">Negative</td> <td class="description-td style-scope patent-text">1.0</td> <td class="description-td style-scope patent-text">0.4-2.6</td> </tr>  </tbody></table> <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%"> <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">bcl2</td> </tr>  </tbody></table> <table align="left" colsep="0" rowsep="0" cols="4" class="description-table style-scope patent-text" width="100%"> <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">Positive</td> <td class="description-td style-scope patent-text">2.8</td> <td class="description-td style-scope patent-text">1.1-7.1</td> <td class="description-td style-scope patent-text">0.01<sup class="style-scope patent-text"></sup> </td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">Negative</td> <td class="description-td style-scope patent-text">0.6</td> <td class="description-td style-scope patent-text">0.2-1.9</td> </tr>  </tbody></table> <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%"> <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">Node status</td> </tr>  </tbody></table> <table align="left" colsep="0" rowsep="0" cols="4" class="description-table style-scope patent-text" width="100%"> <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">Positive</td> <td class="description-td style-scope patent-text">2.2</td> <td class="description-td style-scope patent-text">1.0-4.8</td> <td class="description-td style-scope patent-text">0.04<sup class="style-scope patent-text"></sup> </td> </tr> <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text">Negative</td> <td class="description-td style-scope patent-text">1.1</td> <td class="description-td style-scope patent-text">0.2-4.4</td> </tr> <tr class="description-tr style-scope patent-text"> <td namest="1" nameend="4" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="4"> </td> </tr> <tr class="description-tr style-scope patent-text"> <td namest="1" nameend="4" align="left" id="FOO-00003" class="description-td style-scope patent-text" colspan="4">*From a Cox model in which all variables were included as covariates.</td> </tr> <tr class="description-tr style-scope patent-text"> <td namest="1" nameend="4" align="left" id="FOO-00004" class="description-td style-scope patent-text" colspan="4"> <sup class="style-scope patent-text"></sup>Test for interaction. The interaction terms were, one at a time, added to the final model. Before testing another interaction, both the covariate and the interaction term were removed from the model. Terms for interaction of MN/CA IX with p53, tumor grade, log Ki67, c-erbB2, and T status were not significantly associated with outcome and were not included in the table.</td> </tr>  </tbody></table> </patent-tables> </tables> <br class="style-scope patent-text">
Discussion
</div>
    <div num="p-0158" class="description-paragraph style-scope patent-text">Hypoxia has been implicated as an important component in tumor progression and spread. MN/CA IX was initially identified to be hypoxia inducible in several epithelial cell lines, and its expression was closely correlated with the presence of necrosis, believed to be an indicator of local hypoxia, within invasive breast tumors [Leek et al. (1999)]. As a measure of tumor cell hypoxia, MN/CA IX was shown to be a prognostic factor in different cancers [Koukourakis et al. (2001)], Loncaster et al. (2001), Hui et al., (2002), Swinson et al. (2003), Bui et al. (2004), Hussain et al. (2004)]. Studies have also revealed that MN's expression is restricted to the transformed, dysplastic, and malignant epithelial cells and is rarely expressed in benign or normal tissue.</div>
    <div num="p-0159" class="description-paragraph style-scope patent-text">However, in the studies published to date, MN/CA IX was assessed in tumor samples of patients submitted to heterogeneous adjuvant treatments or no treatment at all after surgery. From such studies, it is very difficult to draw conclusions on MN's predictive role on treatment efficacy, and the heterogeneous treatments administered could have lead to biased results with respect to the disease outcome, while predictive factors can be best evaluated in the context of a prospective randomized clinical trial. In the experiments disclosed herein, the MN/CA IX evaluation was performed in a series of patients prospectively enrolled in a single institution phase III trial comparing epirubicin versus epirubicin+tamoxifen, as primary systemic treatment [Bottini et al. (2005)]. In addition, after surgery, all patients received i.v. CMF regimen in adjuvant setting, and those patients with ER-positive primary tumor in both treatment arms underwent 5 year adjuvant tamoxifen therapy. As previously observed, the MN/CA IX expression was not related to disease stage [Chia et al. (2001)], whereas it was significantly associated with biological tumor prognostic features, such as p53, Ki67, c-erbB2 expression as well as negative steroid hormone receptor status, and negative bcl2 status [Leek et al. (1999)]. Bartosova et al. (2002) reported a weak, but significant, correlation of MN/CA IX in breast cancer with c-erbB2 expression. The present study confirmed that association, and also provides evidence that MN/CA IX with its reversed correlation with ER status and positive correlation with c-erbB2 is associated with resistance to endocrine therapy.</div>
    <div num="p-0160" class="description-paragraph style-scope patent-text">The present experiments are the first to show that MN/CA IX expression is related to the expression of genes regulating apoptosis and proliferative activity. As previously reported, all the biological variables considered in this study are reciprocally correlated [Bottini et al. (2000)]. When the variables associated with MN/CA IX expression in univariate analysis were included in a multivariate logistic regression model, only p53 and bcl2 showed an independent relationship with MN/CA IX expression. The relationship reflects the inverse association with ER, since bcl2 is an estrogen-regulated gene, and p53 expression is associated with ER-negative cases.</div>
    <div num="p-0161" class="description-paragraph style-scope patent-text">Tumor hypoxia regulates many changes in gene expression. In particular, hypoxia selects for p53-mutations [Schmid et al. (2004)] (most p53 detected by immunohistochemical procedures is usually the mutated form) leading to apoptosis inhibition. The direct relationship between MN/CA IX and p53 supports these data, and in cell lines, it has been shown that wild-type p53 suppresses MN/CA IX expression [Kaluzova et al. (2004)], thus providing a mechanism for co-expression in some cases, although most MN/CA IX-positive cases were p53 negative. The inverse relationship with bcl2 reflects the regulation of bcl2 by ER, with hormone receptors being reciprocally related to MN/CA IX.</div>
    <div num="p-0162" class="description-paragraph style-scope patent-text">In this study, MN/CA IX was not predictive of clinical response overall, although no patient with a MN/CA IX-positive tumor had a pCR. The patients were given the maximal dose of epirubicin that can be given without marrow support or cardioprotection on a three weekly basis, as a single agent. The hypothesis tested was that MN/CA IX could mediate one mechanism of resistance relating to poor drug uptake. There was no difference in response in those treated by epirubicin alone versus tamoxifen. Although an effect of MN/CA IX expression was not detected on response, this may be difficult because of the large tumor mass, and effects on elimination of micrometastases could be a more relevant endpoint and represented by poorer DFS.</div>
    <div num="p-0163" class="description-paragraph style-scope patent-text">Few tumors changed the MN/CA IX status before and after treatment. The number of patients with a MN/CA IX-negative tumor at baseline, which becomes positive afterwards is similar to that of patients showing an opposite pattern. The percentage of patients with MN/CA IX-positive tumors did not differ significantly before and after treatment. These data suggest that, as a whole, MN/CA IX immunostaining is not influenced by treatment.</div>
    <div num="p-0164" class="description-paragraph style-scope patent-text">In this series, MN/CA IX expression was significantly associated with poor DFS and OS, confirming previous observations in breast cancer [Chia et al. (2001), Colpaert et al. (2003), Span et al. (2003)]. However, in multivariate analysis, MN/CA IX failed to be an independent predictor of DFS when adjusted for T status, N status, p53, bcl2, Ki67, steroid hormone receptors, and treatment. This observation is in contrast with previous publications [Chia et al. (2001), Span et al. (2003), Chia and Yorida (2004)]. It should be noted, however, that the HR of 1.6 obtained with MN/CA IX in the present study is superimposable to HRs of MN/CA IX reported in multivariate analyses performed in previous studies [Chia et al. (2001), Chia and Yorida (2004), Yorida et al. (2004)]. These data provide further information in favor of the negative prognostic significance of MN/CA IX expression.</div>
    <div num="p-0165" class="description-paragraph style-scope patent-text">A statistical interaction of MN/CA IX was observed with ER, PgR, and bcl2 in determining DFS, indicating that MN/CA IX prognostic significance is limited to (or more pronounced in) patients with hormone-responsive tumors. Hypoxia can cause endocrine therapy resistance as has been shown recently in cell lines in the tissue culture [Cooper et al. (2004), Coradini et al. (2004)], thereby contributing to increased drug resistance. Tamoxifen in particular is a weak basic drug (pK<sub class="style-scope patent-text">a</sub>=8.8), so that possible mechanisms of hypoxia-induced resistance to this drug relate to the acid outside pH gradients that reduce the partitioning of weak basic drugs into the relatively alkaline cells. This phenomenon has its basis in ion trapping, wherein weak bases partition into, and are sequestered by acidic compartments, such as the extracellular matrix [Roos (1978)]. This occurs because uncharged, organic-free bases are more permeable than their protonated and charged counterparts and establish equal concentrations on either side of the cell membrane [Gillies (1978)]. There is evidence that decreased uptake is a possible mechanism of resistance in hormone-resistant breast cancers on tamoxifen therapy, although how this occurred was not described [Dowsett et al. (1995)]. The results suggest a contribution of MN/CA IX expression in the tamoxifen resistance. Since the patient population with ER-positive tumors was homogeneously submitted to 5 year adjuvant tamoxifen in addition to chemotherapy, it is not possible to assess whether the observed interaction is due to an antagonizing effect of MN/CA IX positivity on the efficacy of tamoxifen, or it may be attributable to a true interaction between two different tumor characteristics.</div>
    <div num="p-0166" class="description-paragraph style-scope patent-text">In conclusion, there are presently few clinical markers of resistance to tamoxifen treatment in ER-positive tumors. MN/CA IX expression in breast cancer patients shows a negative predictive role of treatment efficacy in ER-positive patients, particularly in the case of adjuvant tamoxifen after primary chemo-endocrine therapy, and is considered to be predictive of resistance to endocrine therapy in ER-positive breast cancer patients.</div>
    <heading class="style-scope patent-text">Budapest Treaty Deposits</heading>
    <div num="p-0167" class="description-paragraph style-scope patent-text">The materials listed below were deposited with the American Type Culture Collection (ATCC) now at 10801 University Blvd., Manassus, Va. 20110-2209 (USA). The deposits were made under the provisions of the Budapest Treaty on the International Recognition of Deposited Microorganisms for the Purposes of Patent Procedure and Regulations thereunder (Budapest Treaty). Maintenance of a viable culture is assured for thirty years from the date of deposit. The hybridomas and plasmids will be made available by the ATCC under the terms of the Budapest Treaty, and subject to an agreement between the Applicants and the ATCC which assures unrestricted availability of the deposited hybridomas and plasmids to the public upon the granting of patent from the instant application. Availability of the deposited strain is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any Government in accordance with its patent laws.</div>
    <div num="p-0168" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00009" num="00009" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Deposit Date</td>
                <td class="description-td style-scope patent-text">ATCC #</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="3"> </td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Hybridoma</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">VU-M75</td>
                <td class="description-td style-scope patent-text">Sep. 17, 1992</td>
                <td class="description-td style-scope patent-text">HB 11128</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">MN 12.2.2</td>
                <td class="description-td style-scope patent-text">Jun. 9, 1994</td>
                <td class="description-td style-scope patent-text">HB 11647</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Plasmid</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">A4a</td>
                <td class="description-td style-scope patent-text">Jun. 6, 1995</td>
                <td class="description-td style-scope patent-text">97199</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">XE1</td>
                <td class="description-td style-scope patent-text">Jun. 6, 1995</td>
                <td class="description-td style-scope patent-text">97200</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">XE3</td>
                <td class="description-td style-scope patent-text">Jun. 6, 1995</td>
                <td class="description-td style-scope patent-text">97198</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td namest="offset" nameend="3" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="4"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <div num="p-0169" class="description-paragraph style-scope patent-text">Similarly, the hybridoma cell line V/10-VU which produces the V/10 monoclonal antibodies was deposited on Feb. 19, 2003 under the Budapest Treaty at the International Depository Authority (IDA) of the Belgian Coordinated Collections of Microorganisms (BCCM) at the Laboratorium voor Moleculaire Biologie-Plasmidencollectie (LMBP) at the Universeit Gent, K. L. Ledeganckstraat 35, B-9000 Gent, Belgium [BCCM/LMBP] under the Accession No. LMBP 6009CB.</div>
    <div num="p-0170" class="description-paragraph style-scope patent-text">The description of the foregoing embodiments of the invention have been presented for purposes of illustration and description. They are not intended to be exhaustive or to limit the invention to the precise form disclosed, and obviously many modifications and variations are possible in light of the above teachings. The embodiments were chosen and described in order to explain the principles of the invention and its practical application to enable thereby others skilled in the art to utilize the invention in various embodiments and with various modifications as are suited to the particular use contemplated.</div>
    <div num="p-0171" class="description-paragraph style-scope patent-text">All references cited herein are hereby incorporated by reference.</div>
    
  </div>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
            <div class="flex flex-width style-scope patent-result">
              <section id="claims" class="style-scope patent-result">
                <h3 class="style-scope patent-result">
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Claims <span class="style-scope patent-result">(24)</span></div>
                    <div class="collapse style-scope patent-result">
                      Hide Dependent <iron-icon style="height: 15px; width: 15px;" icon="expand-less" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 8l-6 6 1.41 1.41L12 10.83l4.59 4.58L18 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </div>
                  </div>
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result"></div>
                    <div class="righthead style-scope patent-result" hidden="">translated from </div>
                  </div>
                </h3>
                <patent-text name="claims" enable-text-selection="" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><div mxw-id="PCLM38646431" lang="EN" load-source="patent-office" class="claims style-scope patent-text">
    <div class="claim style-scope patent-text"> <div id="CLM-00001" num="00001" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">1. A method of predicting resistance to endocrine therapy in a breast cancer patient with an ER-positive breast tumor, comprising:
<div class="claim-text style-scope patent-text">(a) obtaining a breast tumor tissue sample from said ER-positive breast cancer patient;</div>
<div class="claim-text style-scope patent-text">(b) determining immunologically whether said sample is MN/CA IX-positive, wherein MN/CA IX positivity is indicated by any conventionally detectable MN/CA IX-specific immunohistochemical staining of cells in said sample; and</div>
<div class="claim-text style-scope patent-text">(c) correlating a finding of combined ER-positivity in said tumor and MN/CA IX-positivity in said sample with a greater probability of resistance to said endocrine therapy for said ER-positive breast cancer patient than if said tumor were ER-positive and said sample were MN/CA IX-negative.</div>
</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00002" num="00002" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">2. The method of <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein said endocrine therapy comprises or consists of the use of an antiestrogen or estrogen lowering drug, or drug that modifies endocrine environment.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00003" num="00003" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">3. The method of <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein said endocrine therapy is a selective estrogen receptor modulator (SERM), a pure antiestrogen, a steroidal aromatase inhibitor, a nonsteroidal aromatase inhibitor, or estrogen.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00004" num="00004" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">4. The method of <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein said endocrine therapy is selected from the group consisting of tamoxifen, raloxifene, toremifene, fulvestrant, exemestane, letrozole or anastrozole.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00005" num="00005" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">5. The method of <claim-ref idref="CLM-00002" class="style-scope patent-text">claim 2</claim-ref>, wherein said antiestrogen is tamoxifen.</div>
    </div>
    </div> <div class="claim style-scope patent-text"> <div id="CLM-00006" num="00006" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">6. A method of predicting resistance to endocrine therapy in a breast cancer patient with an ER-positive breast tumor, comprising:
<div class="claim-text style-scope patent-text">(a) obtaining a body fluid sample from said ER-positive breast cancer patient;</div>
<div class="claim-text style-scope patent-text">(b) immunologically detecting the presence or absence of soluble MN/CA IX in said body fluid sample; and</div>
<div class="claim-text style-scope patent-text">(c) correlating a finding of combined ER-positivity in said tumor and detectable soluble MN/CA IX in said body fluid sample with a greater probability of resistance to said endocrine therapy for said ER-positive breast cancer patient than if said tumor were ER-positive and said body fluid sample were MN/CA IX-negative.</div>
</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00007" num="00007" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">7. The method of <claim-ref idref="CLM-00006" class="style-scope patent-text">claim 6</claim-ref>, wherein said endocrine therapy comprises or consists of the use of an antiestrogen.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00008" num="00008" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">8. The method of <claim-ref idref="CLM-00007" class="style-scope patent-text">claim 7</claim-ref>, wherein said antiestrogen is tamoxifen.</div>
    </div>
    </div> <div class="claim style-scope patent-text"> <div id="CLM-00009" num="00009" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">9. A method of predicting resistance to an antiestrogen therapy in a breast cancer patient with an ER-positive breast tumor, comprising:
<div class="claim-text style-scope patent-text">(a) employing diagnostic/prognostic imaging to detect the presence or absence of MN/CA IX in one or more tumors in said ER-positive breast cancer patient, wherein said imaging comprises the use of labeled MN/CA IX-specific antibodies; and</div>
<div class="claim-text style-scope patent-text">(b) correlating a finding of combined ER-positivity in said breast tumor and the presence of MN/CA IX in said one or more tumors with a greater probability of resistance to said antiestrogen therapy for said ER-positive breast cancer patient than if said breast tumor were ER-positive and said one or more tumors were MN/CA IX-negative.</div>
</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00010" num="00010" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">10. The method of <claim-ref idref="CLM-00009" class="style-scope patent-text">claim 9</claim-ref>, wherein said one or more tumors is or are metastatic tumor(s).</div>
    </div>
    </div> <div class="claim style-scope patent-text"> <div id="CLM-00011" num="00011" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">11. A method for selecting an appropriate therapy for a breast cancer patient with an ER-positive breast tumor, comprising:
<div class="claim-text style-scope patent-text">(a) immunologically detecting the presence or absence of MN/CA IX in said ER-positive tumor or in a metastasis of said tumor;</div>
<div class="claim-text style-scope patent-text">(b) correlating a finding of combined ER-positivity in said breast tumor and the presence of MN/CA IX in said tumor or said metastasis with a greater probability of resistance to antiestrogen therapy for said ER-positive breast cancer patient, than if said breast tumor were ER-positive and said tumor or said metastasis were MN/CA IX-negative; and</div>
<div class="claim-text style-scope patent-text">(c) selecting an additional or alternative therapy to antiestrogen therapy for said ER-positive, MN/CA IX-positive breast cancer patient identified in step (b) as having a greater probability of resistance to antiestrogen therapy.</div>
</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00012" num="00012" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">12. The method of <claim-ref idref="CLM-00011" class="style-scope patent-text">claim 11</claim-ref>, wherein said antiestrogen therapy is tamoxifen.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00013" num="00013" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">13. The method of <claim-ref idref="CLM-00011" class="style-scope patent-text">claim 11</claim-ref>, wherein said MN/CA IX comprises soluble MN/CA IX antigen (s-CA IX), a MN protein or a MN polypeptide.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00014" num="00014" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">14. The method of <claim-ref idref="CLM-00011" class="style-scope patent-text">claim 11</claim-ref>, wherein said additional or alternative therapy is an anthracycline.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00015" num="00015" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">15. The method of <claim-ref idref="CLM-00014" class="style-scope patent-text">claim 14</claim-ref>, wherein said anthracycline is epirubicin or doxorubicin.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00016" num="00016" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">16. The method of <claim-ref idref="CLM-00011" class="style-scope patent-text">claim 11</claim-ref>, wherein said additional or alternative therapy is not substantially inhibited by acidic pH.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00017" num="00017" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">17. The method of <claim-ref idref="CLM-00011" class="style-scope patent-text">claim 11</claim-ref>, wherein said additional or alternative therapy is selected from adjuvant chemotherapy, alternative endocrine therapy, or MN-targeted therapy.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00018" num="00018" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">18. The method of <claim-ref idref="CLM-00017" class="style-scope patent-text">claim 17</claim-ref>, wherein said adjuvant chemotherapy is a taxane.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00019" num="00019" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">19. The method of <claim-ref idref="CLM-00018" class="style-scope patent-text">claim 18</claim-ref>, wherein said taxane is paclitaxel or docetaxel.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00020" num="00020" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">20. The method of <claim-ref idref="CLM-00012" class="style-scope patent-text">claim 12</claim-ref>, wherein if MN/CA IX is present in said tumor or said metastasis, said method further comprises deciding not to use chemotherapy or alternative endocrine therapy substantially inhibited by acidic pH.</div>
    </div>
    </div> <div class="claim style-scope patent-text"> <div id="CLM-00021" num="00021" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">21. A method of predicting resistance to tamoxifen in a breast cancer patient with an ER-positive breast tumor, comprising:
<div class="claim-text style-scope patent-text">(a) obtaining a breast tumor tissue sample from said ER-positive breast cancer patient;</div>
<div class="claim-text style-scope patent-text">(b) immunologically detecting MN/CA IX overexpression in said sample, wherein any conventionally detectable MN/CA IX-specific immunohistochemical staining of cells in said sample indicates MN/CA IX overexpression; and</div>
<div class="claim-text style-scope patent-text">(c) correlating a finding of combined ER-positivity in said tumor and MN/CA IX overexpression in said sample with a greater probability of resistance to tamoxifen for said ER-positive breast cancer patient than if said sample were MN/CA IX-negative, and identifying said ER-positive, MN/CA IX-positive breast cancer patient as a candidate for an additional or alternative therapy to tamoxifen.</div>
</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00022" num="00022" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">22. The method of <claim-ref idref="CLM-00009" class="style-scope patent-text">claim 9</claim-ref>, wherein said imaging is positron emission tomography (PET) imaging.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00023" num="00023" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">23. The method of <claim-ref idref="CLM-00022" class="style-scope patent-text">claim 22</claim-ref>, wherein the MN/CA IX-specific antibodies are labeled using the fluorine isotope <sup class="style-scope patent-text">18</sup>F.</div>
    </div>
    </div> <div class="claim style-scope patent-text"> <div id="CLM-00024" num="00024" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">24. A method of predicting resistance to endocrine therapy in a breast cancer patient with an ER-positive breast tumor, comprising:
<div class="claim-text style-scope patent-text">(a) obtaining a breast tumor tissue sample from said ER-positive breast cancer patient;</div>
<div class="claim-text style-scope patent-text">(b) determining by MN/CA IX-specific immunohistochemical staining of cells in said sample an MN/CA IX immunoreactivity score of said sample, wherein said sample is assigned an immunoreactivity score with</div>
<div class="claim-text style-scope patent-text">a value of 0 (zero) if no staining,</div>
<div class="claim-text style-scope patent-text">a value of 1 if weak staining, or</div>
<div class="claim-text style-scope patent-text">a value of 2 if strong staining;</div>
<div class="claim-text style-scope patent-text">and</div>
<div class="claim-text style-scope patent-text">(c) correlating a finding of combined ER-positivity in said tumor and an MN/CA IX immunoreactivity score of the sample greater than 0 (zero), with a greater probability of resistance to said endocrine therapy for said ER-positive breast cancer patient, than if said tumor were ER-positive and said sample had an MN/CA IX immunoreactivity score of 0 (zero).</div>
</div>
    </div>
  </div> </div>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
          </div>

          <div class="footer style-scope patent-result">

            
            <h3 id="patentCitations" class="scroll-target style-scope patent-result">
              Patent Citations (5)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1993018152A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1993018152A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-03-11</span>
                    <span class="td style-scope patent-result">1993-09-16</span>
                    <span class="td style-scope patent-result">Ciba Corning Diagnostics Corp.</span>
                    <span class="td style-scope patent-result">Mn gene and protein 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1995034650A2/en"><a id="link" href="#" class="style-scope state-modifier">WO1995034650A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1994-06-15</span>
                    <span class="td style-scope patent-result">1995-12-21</span>
                    <span class="td style-scope patent-result">Ciba Corning Diagnostics Corp.</span>
                    <span class="td style-scope patent-result">Mn gene and protein 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5989838A/en"><a id="link" href="#" class="style-scope state-modifier">US5989838A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-03-11</span>
                    <span class="td style-scope patent-result">1999-11-23</span>
                    <span class="td style-scope patent-result">Institute Of Virology, Slovak Academy Of Sciences</span>
                    <span class="td style-scope patent-result">Immunological methods of detecting MN proteins and MN polypeptides 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003100029A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2003100029A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-02-21</span>
                    <span class="td style-scope patent-result">2003-12-04</span>
                    <span class="td style-scope patent-result">Bayer Healthcare</span>
                    <span class="td style-scope patent-result">Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20080138345A1/en"><a id="link" href="#" class="style-scope state-modifier">US20080138345A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-01-25</span>
                    <span class="td style-scope patent-result">2008-06-12</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Compositions and methods for treatment of cancer 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  <template is="dom-repeat" class="style-scope patent-result"></template>

                </div>
              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner,  Cited by third party</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="nplCitations" class="scroll-target style-scope patent-result">
              Non-Patent Citations (36)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Bartosova et al., "Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2," Journal of Pathology, 197: 314-321 (2002).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Bottini et al., "Cytotoxic and antiproliferative activity of the single agent epirubicin versus eprirbicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial ," Endocrine-Related Cancer, 12: 383-392 (2005).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Bottini et al., "p53 but not bcl-2 Immunostaining Is Predictive of Poor Clinical Complete Response to Primary Chemotherapy in Breast Cancer Patients," Clinical Cancer Research, 6: 2751-2758 (Jul. 2000).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Brennan et al., "CA IX is an Independent Prognostic Marker in Premenopausal Breast Cancer Patients with One to Three Positive Lymph Nodes and a Putative Marker of Radiation Resistance," Clinical Cancer Research, 12(21):6412-6431 (Nov. 1, 2006).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Chia et al., "Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma," Journal of Clinical Oncology, 19(16): 3660-3668 (Aug. 15, 2001).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Chia, et al., "Carbonic anhydrase IX (CA IX) is an independent poor prognostic factor in early stage breast cancer: results from a large population-based tissue microarray (TMA) series," Breast Cancer Research and Treatment, 88(Supp. 1): S116-S117, Abstract 3015 (2004).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Colpaert et al., "The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis," Breast Cancer Research and Treatment, 81: 137-147 (2003).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Cooper et al., "Intermittent Hypoxia Induces Proteasome-Dependent Down-Regulation of Estrogen Receptor Alpha in Human Breast Carcinoma," Clinical Cancer Research, 10: 8720-8727 (Dec. 15, 2004).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Coradini et al., "Hypoxia and estrogen receptor profile influence the responsiveness of human breast cancer cells to estradiol and antiestrogens," Cellular and Molecular Life Sciences, 61: 76-82 (2004).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Dowsett et al., "Response to specific antioestrogen (IC1182780) in tamoxifen-resistant breast cancer," Lancet, 345: 525 (Feb. 25, 1995).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Generali et al, "Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer," Endocrine-Related Cancer, 13(3): 921-930 (Sep. 2006).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Generali et al., "Hypoxia-Inducible Factor-1alpha Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer," Clin. Cancer Res., 12(15): 4562-4568 (Aug. 1, 2006).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Generali et al., "Regulation of Hepatocyte Growth Factor Activator Inhibitor 2 by Hypoxia in Breast Cancer," Clin. Cancer Res., 13(2 Pt 1): 550-8 (Jan. 15, 2007).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Gerweck, L.E., "Tumor pH: Implications for Treatment and Novel Drug Design," Seminars in Radiation Oncology, 8(3): 176-182 (1998).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Harris, A.L., "Hypoxia-A Key Regulatory Factor in Tumour Growth," Nature Reviews Cancer, 2: 38-47 (Jan. 2002).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Hornberger et al., "Economic Analysis of Targeting Chemotherapy Using a 21-Gene RT-PCT Assay in Lymph-Node-Negative, Estrogen-Receptor-Positive, Early-Stage Breast Cancer," American Journal of Managed Care, 11(5): 313-324 (2005).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Hussain et al., "Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer," British Journal of Cancer, 96(1): 104-109 (Jan. 15, 2007).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Leek et al., "Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast," British Journal of Cancer, 79(5/6): 991-995 (1999).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Lyman et al., "Impact of a 21-Gene RT-PCR Assay on Treatment Decisions in Early-Stage Breast Cancer," Cancer, 109(6): 1011-1018 (Mar. 15, 2007).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Paik, et al., "Multi-gene RT-PCR assay for Predicting recurrence in node negative breast cancer patients-NSABP studies B-20 and B-14," Breast Cancer Research Treatment., 82: S10 (2003).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Pastorekova and Zavada, "Carbonic anhydrase IX (CA IX) as a potential target for cancer therapy," Cancer Therapy, 2: 245-262 (2004).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Pastorekova et al., "A Novel Quasi-Viral Agent, MaTu, Is a Two-Component System," Virology, 187: 620-626 (1992).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Potter and Harris, "Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer," British Journal of Cancer, 89: 2-7 (2003).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Raghunand and Gillies, "pH and chemotherapy," Novartis Foundation Symposium, 240: 199-211 (discussion 265-268) (2001).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Raghunand et al., "Enhancement of chemotherapy by manipulation of tumour pH," British Journal of Cancer, 80(17): 1005-1011 (1999).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Robertson et al., "Role of Carbonic Anhydrase IX in Human Tumor Cell Growth, Survival, and Invasion," Cancer Res., 64(17): 6160-6165 (Sep. 1, 2004).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Sargent and Allegra, "Issues in Clinical Trial Design for Tumor Marker Studies," Seminars in Oncology, 29(3): 222-230 (Jun. 2002).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Span et al., "Carbonic anhydrase IX expression is more predictive than prognostic in breast cancer," British Journal of Cancer, 96(8): 1309 (Apr. 23, 2007).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Span et al., "Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome," British Journal of Cancer, 89: 271-276 (2003).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Svastova et al. "Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH," FEBS Letters, 577: 439-445 (2004).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Tockman et al., "Considerations in Bringing a Cancer Biomarker to Clinical Application " Cancer Research (Suppl.), 52: 2711s-2718s (May 1, 1992).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Tomes et al., "Necrosis and hypoxia in invasive breast carcinoma," Breast Cancer Research and Treatment, 81(1): 61-69 (Sep. 2003).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Trastour et al., "HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome," Int. J. Cancer, 120(7): 1451-1458 (Apr. 1, 2007).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Vleugel et al., "Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer," Journal of Clinical Pathology, 58(2): 172-177 (Feb. 2005).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Wykoff et al., "Expression of the Hypoxia-Inducible and Tumor-Associated Carbonic Anhydrases in Ductal Carcinoma in Situ of the Breast," American Journal of Pathology, 158(3): 1011-1019 (2001).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Wykoff et al., "Hypoxia-Inducible Expression of Tumor-Associated Carbonic Anhydrases," Cancer Research, 60: 7075-7083 (Dec. 15. 2000).
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner,  Cited by third party</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="citedBy" class="scroll-target style-scope patent-result">
              Cited By (6)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2808859A1/en"><a id="link" href="#" class="style-scope state-modifier">CA2808859A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-08-20</span>
                    <span class="td style-scope patent-result">2012-02-23</span>
                    <span class="td style-scope patent-result">Pangea Biosciences, Inc.</span>
                    <span class="td style-scope patent-result">Cancer diagnostic and cancer therapeutic 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN103339509A/en"><a id="link" href="#" class="style-scope state-modifier">CN103339509A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-01-28</span>
                    <span class="td style-scope patent-result">2013-10-02</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Predictive test for selection of metastatic breast cancer patients for hormonal and combination therapy 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2013112881A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2013112881A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-01-27</span>
                    <span class="td style-scope patent-result">2013-08-01</span>
                    <span class="td style-scope patent-result">Thomas Jefferson University</span>
                    <span class="td style-scope patent-result">Mct protein inhibitor-related prognostic and therapeutic methods 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2014038524A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2014038524A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-09-05</span>
                    <span class="td style-scope patent-result">2014-03-13</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Method for determining breast cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2986290A4/en"><a id="link" href="#" class="style-scope state-modifier">EP2986290A4</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-04-19</span>
                    <span class="td style-scope patent-result">2017-01-04</span>
                    <span class="td style-scope patent-result">Thomas Jefferson University</span>
                    <span class="td style-scope patent-result">Caveolin-1 related methods for treating glioblastoma with temozolomide 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2019526304A/en"><a id="link" href="#" class="style-scope state-modifier">JP2019526304A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-06-29</span>
                    <span class="td style-scope patent-result">2019-09-19</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Classification of hormone receptor status in malignant neoplastic tissue by chest thermography image
 
     </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>

              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner,  Cited by third party,  Family to family citation</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="similarDocuments" class="scroll-target style-scope patent-result">
              Similar Documents
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication</span>
                    <span class="th style-scope patent-result">Publication Date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7838240B2/en"><a id="link" href="#" class="style-scope state-modifier">US7838240B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-11-23</span>
                    <span class="td style-scope patent-result">MN/CA IX/CA9 and renal cancer prognosis 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8007995B2/en"><a id="link" href="#" class="style-scope state-modifier">US8007995B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-08-30</span>
                    <span class="td style-scope patent-result">Moesin, caveolin 1 and yes associated protein 1 as predictive markers of response to dasatinib in breast cancers 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8097423B2/en"><a id="link" href="#" class="style-scope state-modifier">US8097423B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-01-17</span>
                    <span class="td style-scope patent-result">MN/CA IX and breast cancer therapy 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="scholar/2717075647415015982"><a id="link" href="#" class="style-scope state-modifier">Shaoyan et al.</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013</span>
                    <span class="td style-scope patent-result">Downregulation of EIF4A2 in nonsmall-cell lung cancer associates with poor prognosis</span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2473621B1/en"><a id="link" href="#" class="style-scope state-modifier">EP2473621B1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-01-09</span>
                    <span class="td style-scope patent-result">Methods for detection of lethal cell and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7993852B2/en"><a id="link" href="#" class="style-scope state-modifier">US7993852B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-08-09</span>
                    <span class="td style-scope patent-result">MN/CA IX and cancer prognosis 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="scholar/16539082414491907998"><a id="link" href="#" class="style-scope state-modifier">Yang et al.</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008</span>
                    <span class="td style-scope patent-result">LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma</span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9110082B2/en"><a id="link" href="#" class="style-scope state-modifier">US9110082B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-08-18</span>
                    <span class="td style-scope patent-result">Methods for the identification and treatment of patients sensitive to anti IGF-1R inhibition therapy 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="scholar/6059512719197953863"><a id="link" href="#" class="style-scope state-modifier">Han et al.</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007</span>
                    <span class="td style-scope patent-result">HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target</span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2015108639A/en"><a id="link" href="#" class="style-scope state-modifier">JP2015108639A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-06-11</span>
                    <span class="td style-scope patent-result">Akt phosphorylation at ser473 as indicator for taxane-based chemotherapy 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2011000573A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2011000573A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-01-06</span>
                    <span class="td style-scope patent-result">Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2702409B1/en"><a id="link" href="#" class="style-scope state-modifier">EP2702409B1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-09-09</span>
                    <span class="td style-scope patent-result">CXCR1 as a predictor of response to treatment with epidermal growth factor receptor targeted therapeutic 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20090263838A1/en"><a id="link" href="#" class="style-scope state-modifier">US20090263838A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-10-22</span>
                    <span class="td style-scope patent-result">Method for determining a lung cancer treatment and method for determining the effectiveness of an agent for treatment of lung cancer 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2013521487A/en"><a id="link" href="#" class="style-scope state-modifier">JP2013521487A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-06-10</span>
                    <span class="td style-scope patent-result">
  Method for selecting a patient for treatment with an EGFR inhibitor
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2010131080A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2010131080A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-11-18</span>
                    <span class="td style-scope patent-result">A method for predicting the therapeutic responsiveness of a patient to a medical treatment with an egfr inhibitor 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20240072324A/en"><a id="link" href="#" class="style-scope state-modifier">KR20240072324A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2024-05-24</span>
                    <span class="td style-scope patent-result">Use of serotonin, somatostatin and PYY as a prognostic biomarker for rectal neuroendocrine tumor 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2008103327A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2008103327A2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-08-28</span>
                    <span class="td style-scope patent-result">Mn/ca ix and bladder cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2009518043A/en"><a id="link" href="#" class="style-scope state-modifier">JP2009518043A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-05-07</span>
                    <span class="td style-scope patent-result">
  Diagnosis and treatment of diseases related to FLJ13639 gene
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN110546510A/en"><a id="link" href="#" class="style-scope state-modifier">CN110546510A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-12-06</span>
                    <span class="td style-scope patent-result">Prognostic method and kit useful in said method 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="relatedApplications" class="scroll-target style-scope patent-result">Priority And Related Applications</h3>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="applicationPriorityApps" class="scroll-target style-scope patent-result">
              Priority Applications (1)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8097423B2/en"><a id="link" href="#" class="style-scope state-modifier">US12/181,951</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2007-07-30</span>
                    <span class="td nowrap style-scope patent-result">2008-07-29</span>
                    <span class="td style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        MN/CA IX and breast cancer therapy 
       <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="appsClaimingPriority" class="scroll-target style-scope patent-result">
              Applications Claiming Priority (2)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US95280907P<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2007-07-30</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8097423B2/en"><a id="link" href="#" class="style-scope state-modifier">US12/181,951</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2008-07-29</span>
                    <span class="td style-scope patent-result">MN/CA IX and breast cancer therapy 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="legalEvents" class="scroll-target style-scope patent-result">
              Legal Events
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Date</span>
                    <span class="th style-scope patent-result">Code</span>
                    <span class="th style-scope patent-result">Title</span>
                    <span class="th style-scope patent-result">Description</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2008-09-02</span>
                    <span class="td nowrap style-scope patent-result">AS</span>
                    <span class="td nowrap style-scope patent-result">Assignment</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Owner name</strong>: INSTITUTE OF VIROLOGY, SLOVAKIA</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HARRIS, ADRIAN L.;REEL/FRAME:021475/0861</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Effective date</strong>: 20080804</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2011-12-28</span>
                    <span class="td nowrap style-scope patent-result">STCF</span>
                    <span class="td nowrap style-scope patent-result">Information on status: patent grant</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: PATENTED CASE</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2013-04-30</span>
                    <span class="td nowrap style-scope patent-result">CC</span>
                    <span class="td nowrap style-scope patent-result">Certificate of correction</span>
                    <span class="td style-scope patent-result">
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2014-12-05</span>
                    <span class="td nowrap style-scope patent-result">FEPP</span>
                    <span class="td nowrap style-scope patent-result">Fee payment procedure</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: PAT HOLDER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: LTOS); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2015-07-01</span>
                    <span class="td nowrap style-scope patent-result">FPAY</span>
                    <span class="td nowrap style-scope patent-result">Fee payment</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Year of fee payment</strong>: 4</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2018-06-05</span>
                    <span class="td nowrap style-scope patent-result">AS</span>
                    <span class="td nowrap style-scope patent-result">Assignment</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Owner name</strong>: BIOMEDICAL RESEARCH CENTRE OF THE SLOVAK ACADEMY O</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INSTITUTE OF VIROLOGY OF THE SLOVAK ACADEMY OF SCIENCES;REEL/FRAME:046294/0714</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Effective date</strong>: 20180329</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2019-09-09</span>
                    <span class="td nowrap style-scope patent-result">FEPP</span>
                    <span class="td nowrap style-scope patent-result">Fee payment procedure</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2020-02-24</span>
                    <span class="td nowrap style-scope patent-result">LAPS</span>
                    <span class="td nowrap style-scope patent-result">Lapse for failure to pay maintenance fees</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2020-02-24</span>
                    <span class="td nowrap style-scope patent-result">STCH</span>
                    <span class="td nowrap style-scope patent-result">Information on status: patent discontinuation</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2020-03-17</span>
                    <span class="td nowrap style-scope patent-result">FP</span>
                    <span class="td nowrap style-scope patent-result">Lapsed due to failure to pay maintenance fee</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Effective date</strong>: 20200117</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <div id="notices" class="vertical layout center style-scope patent-result">
              
                <span class="style-scope patent-result">Data provided by IFI CLAIMS Patent Services</span>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
          </div>
          <div class="bottombar style-scope patent-result">
            <bottom-bar class="style-scope patent-result"><template is="dom-if" class="style-scope bottom-bar"></template>
</bottom-bar>
          </div>
        </div>
      </div>
      <template is="dom-if" class="style-scope patent-result"></template>
    </div>
  </patent-result>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
  </result-container>
        </div>
      </div>
    
        </div>
      </div>
      <search-footer class="style-scope search-ui">
    
    

    <div id="footer" class="vertical layout center style-scope search-footer">
        <span class="links style-scope search-footer">
          <overlay-tooltip positioning-target="#footerAbout" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Learn more about data coverage, search syntax and other features.
    </div>
  </overlay-tooltip>
          <a id="footerAbout" data-proto="ABOUT" href="https://support.google.com/faqs/answer/6390996" target="_blank" class="style-scope search-footer">About</a>
          <overlay-tooltip positioning-target="#footerFeedback" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Send feedback about technical issues or feature requests for Google Patents.
    </div>
  </overlay-tooltip>
          <a id="footerFeedback" data-proto="SEND_FEEDBACK" href="#" onclick="sendFeedback();" class="style-scope search-footer">Send Feedback</a>
          <a data-proto="PUBLIC_DATASETS" href="https://console.cloud.google.com/marketplace/product/google_patents_public_datasets/google-patents-public-data" target="_blank" class="style-scope search-footer">Public Datasets</a>
          <a data-proto="TERMS" href="https://www.google.com/policies/terms/" target="_blank" class="style-scope search-footer">Terms</a>
          <a data-proto="PRIVACY_POLICY" href="https://www.google.com/privacy/privacy-policy.html" target="blank" class="style-scope search-footer">Privacy Policy</a>
          <a data-proto="SEARCH_HELP" href="https://support.google.com/websearch/" target="_blank" class="style-scope search-footer">Help</a>
        </span>
    </div>
  </search-footer>
    </div>

  </search-ui>
  </search-result>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <paper-toast id="toast" duration="3000" class="style-scope search-app x-scope paper-toast-0" aria-hidden="true" style="outline: none; display: none;">
    

    <span id="label" class="style-scope paper-toast"></span>
    
      <div id="noticeContent" class="style-scope search-app"></div>
    
  </paper-toast>
  </search-app>
    <script type="text/javascript" src="//www.gstatic.com/feedback/api.js"></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/js/help/prod/service/lazy.min.js"></script>
    <script type="text/javascript">
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    </script>
    <script src="/sw/null_loader.js"></script>
  

<iframe id="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.1249677264" name="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.1249677264" style="width: 1px; height: 1px; position: absolute; top: -100px; display: none;" src="https://scone-pa.clients6.google.com/static/proxy.html?usegapi=1&amp;jsh=m%3B%2F_%2Fscs%2Fabc-static%2F_%2Fjs%2Fk%3Dgapi.lb.en.IKZeRvoAYNY.O%2Fam%3DAAAQ%2Fd%3D1%2Frs%3DAHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw%2Fm%3D__features__#parent=https%3A%2F%2Fpatents.google.com&amp;rpctoken=348412779" tabindex="-1" aria-hidden="true"></iframe><iron-a11y-announcer>
    
    <div class="style-scope iron-a11y-announcer" aria-live="polite"></div>
  </iron-a11y-announcer></body></html>